NEW RESEARCH ON ALZHEIMER’S DISEASE
No part of this digital document may be reproduced, stored in a retrieval system or transmitted in any form or by any means. The publisher has taken reasonable care in the preparation of this digital document, but makes no expressed or implied warranty of any kind and assumes no responsibility for any errors or omissions. No liability is assumed for incidental or consequential damages in connection with or arising out of information contained herein. This digital document is sold with the clear understanding that the publisher is not engaged in rendering legal, medical or any other professional services.
NEW RESEARCH ON ALZHEIMER’S DISEASE
EILEEN M. WELSH EDITOR
Nova Science Publishers, Inc. New York
Copyright © 2006 by Nova Science Publishers, Inc.
All rights reserved. No part of this book may be reproduced, stored in a retrieval system or transmitted in any form or by any means: electronic, electrostatic, magnetic, tape, mechanical photocopying, recording or otherwise without the written permission of the Publisher. For permission to use material from this book please contact us: Telephone 631-231-7269; Fax 631-231-8175 Web Site: http://www.novapublishers.com NOTICE TO THE READER The Publisher has taken reasonable care in the preparation of this book, but makes no expressed or implied warranty of any kind and assumes no responsibility for any errors or omissions. No liability is assumed for incidental or consequential damages in connection with or arising out of information contained in this book. The Publisher shall not be liable for any special, consequential, or exemplary damages resulting, in whole or in part, from the readers’ use of, or reliance upon, this material. This publication is designed to provide accurate and authoritative information with regard to the subject matter covered herein. It is sold with the clear understanding that the Publisher is not engaged in rendering legal or any other professional services. If legal or any other expert assistance is required, the services of a competent person should be sought. FROM A DECLARATION OF PARTICIPANTS JOINTLY ADOPTED BY A COMMITTEE OF THE AMERICAN BAR ASSOCIATION AND A COMMITTEE OF PUBLISHERS. Library of Congress Cataloging-in-Publication Data New research on Alzheimer's disease / Eileen M. Welsh (editor). p. ; cm. Includes index. ISBN 978-1-60876-520-1 (E-Book) 1. Alzheimer's disease--Research. I. Welsh, Eileen M. [DNLM: 1. Alzheimer Disease. WT 155 N5315 2006] RC523.R472 616.8'310072--dc22
Published by Nova Science Publishers, Inc. New York
2006 2005035992
Contents Preface Chapter I
vii Insights on Alzheimer’s Disease from the Intracerebral Injection and Infusion of Amyloid-β Glenda M. Bishop and Stephen R. Robinson
Chapter II
The Role of Phospholipase A2 in Alzheimer's Disease Wagner F. Gattaz, Evelin L. Schaeffer and Orestes V. Forlenza
Chapter III
Low Molecular Weight Glycosaminoglycans and Apoptosis: Potential Treatment of Neurodegenerative Disorders Including Alzheimer’s Disease Bertalan Dudas
Chapter IV
Chapter V
Chapter VI
Chapter VII
Low Density Lipoprotein Receptor-Related Protein 1 (LRP1): One of the Hallmarks ofAlzheimer’s Disease and Other Complex Degenerative Processes Christiane Gläser, Gerd Birkenmeier, Susanne Schulz and Klaus Huse
1 57
87
99
The Role of Peroxisome Proliferator-Activated Receptors in Alzheimer’s Disease Dokmeci Dikmen
125
Role of Sphingomyelin Cycle Signaling System in Alzheimer’s Disease A. V. Alessenko
165
Ischemia-Reperfusion Factors in Sporadic Alzheimer’s Disease Ryszard Pluta
183
vi
Chapter VIII
Index
Eileen M. Welsh
Amyloid Beta (Aβ) Peptides in Plasma as Biochemical Markers of Alzheimer's Disease and Mild Cognitive Impairment Tomasz Sobow, Marcin Flirski, Pawel P. Liberski and Iwona Kloszewska
235
251
Preface Dementia is a brain disorder that seriously affects a person's ability to carry out daily activities. The most common form of dementia among older people is Alzheimer's Disease (AD), which involves the parts of the brain that contol memory, thought and language. Age is the most important known risk factor for AD. The number of people with the disease doubles every 5 years beyond age 65. AD is a slow disease, starting with mild memory loss and ending with severe brain damage. The course the disease takes and how fast changes occur vary from person to person. On average, AD patients live from 8 to 10 years after they are diagnosed, though the disease can last for as many as 20 years. Current research is aimed at understanding why AD occurs and who is at greatest risk for developing it, improving the accuracy of diagnosis and ability to identify who is at risk, developing, discovering and testing new treatments for behavioral problems in patients with AD. This new book gathers state-of-the-art research from leading scientists throughout the world which offers important information on understanding the underlying causes and discovering the most effective treatments for Alzheimer's Disease. The notion that the amyloid-beta (Aβ) peptide plays a role in the pathogenesis of Alzheimer’s disease (AD) has received strong support from in vitro demonstrations that Aβ is toxic to cultured neurones, but its support from in vivo models has been equivocal. In order to understand the reasons for this difference, the authors of chapter I have critically appraised the numerous in vivo studies that have investigated the toxicity of Aβ by injecting or infusing Aβ into the brains of rodents or primates. Taken together, these studies indicate that neuronal loss is not a consistent response to Aβ, yet it does induce subtle changes in neuronal function by altering several neurotransmitter systems, particularly the cholinergic system. Behavioural impairments are evident on spatial and discriminative learning tasks and are paralleled by a reduced capacity to induce LTP. In addition, Aβ induces astrocytic and microglial reactivity which may be associated with increased indices of oxidative stress. The Aβ injection/infusion models have also shown some brain regions to be more susceptible to the neuroactive properties of Aβ than others. The superior spatial and temporal resolution of injection/infusion models allows comparisons of the effects of individual isoforms or fragments of Aβ, and of agents that enhance or reduce the bioactivity of this peptide. They conclude that the Aβ injection/infusion models are a valuable adjunct to transgenic mouse
viii
Eileen M. Welsh
models, and they may help to elucidate the physiological actions of Aβ and further our understanding of the pathogenesis of AD. Phospholipase A2 (PLA2) is a key enzyme in phospholipid metabolism. In the brain, PLA2 is involved in the liberation of membrane choline for acetylcholine synthesis, as well as in the processing of the amyloid precursor protein to form the beta-amyloid, the major component of senile plaques in Alzheimer's disease (AD) as described in chapter II. In previous post-mortem studies the authors reported on decreased PLA2 activity in the frontal and in the parietal cortex of patients with AD, suggesting reduced phospholipid metabolism in the disease. Interestingly, they found also a reduction of PLA2 activity in platelet membranes of AD patients, suggesting that reduced phospholipid turnover may also be observed in peripheral cells of AD patients. In an in vivo study they investigated the intracerebral phospholipid metabolism in 16 patients with probable AD and 18 age-matched controls through 31P-Magnetic Resonance Spectroscopy of the pre-frontal cortex. Cognitive assessment was performed by the CAMDEX schedule. PME resonance was significantly higher and PDE was lower among AD than controls. PME correlated negatively with cognitive performance. Higher PME indicates reduced breakdown of membrane phospholipids, which is in line with reduced PLA2 activity. The findings in the pre-frontal cortex suggest that reduced membrane phospholipid turnover may be a widespread cerebral phenomenon in AD brains, since the pre-frontal cortex is a region not as severely affected by the neurodegenerative process as temporal and parietal areas, specially in early stages of dementia. To investigate further the implications of reduced PLA2 in the neurobiology of AD, they carried out a series of in vitro and animal experiments, to respectively test the effects of the inhibition of PLA2 on neuronal homeostasis in cultured neurons, and in memory formation in rats. In primary cultures of cortical and hippocampal neurons, the inhibition of PLA2 precluded neurite outgrowth, and the sustained inhibition of the enzyme in mature cultures lead to loss of viability. These findings reinforce the involvement of PLA2 enzymes in neurodevelopment and neurodegeneration. In early stages of AD there is an impairment of episodic short-term (STM) and long-term memory (LTM). In rat hippocampal slices, PLA2 has been implicated in mechanisms of synaptic plasticity involved in memory formation. Using adult Wistar rats, we investigated the effects of injections of PLA2 inhibitors into rat hippocampus on the formation of STM and LTM of a one-trial step-down inhibitory avoidance task. Infusion of the PLA2 inhibitors impaired both STM and LTM in a dosedependent manner. Additionally, because memory function is largely dependent on the fluidity of brain membranes, they investigated the effects of in vivo PLA2 inhibition on the fluidity of hippocampal membranes from rats subjected to inhibitory avoidance training. Hippocampal tissue from rats injected with PLA2 inhibitor showed reduced membrane fluidity, and this reduction was highly correlated with PLA2 inhibition. Taken together, the findings suggest that reduced PLA2 activity, probably reducing membrane phospholipids breakdown, may contribute to the memory impairment in AD. Previous studies have shown that apoptosis (programmed cell death) plays a crucial role in the pathomechanism of neurodegenerative disorders. It is a general consensus that apoptosis can be triggered by dysregulation of nerve growth factor physiology and/or oxidative stress processes. As reported in chapter III, since both of these pathological changes are characteristic to AD, it is conceivable that influencing apoptosis can be a valuable tool in
Preface
ix
the treatment of neurodegenerative disorders. Glucosaminoglycans (GAGs) exhibit neuroprotective properties in several animal models of AD. Low molecular weight GAG, C3, attenuates Aβ(25-35)-induced tau-2 immunoreactivity, and AF64A-induced cholinergic lesion in rat brain. Recent studies have also revealed that C3 influences p75 nerve growth factor receptor expression. However, the exact mechanism of the neuroprotective attributes of C3 is not elucidated yet. Since apoptosis is believed to play a pivotal role in numerous neurodegenerative disorders, C3 may induce neuroprotection/neurorepair via affecting apoptotic processes. The neuroprotective effect of glucosaminoglycans including C3 thus may involve multiple mechanisms, including an influence on processes that lead to programmed cell death. Since apoptosis is a crucial event not only in neurodegenerative diseases but also in the general process of aging, C3 may be a valuable therapeutic agent in Alzheimer’s disease-related senile dementia and in other age-related malfunctions. Susceptibility to Alzheimer´s disease (AD) is governed by multiple factors. Remarkably, LDL receptor-related proteins (LRPs) and several of their numerous ligands were associated to AD. Alpha2-macroglobulin (A2M), apolipoprotein E (Apo E), but also amyloid precursor protein (APP) belong to the functionally and genetically interesting molecules involved in the complex degenerative processes resulting in AD as suggested by the findings in chapter IV. LRP1 (CD91) (MIM 107770) is a 4,544-amino acid protein containing a single transmembrane segment and is located on chromosome 12q13.1-12q13.3 within a region shown to be linked to AD. It consists of 84 exons and belongs to the largest human proteins and is highly evolutionary conserved. It could be demonstrated that several genomic variants of LRP1 were associated to AD but also to other degenerative diseases like atherosclerosis and cancer suggesting a complex role in fundamental cellular processes. LRP1 functions as a clearance receptor for several ligands, including amyloid ß (Aß), and mediates signaling pathways affecting the processes of neurite outgrowth and calcium influx. While clearance of Aß diminishes the extracellular Aß-load the interaction with APP may enhance formation of Aß. LRP1 is expressed in brain, blood vessels as well as in endothelial cells of the brainblood-barrier mediating the transcytosis of Aß between blood circulation and brain. Internalization via LRP1 concerns also extracellular proteases and protease-inhibitor complexes involved in Aß degradation. In AD as well as in other diseases genetic variations and structure-caused failure of LRP1 leading to dysfunctions as well as alteration in the expression of LRP1 ligands may determine common degenerative processes. Age-related changes in the level of LRP1 and its ligands may increase the risk for degenerative diseases. The modulation of LRP1 and its ligands by cytokines and growth factors was detected in and outside the brain. There are indications that also inflammatory processes play an important role in the development of degenerative diseases. Alzheimer’s disease (AD) is characterized by a progressive loss of cognitive function with cerebral deposits of amyloid-β (Aβ) senile plaques and neurofibrillary tangles (NFTs) surrounded by inflammatory cells. Neuroinflammation, oxidative stress and impaired glucose and lipid metabolism are postulated to be the mechanisms playing role in the pathophysiology of AD. Recent evidence suggests that inflammatory events are associated with plaque formation in the brains of patients with AD and non-steroid anti-inflammatory drugs (NSAIDs) might influence central nervous system (CNS) inflammation and AD pathology. Reactive oxygen and nitrogen species production may also participate in part to
x
Eileen M. Welsh
neurodegeneration in AD brains; antioxidant and/or free radical scavengers reduce inflammation in AD via free radical quenching and possess neuroprotective activity. In addition, AD patients show hyperinsulinemia and reduced insulin sensitivity during fasting and glucose tolerance tests; and insulin gene polymorphism might act as a modifier of AD progression. An increased number of insulin receptors are also observed in post-mortem brain tissues of AD patients. Furthermore, augmented plasma insulin levels and reduced cerebrospinal fluid (CSF) levels and CSF/plasma insulin ratio are observed in AD patients. Chapter V discusses treatment of insulin resistance may reduce the risk or retard the progression of AD. Peroxisome proliferator-activated receptors (PPARs), members of the nuclear receptor family, are ligand-activated transcription factors. To date, three isoforms, encoded by separated genes, have been identified: PPARα [NR1C1], PPARβ (NUC-1 or PPARδ) [NR1C2] and PPARγ [NR1C3]. All PPAR isotypes are detected and found to exhibit specific patterns of localization in the different areas of the brain. PPARs may have specific functions in regulating the expression of genes involved in neurotransmission, and therefore play roles in complex processes, such as neurodegeneration, learning and memory. It is likely that at least some effects of PPAR agonists and NSAIDs on AD pathology are mediated through PPARs, since both PPARs and cyclooxygenase (COX) expression are increased in AD brains. Recently, NSAIDs, activating PPARα and γ, have been identified. In addition, NSAIDs and PPARα and γ agonists have anti-inflammatory, antioxidant and neuroprotective effects. This neuroprotective effect correlates with the modulation of β-catenin levels, inhibition of glycogen synthase kinase-3β (GSK-3β) activity and increased mRNA levels of the Wnt-target genes engrailed-1, cyclin D1 and PPARδ. Thiazolidinediones (TZDs) such as pioglitazone and rosiglitazone are insulin sensitizers, used to control glucose concentrations in patients with type 2 diabetes. These are potent synthetic PPARγ agonists, which exert both anti-inflammatory and antioxidant effects. PPARα and γ ligands, NSAIDs and TZDs inhibit activation of nuclear factor (NF)-κB, signal transducers and activators of transcription-1 (STAT-1), the nuclear factor of activated T-cells (NFAT) and activating protein-1 (AP-1). Moreover, they prevent the expression of COX-2 and inducible nitric oxide synthase (iNOS) and production of inflammatory cytokines such as interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α in human monocytes and arrest the differentiation of monocytes into activated macrophages. In conclusion, the development of new drugs targeting PPARs would be a great interest for future treatments of AD. Alzheimer’s disease (AD) is characterized by a progressive decline in cognition, memory and intellect. Possible mechanisms for AD neurotoxicity include: alteration in Ca2+ homeostasis, activation of specific receptors affecting cellular homeostasis, activation of oxidative processes, direct disruption of membrane integrity and disorders in lipid metabolism, or a combination of two or more of the above mechanisms. It was established that conformational changes in amyloid-beta peptide (Aβ) may occur in lipid rafts under the control of specific sphingolipids. Chapter VI demonstrates a novel mechanism for development of AD. It has been hypothesized that Aβ and TNF-α may have a prominent role in neurodegeneration. It is well-known that neuronal death is developed according to apoptotic program. Most signaling pathways that trigger apoptosis remain unknown, but the sphingomyelin pathway has been recognized as an ubiquitous signaling system that links specific cell-surface receptors and environmental stresses to the nucleus. This pathway is
Preface
xi
initiated by the hydrolysis of sphingomyelin via the action of sphingomyelinases to generate ceramide. Ceramide then serves as a second messenger in this system, leading to apoptosis. Oxidative mechanisms have been implicated in this pathway. TNF-α activates receptors linked to multiple effector systems, including a sphingomyelin pathway and peroxide oxidation. Recently, it was shown that superoxide radicals are used as signaling molecules within the sphingomyelin pathway. It means that cross-talk between the oxidation system and sphingomyelin cycle exists in cells and could have important implications for the induction phase and evolution of AD. The role of TNF-α in the pathogenesis of AD is unclear, because it has been shown to be involved in both neuroprotection and neurodegeneration, depending on doses and the age of animals. Small doses of this cytokine induced a protective effect against Aβ neurotoxicity. It was suggested that using low doses of TNF-α in the clinic for the prevention of AD development might be a perspective. Identification of the N-SMaseceramide pathway may lead to the development of more effective therapeutic strategies, aimed at preventing Aβ-induced cell death. The study of neurobiology of Alzheimer’s disease, now more than ever, needs an infusion of a new concept. Despite ongoing interest in Alzheimer’s disease, the basis of this entity is not yet clear. For now, the best-established and accepted “culprit” in Alzheimer’s disease pathology by most scientists is the amyloid, as the main molecular factor of neurodegeneration in Alzheimer’s disease. Abnormal upregulation of amyloid production or a disturbed clearance mechanism may lead to pathological accumulation of amyloid in the brain. Chapter VII will critically review these observations and highlight inconsistencies between the predictions of the “amyloid hypothesis” and the published data. There is still controversy over the role of amyloid in the pathological process – is it responsible for the neurodegeneration or does it accumulate because of the neurodegeneration? Recent evidence suggests that the neuropathology of Alzheimer’s disease comprises more than amyloid accumulation, tau protein pathology and finally brain atrophy. At least one third of Alzheimer types of dementia cases exhibit different cerebrovascular diseases. In addition, micro- and macroinfarctions and ischemic white matter changes are also evident in brains of Alzheimer’s disease patients. The presence of vascular abnormalities seems usually ignored and regarded by researchers as insignificant or considered incidental in Alzheimer’s disease etiology. Interestingly, that Alzheimer, in his own report presenting changes in the brain of the first patient had described, that besides “storage of peculiar material in the cortex, one sees endothelial proliferation and also occasionally neovascularisation”. Endothelial proliferation and angiogenesis and moderate arteriosclerosis in the brain arteries of the first case, provide evidence that cerebrovascular diseases were also evident in Alzheimer’s original case, which now defines Alzheimer’s disease. These raise the question of what was the first cerebrovascular disease as trigger of Alzheimer’s disease or neurodegeneration of Alzheimer’s type itself? New findings propose an early and significant role for ischemiareperfusion factors contributing to the neurodegenerative processes in Alzheimer’s disease. The ischemia hypothesis was primarily aimed at stimulating research and redirecting the focus of studies towards ischemic cellular mechanisms of Alzheimer’s disease. In this review, the authors will show that experimental brain ischemia-reperfusion episode produces neurochemical and neuropathological changes that simulate the early stage of Alzheimer’s disease process. Presented data suggest that ischemic mechanisms of neuronal death with β-
xii
Eileen M. Welsh
amyloid peptide from circulatory network modulate neuropathology of cerebral ischemiareperfusion injury via molecular events in common with Alzheimer-type neuropathology. These results indicate that ischemic brain processes might be a key factor in the development of the picture of Alzheimer-type dementia over years. The collective data summarized in this review strongly support the idea that sporadic from of Alzheimer’s disease is a neurovascular disorder. Considerable progress has been made in recent years by a handful of researchers in understanding the role of ischemia in the aging process generally and in contributing to the development of Alzheimer’s disease. To accommodate the recent progress of study in Alzheimer’s disease there is a need to synthesize all the divergent pieces of data into a coherent story. This review provides a synopsis of current information about ischemic cellular and molecular mediators involved in Alzheimer’s neuropathology as well as interactions between these mediators that influence pathology. In this review, current knowledge on the relation between ischemia-reperfusion factors and Alzheimer’s-type dementia will be reviewed. They will summarize the results with a special focus on Alzheimer lesions in experimental brain ischemia. Taken all together, evidence presented in this review suggests a scheme for Alzheimer’s pathogenesis with ischemia-reperfusion playing a crucial role in influencing and linking β-amyloid deposition to neuronal damage and clinical disease. Plasma levels of amyloid β peptides (Aβ) represent a potentially attractive biomarker of Alzheimer’s disease (AD). Although plasma Aβ levels are increased in patients with familial AD mutations, results of the studies encompassing sporadic AD cases are equivocal. In several studies elevated plasma Aβ42 levels could be detected long before the onset of symptoms, though the value of that effect in predicting progression to dementia in mildly cognitively impaired (MCI) subjects is not known. It has recently been proposed that plasma Aβ levels increase merely with age and are neither sensitive nor specific for AD or MCI. Additionally, an increase of Aβ42 plasma levels in women with MCI has been reported and thus suggested to represent a biologic explanation for the increased prevalence of females in the population of late-onset AD patients identified by epidemiologic studies. In chapter VIII the authors have assessed the levels of Aβ peptides in plasma of carefully selected AD patients and MCI subjects compared to healthy controls matched for age, gender and education. The selection procedure employed in the study has been aimed at excluding patients with mixed AD as well as patients fulfilling current diagnostic criteria for both AD and other specific forms of dementia (e.g. dementia with Lewy bodies). No difference in any of the evaluated parameters (Aβ40, Aβ42, Aβ40/Aβ42 ratio) was observed between the AD and control groups. In subjects with MCI plasma Aβ42 levels were significantly elevated versus both AD (p<0,001) and controls (p<0,001), whereas Aβ40 concentrations were not significantly altered; no correlation with age or gender was found. A hypothesis can be formulated that the elevation of plasma Aβ42 in MCI is a reflection of efforts to eliminate the pathological peptide from the central nervous system (CNS) through the yet viable bloodbrain barrier (BBB). It is therefore probable that in a very early stage of AD alterations in the catabolism of a β-amyloid precursor protein (βAPP) occur, resulting in a preferential synthesis of longer, more amyloidogenic isoform of Aβ peptide - Aβ42; Aβ42 is initially effectively removed via the BBB which brings about a gradual increase in plasma Aβ42, but
Preface
xiii
not Aβ40, still competently transported backwards. The results of the study, indicating an elevation of Aβ42, but not Aβ40 in MCI subjects, would support this hypothesis.
In: New Research on Alzheimer’s Disease Editor: Eileen M. Welsh, pp. 1-55
ISBN 1-59454-939-7 © 2006 Nova Science Publishers, Inc.
Chapter I
Insights on Alzheimer’s Disease from the Intracerebral Injection and Infusion of Amyloid-β Glenda M. Bishop∗ and Stephen R. Robinson School of Psychology, Psychiatry and Psychological Medicine, Monash University, Victoria, Australia
Abstract The notion that the amyloid-beta (Aβ) peptide plays a role in the pathogenesis of Alzheimer’s disease (AD) has received strong support from in vitro demonstrations that Aβ is toxic to cultured neurones, but its support from in vivo models has been equivocal. In order to understand the reasons for this difference, we have critically appraised the numerous in vivo studies that have investigated the toxicity of Aβ by injecting or infusing Aβ into the brains of rodents or primates. Taken together, these studies indicate that neuronal loss is not a consistent response to Aβ, yet it does induce subtle changes in neuronal function by altering several neurotransmitter systems, particularly the cholinergic system. Behavioural impairments are evident on spatial and discriminative learning tasks and are paralleled by a reduced capacity to induce LTP. In addition, Aβ induces astrocytic and microglial reactivity which may be associated with increased indices of oxidative stress. The Aβ injection/infusion models have also shown some brain regions to be more susceptible to the neuroactive properties of Aβ than others. The superior spatial and temporal resolution of injection/infusion models allows comparisons of the effects of individual isoforms or fragments of Aβ, and of agents that enhance or reduce the bioactivity of this peptide. We conclude that the Aβ injection/infusion models
∗
Corresponding Author: Glenda Bishop, School of Psychology, Psychiatry and Psychological Medicine, Monash University, Wellington Road, Clayton VIC 3800 Australia. Tel: 61-3-990-54565; Fax: 61-3990-53948; Email:
[email protected]
Glenda M. Bishop and Stephen R. Robinson
2
are a valuable adjunct to transgenic mouse models, and they may help to elucidate the physiological actions of Aβ and further our understanding of the pathogenesis of AD.
Abbreviations ACh: AChE: AD: Alz50: Am: Aβ: ATCtx: A/TFA: BS: CD68: ChAT: CR: CSF: Ctx: DβH: ED1: ELISA: EM: FCtx: GFAP: GPx: H and E: HFS: Hipp: IL-1β: Immuno: iNOS: LTP: LTD: MAP-2: MNB: NA: NB: NE: Nissl: nNOS: NOS: OX-42:
acetylcholine; acetylcholinesterase; Alzheimer’s disease; antibody that recognises abnormally phosphorylated tau; amygdala; amyloid-β; anterior temporal cortex; acetonitrile plus trifluoacetic acid; Bielschowsky silver; factor expressed by microglia; choline acetyltransferase; Congo red; cerebrospinal fluid; cerebral cortex; dopamine β-hydroxylase; antibody that recognises microglia and macrophages; enzyme-linked immunosorbent assay; electron microscopy; frontal cortex; glial fibrillary acidic protein, an astrocytic protein; glutathione peroxidase; haematoxylin and eosin; high-frequency stimulation; hippocampus; interleukin-1β (cytokine expressed by microglia); immunohistochemical labelling; inducible nitric oxide synthase; long-term potentiation; long-term depression; microtubule-associated protein type 2 (expressed in neuronal dendrites); magnocellular layer of the nucleus basalis; nucleus accumbens; nucleus basalis; norepinephrine; a cell stain that labels ribosomes and DNA; neuronal nitric oxide synthase; nitric oxide synthase; a specific antibody clone that recognises CD11b in activated microglia;
Insights on Alzheimer’s Disease from the Intracerebral Injection and Infusion … OX-6: PCtx: PHF: revAβ: ROS: scrAβ: SI: SOD: Th-T: ThS: TUNEL: VEGF: VP: WB:
3
a specific antibody clone that recognises MHC Class II in microglia; parietal cortex; paired helical filament; reverse sequence of Aβ peptide; reactive oxygen species; scrambled sequence of Aβ peptide; substantia innominata; superoxide dismutase; Thioflavin-T; thioflavin-S; terminal deoxynucleotide transferase (TdT)-mediated dUTP-biotin nick end labelling (marker of apoptosis); vascular endothelial growth factor; ventral pallidum; Western blot.
Introduction The brains of patients with Alzheimer’s disease (AD) are characterised by neurodegeneration, the presence of neurofibrillary tangles and the accumulation of senile plaques, which are extracellular deposits composed largely of the amyloid-β (Aβ) peptide. Aβ is a 39-43 amino acid peptide that is naturally produced by the brain; the most commonly detected variants are Aβ1-40 and Aβ1-42. Aβ is normally dissolved in the extracellular fluid of the brain and cerebrospinal fluid (CSF), but under certain circumstances it forms into small fibrils which adopt a β-sheet formation, that precipitate out of solution as fibrillar aggregates and are deposited extracellularly into plaques. The aggregation process of Aβ is one of the mechanisms believed to underpin the neurodegeneration in AD. Since the Aβ peptide was sequenced in the early 1980s [Glenner and Wong, 1984; Masters et al., 1985], the aggregation of Aβ and its effects on brain cells have been studied extensively in vitro. These studies have contributed to the prevailing view that Aβ is toxic to neurones [e.g. Pike et al., 1992; Roher et al., 1991], particularly when in a fibrillar state [Hartley et al., 1999; Pike et al., 1991]. Aβ toxicity has been conjectured to be due to the generation of free radicals which lead to oxidative damage [e.g. Harris et al., 1995], the influx of calcium via the formation of membrane-spanning channels [e.g. Durell et al., 1994], the potentiation of neuronal excitotoxicity [e.g. Koh et al., 1990], and the release of neurotoxic agents from activated microglia [e.g. Giulian et al., 1996]. The data obtained from in vitro studies have provided useful information regarding the mechanisms of Aβ toxicity and how this may relate to the pathology of AD. Their physiological relevance is limited however, by the necessary use of simplified conditions which employ neuronal cultures obtained from neonatal animals or cancerous cell lines. Such cultures differ greatly from the intact adult brain where the interactions between different neural cell types permit an integrated response to a potentially toxic agent.
4
Glenda M. Bishop and Stephen R. Robinson
Another way to assess the effects of Aβ on the living brain is to utilise transgenic mice that overexpress mutant forms of the human Aβ precursor protein (APP) which are associated with familial cases of AD [e.g. Games et al., 1995; Hsiao et al., 1996]. In these mice, Aβ plaques begin to deposit around 4 months of age, gradually increasing in number until they occupy up to 30% of the cortical and hippocampal volume when the mice are 18 months old [Games et al., 1995; Schenk et al., 1999]. While much emphasis has been put on the value of these transgenic models, they are limited with respect to the information they can provide about the spatio-temporal relationships between Aβ deposition and neuronal and cognitive dysfunction. This is because while the average Aβ deposition rate in a transgenic line can be determined, the exact time and location of individual deposits cannot be known. Thus there is a need for other in vivo models that can examine the effects of Aβ on specific brain regions in a time-dependent manner. In vivo models have been developed that either inject or infuse synthetic human Aβ variants into specific brain regions. For discrete microinjections, a small burr hole is drilled in the skull and a fine-tipped bevelled needle is used to inject the Aβ solution into the desired brain region. For infusion studies, a cannula is inserted into the brain and then attached via synthetic tubing to a subcutaneously-implanted mini-osmotic pump that contains the Aβ solution, allowing continual infusion of Aβ into the brain. To control for potential toxicity of the solvent that the Aβ is dissolved in, as well as the unavoidable mechanical damage of the injection procedure, control injections are given in the contralateral hemisphere or in a control group of animals. The brain is usually analysed to determine whether Aβ was deposited at the site of injection, and is then assessed for neuronal degeneration. Alternatively the brain is assessed for inflammatory responses, specific neuronal markers, or other markers that may be affected by Aβ. Table 1. Comparison of the features of transgenic and injection/infusion models of AD. Transgenic mouse models of AD No direct tissue damage Physiological Aβ deposition due to up-regulation of genes Allows investigations of chronic Aβ deposition, but has little temporal resolution Has global effects rather than local target Allows intracellular Aβ deposition No control over the contaminants present in plaques Involves overexpression of mutant genes (not physiological) Effects of genes are present throughout development Promoter is present in specific cell types and regions – biases outcome Only possible in rodents, which have different Aβ sequence and a limited cognitive capacity
Aβ injection or infusion models Tissue damage (solvent, needle, etc) Non-physiological deposition of Aβ, primarily as a bolus Allows acute investigations of Aβ deposition with high temporal resolution Local effects rather than global target (spatial resolution) Aβ treatment is exclusively extracellular Allows Aβ to be co-injected or co-infused with other agents Allows comparison of specific Aβ isoforms Allows specific ages to be targeted after normal brain maturation Can equally affect all cells in the vicinity Possible in all species including primates
Insights on Alzheimer’s Disease from the Intracerebral Injection and Infusion …
5
The main advantages of injection/infusion in vivo models (see Table 1) include the spatial resolution of Aβ deposition, the temporal resolution after Aβ deposition, and the ability to examine specific Aβ isoforms. By contrast, transgenic mouse models have the advantage of being non-invasive, Aβ accumulates both extracellularly and intracellularly in their brains, and they have a slow but chronic build-up of Aβ. Clearly each model has its own strengths, and their advantages are complementary. More than 180 in vivo studies have assessed the actions of Aβ that has been delivered to a specific region of the brain, potentially allowing for an investigation of spatio-temporal effects. However, no consensus has yet been reached concerning whether Aβ delivered in this way is toxic to living brain tissue. The purpose of this chapter is to search for trends among these studies, to review correlations between the results obtained by researchers using similar protocols, to gain a better understanding of the reason for the variations, and to achieve a greater appreciation of the effects that Aβ has on the living brain.
Critical Analysis of the in vivo Studies: Selection Criteria The published literature was searched using the PubMed website (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed) to find primary data papers that had either injected or infused Aβ into the brains of animals. There were five primary criteria that had to be met for inclusion in this review: (1) the research paper had to be published in English; (2) the animals used had to be of a wild-type strain which was readily available, had not been genetically modified and had not been put under experimental stress; (3) the Aβ that was injected or infused had to be in a pure form (not mixed with a carrier or co-injected with another substance; these studies are discussed at the end of this chapter); (4) an appropriate control must have been used to compare the effects of Aβ, such as a vehicle control or a control peptide. Occasionally studies were found that did not include such controls, normally because they had examined the effects of Aβ in previous work and in the new study chose to make comparisons between pure Aβ and co-injections of Aβ with another substance [e.g. Takata et al., 2003], thus assuming consistency with previous experimental work; and (5) the study had to assess the effects of Aβ, not simply measure the deposition and clearance of the peptide after injection. These criteria enabled us to identify 146 papers published from 1991 to 2005, with approximately 20 papers published each year from 2001 onwards (Figure 1). The primary purpose of most studies was to determine whether Aβ was toxic to the living brain, but the measure of ‘toxicity’ varied considerably and could be broadly grouped into 7 categories: (1) neuronal degeneration, determined primarily by histological stains that detect dead or living neurones (Tables 2A-D); (2) changes in neuronal subpopulations, determined primarily by examining the expression or activity of neurotransmitter-related enzymes or markers (Tables 3A and 3B); (3) induction of gliosis using markers of activated astrocytes and microglia (Tables 4A-D); (4) behavioural changes (Tables 5A and 5B); (5) changes in normal synaptic function, generally determined from electrophysiological recordings (Tables 6A and 6B); (6) indices of oxidative stress (Tables 7A and 7B); and (7) miscellaneous
Glenda M. Bishop and Stephen R. Robinson
6
expression of cytokines, growth factors, cell-signalling molecules and hormones (Tables 8A and 8B). When studies performed multiple investigations, they were assigned to several categories. For instance, a paper may have examined neuronal death, changes in neurotransmitter expression and behavioural changes. 22
Number of published studies
20 18 16 14 12 10 8 6 4 2
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
0
Year of Publication Figure 1. Published studies. Distribution of the published studies that met the criteria for inclusion in the present review, listed according to the year of publication.
Each of the tables include information about the species used, Aβ sequence, the use of a physiological solvent, the type of controls, the site of injection or infusion, whether Aβ deposition was analysed and the specific type of analysis that was performed. The analysis was described in terms of the quantitative or qualitative assay that was used. In recent years much emphasis has been placed on the influence of the secondary structure of Aβ on toxicity, yet there is a lack of agreement concerning the best way to encourage Aβ to assume a desired conformation. Furthermore, the terms ‘fibrillar’ and ‘aggregated’ are often applied differently by researchers, such that an aggregated preparation of Aβ generated by one researcher may have more or less fibrils than that generated by another researcher. For this reason, the secondary structure of Aβ was not defined in the summary tables, except in two cases where different secondary structures were examined and opposing results were observed for the two preparations [Geula et al., 1998; Weldon et al., 1998]. The summary tables show that an extraordinary degree of methodological variability exists.
Table 2A. Injection of Aβ induces neuronal degeneration. Physiological solvent?
Controls
Site of injection
Assay to detect Aβ
Type of analysis
Aβ25-35 Aβ25-35, Aβ142 Aβ25-35 Aβ25-35 Aβ1-40
N N
revAβ25-35 Vehicle
CA1 Right Am
None None
Nissl-qualitative Tau-2; tau protein levels
N N N
Hipp Right Am FCtx/Hipp, PCtx/Hipp
None None None
Nissl-qualitative Tau-2 cell counts in Hipp Nissl-lesion area
Y
FCtx, PCtx, ATCx
Aβ immuno
Nissl-lesion area; phosphorylated tau
rabbit
Aβ40, Aβ42 (fibrillar) Aβ1-42
Vehicle Vehicle Vehicle, revAβ1-40 Vehicle
Y
Vehicle
Cistern
None
Ghribi et al., 2003*
rabbit
Aβ1-42
Y
Vehicle
Cistern
None
Ghribi et al., 2004*
rabbit
Aβ1-42
Y
Vehicle
Cistern
None
rat young/old rat
Aβ1-40
N
Aβ1-40
Y
WB for apoptosis signals (Bcl-2, caspase cleavage) WB for apoptosis signals (Bcl-2, Bax, caspase cleavage) WB for apoptosis signals (caspase cleavage), tau phosphorylation; TUNELcell counts Nissl-living neurons (3×0.64µm2 sections); Alz50 Nissl-qualitative
rat
Aβ1-42
Y
rat
Aβ1-40, Aβ142 Aβ1-40
Y
Reference
Species
Aβ sequence
Bhagat et al., 2002 Chambers et al., 2000
rat rat
Chen et al., 1996 Dudas et al., 2002 Emre et al., 1992
rat rat rat
Geula et al., 1998*
monkey old
Ghribi et al., 2001*
Giordano et al., 1994 Gonzalo-Ruiz et al., 2003* Jantaratnotai et al., 2003* Jen et al., 1998* Kowall et al., 1991 Kowall et al., 1992
rat
rat, monkey Aβ1-40, Aβ25young/old 35
Vehicle, saline, FCtx revAβ1-40 Vehicle Retrosplenial granular Ctx Vehicle, Corpus callosum revAβ1-42 Vehicle Vitreous chamber
None Aβ immuno Aβ immuno None
N
revAβ1-40
Deep FCtx, or Hipp
Aβ immuno
N
revAβ1-40, scrAβ1-40
Deep Ctx; FCtx
Aβ immuno
Neurofilament medium subunit-fibre density; Luxol Fast Blue-demyelination Number of TUNEL positive-cells in retina Nissl-living neurons (3×0.64µm2 sections); Alz50, Gallays, tau Nissl-living neurons (3×0.64µm2 sections); Alz50, tau
Table 2A. Injection of Aβ induces neuronal degeneration. (Continued) Species
Aβ sequence
Physiological solvent?
rat
Aβ1-40
N
mice rat
Aβ25-35, Aβ1-28 Aβ1-40
Reyes et al., 2004*
rat
Rush et al., 1992
Reference
Controls
Site of injection
N N
Vehicle, revAβ1-42 Vehicle Vehicle
Hipp, 7 injections bilaterally Right ventricle ICV
Y
Vehicle
rat
Aβ1-40, RatAβ140 Aβ1-40, Aβ25-35
N
Vehicle
Dentate gyrus bilateral Dorsal Hipp
Ryu et al., 2004* Sigurdsson et al., 1996
rat rat
Aβ1-42 Aβ25-35
Y N
Right Hipp Right Am
Sigurdsson et al., 1997a Sigurdsson et al., 1997b Sigurdsson et al., 2000
rat
Aβ25-35
N
rat
Aβ25-35
N
revAβ1-42 Vehicle, revAβ25-35 Vehicle, revAβ25-35 Vehicle
rat
Aβ1-42
N
Vehicle
Am bilateral
Stepanichev et al., 2003b Stepanichev et al., 2004 Stephan et al., 2001
rat
Aβ25-35
N
Vehicle
Hipp
rat
Aβ25-35
N
Vehicle
ICV bilateral
rat
Aβ40+Aβ43
N
Vehicle
Stephan et al., 2003
rat
Aβ40+Aβ43
N
Vehicle
mouse
Aβ25-35
N
Saline, revAβ25-35
Dentate gyrus, 8 bilateral injections Dentate gyrus, 8 bilateral injections Right ventricle
Malin et al., 2001 Maurice et al., 1996 Minogue et al., 2003
Tohda et al., 2003
Am Am
Assay to detect Aβ
Type of analysis
Aβ immuno
Nissl-semi-quantitative
CR None
Nissl-Hipp living neurons in 5000µm2 Levels of Bax, cytochrome c, PARP, FasL (apoptosis) Nissl-living neurons
Aβ immuno, CR, ThS None Nissl-area of tissue loss, area of neuronal loss, total area of damage None NeuN-cell counts None Nissl-qualitative, neuronal size; tau-2, Alz50 CR Nissl-neuronal size; tau-2-cell counts in 6 sections CR Nissl-neuronal size; tau-2-cell counts in 6 sections Aβ immuno, Nissl-neuronal size CR None Nissl-area of degeneration; TUNELqualitative; caspase-3 activity None H&E-living neuron counts Aβ immuno, ThS Aβ immuno, ThS None
Nissl and NeuN-qualitative Nissl-qualitative Nissl-neuron density
Table 2A. Injection of Aβ induces neuronal degeneration. (Continued) Reference
Physiological solvent?
Species
Aβ sequence
Waite et al., 1992
rat
N
Walsh et al., 2002*
rat
Aβ1-40, Aβ1-42, RatAβ1-42 Aβ1-42
Walzer et al., 2002 Whitehead et al., 2005 Yagami et al., 2004*
rat rat rat
Aβ25-35 Aβ25-35 Aβ25-35, Aβ140, Aβ1-42
N Y Y
Zou et al., 2003
rat
Aβ1-42
N
Y
Controls
Site of injection
Vehicle, revAβ1-40 Vehicle, revAβ1-42 Vehicle Vehicle Vehicle, scrAβ25-35, revAβ25-35 PBS
Hipp
Assay to detect Aβ
Type of analysis
Right Am ICV bilateral Striatum
Aβ immuno, ThS Fluoresceintagged Aβ CR CR None
Number of TUNEL positive-cells and Nissl-stained cells in retina Tau-2 cell counts Tau-2 cell counts Nissl-area of degeneration
Entorhinal Ctx
CR
Tau phosphorylation (WB)
Vitreous chamber
Nissl-qualitative
Table 2B. Injection of Aβ does not induce neuronal degeneration Reference
Aβ25-35
*
rat
*
rat
Aβ1-40, Aβ1-42, RatAβ1-40 Aβ1-42, RatAβ1-42 Aβ1-42 Aβ1-43, Aβ1-40
N
Aβ25-35 Aβ1-40, Aβ1-38, Aβ25-35
Y Y or N
Bishop & Robinson, 2003b
Bishop & Robinson, 2004 Clemens & Stephenson, 1992
Games et al., 1992
*
Y
rat
Bishop & Robinson, 2003a
Dornan et al., 1993
revAβ25-35
Aβ sequence
Arias et al., 2002
*
Physiological solvent? Y
Species
rat rat young/ middle aged rat rat
Controls
Site of injection Assay to detect Aβ
Type of analysis
None
Nissl-lesion size
Vehicle
Hipp (dentate gyrus) Ctx
Aβ immuno, EM
Fluoro-Jade-total counts
Y
Vehicle
Ctx
Aβ immuno, EM
Fluoro-Jade-total counts
Y
Vehicle
Ctx
Aβ immuno
Fluoro-Jade-total counts
Aβ immuno
Nissl, H&E-qualitative lesion size; Alz50 Nissl-qualitative lesion size H&E-qualitative; BS Gallays, phosphorylated neurofilament, tau, Alz50
Prolactin in vehicle, Striatum, dorsal scrAβ1-40 Hipp Vehicle Hipp bilateral Vehicle, scrAβ1-40, Ctx or Hipp revAβ1-40, revAβ25 -35, scrAβ25-35
CR Aβ immuno, CR
Table 2B. Injection of Aβ does not induce neuronal degeneration. (Continued) Physiological solvent? rat young/old, Aβ40, Aβ42 (fibrillar Y monkey young or soluble) rat Aβ25-35, Aβ1-40 N rat Aβ1-40 N rat Aβ1-28 N
Reference Geula et al., 1998
Species
*
Giovannelli et al., 1995 Giovannelli et al., 1998 Miguel-Hidalgo et al., 1998
Aβ sequence
Controls
Site of injection
Vehicle Saline, scrAβ25-35 Saline Vehicle
FCtx, PCtx, ATCx Right NB Right NB Right Hipp
Vehicle, revAβ1-40
Hipp
Assay to detect Aβ Aβ immuno
Nissl-lesion area; phosphorylated tau
rat
Aβ25-35, Aβ1-40
rat
Aβ1-40
Y
Vehicle
Hipp
None
Nissl-qualitative lesion size Nissl-total neuronal counts in NB Haematoxylin, MAP2-lateromedial extension of neuronal loss Nissl, H&E-volume of depleted Hipp neurons; MAP-2, TUNEL Nissl-area of degeneration
rat
Aβ1-42
Y
Vehicle
Right ventricle
Aβ immuno, CR
H&E, Bodian’s stain-qualitative
Podlisny et al., 1992
sheep monkey
Aβ1-40 Aβ1-40, Aβ25-35
N Y or N
Vehicle Vehicle, revAβ1-40, scrAβ1-40, scrAβ25-35
Ctx Ctx
Aβ immuno Aβ immuno
Podlisny et al., 1993
monkey
Aβ1-40, Aβ25-35
Y or N
Vehicle, revAβ1-40, scrAβ1-40, scrAβ25-35
Ctx
Sigurdsson et al., 1995 Smyth et al., 1994 Soto et al., 1998
rat rat rat
Aβ25-35 Aβ1-42, Aβ25-35 Aβ1-42
Y or N N N
Vehicle Vehicle, scrAβ25-35 Vehicle
VP/SI Hipp Am
Stein-Behrens et al., 1992
rat
Aβ25-35
Y or N
Vehicle, scrAβ25-35
Stephenson & Clemens, 1992
rat
Aβ1-43
N
Prolactin in vehicle
rat
Y
Vehicle, revAβ1-40
rat
Aβ1-40, Aβ1-42, RatAβ1-42 RatAβ1-42
Y
Vehicle
rat
Aβ1-42+Aβ1-40
N
PBS
Morimoto et al., 1998
*
Morimoto & Oda, 2003
*
*
Nakagawa et al., 2004 Nelson & Saper, 1996 *
*
Waite et al., 1992
Winkler et al., 1994 *
Zou et al., 2003
*
Y
CR CR, EM None
Type of analysis
Aβ immuno, CR
Alz50, tau-qualitative dystrophic neurites H&E-lesion width, neuronal cell counts; tau, BS, Alz50, phosphorylated neurofilament Aβ immuno H&E-lesion width, neuronal cell counts; tau, BS, Alz50, phosphorylated neurofilament CR Nissl-size of cavitation Aβ immuno Nissl-lesion volume Aβ immuno, CR, Nissl-gross level description ThS, EM None Nissl-area/volume of damage
Hipp (dentate gyrus) Corpus striatum, Aβ immuno Nissl, H&E-semiquantitation of neuronal dorsal Hipp damage; BS Hipp Aβ immuno, ThS Nissl-qualitative CA1 or lateral ventricle Entorhinal Ctx
Aβ immuno
Nissl-qualitative extent of reaction
CR
Tau phosphorylation (WB)
Table 2C. Infusion of Aβ induces neuronal degeneration. Reference
Physiological solvent?
Species
Aβ sequence
rat
Y
Aguado-Llera et al., 2005 Frautschy et al., 1998*
rat
Aβ25-35, Aβ142 Aβ40
N
Nakamura et al., 2001*
rat
Aβ1-42
N
Wang et al., 2001*
rat
Aβ1-40
N
Controls
Site of infusion
Assay to detect Aβ
Type of analysis
Saline, revAβ2535 Vehicle
Right ventricle
None
Cell death detection ELISA kit
Ventricle
Aβ immuno. CR, ThS
Vehicle, revAβ140 Vehicle
Right ventricle
None
TUNEL cells in four fields in frontal cortex; phosphorylated tau Nissl-qualitative
Left ventricle, 3 injections over 8 days
CR
H&E, EM, TUNEL-qualitative; Bax, P53, Bcl-2 immunoquantitative
Table 2D. Infusion of Aβ does not induce neuronal degeneration. Species
Aβ sequence
Physiological solvent?
Controls
Site of infusion
Brining et al., 1996*
rat
Aβ1-40
N
Vehicle
Ventricle
Games et al., 1992*
rat
N
rat
N
Vehicle, aCSF, revAβ1-40 Vehicle
Hipp
Nag et al., 1999*
Aβ1-40, Aβ138, Aβ25-35 Aβ1-40
Nitta et al., 1997* Snow et al., 1994*
rat rat
Aβ1-40 Aβ1-40
N N
Vehicle Vehicle, saline
Reference
Left or right ventricle Right ventricle Hipp
Assay to detect Aβ
Aβ immuno, ThS Aβ immuno, CR Aβ immuno
Type of analysis
Silver staining – qualitative H&E, Gallays silver, Alz50, BS-qualitative Nissl-gross observations
None Nissl-gross observations Aβ immuno, BS/Nissl-neuron counts; Alz50CR, ThS intensity
Table 3A. Effect of Aβ injection on neuronal subpopulations. Controls
Site of injection
Assay to detect Aβ
Medial septum
CR
N Y N
Vehicle, scrAβ2535 Contralateral MNB Saline Vehicle
Right MNB ICV Right Am
None None None
Aβ1-40
N
Vehicle, revAβ1-40
None
rat
Aβ25-35, Aβ1-40
N
Giovannelli et al., 1998
rat
Aβ1-40
N
Contralateral NB, saline, scrAβ25-35 Saline
FCtx/Hipp, PCtx/Hipp Right NB Right NB
CR, EM
Giovannini et al., 2002
rat
Aβ1-42
N
Saline
Right NBM
Aβ, CR
Gonzalo-Ruiz et al., 2003* Gonzalo-Ruiz et al., 2005* Harkany et al., 1995a Harkany et al., 1995b Harkany et al., 1999a Harkany et al., 1999b Harkany et al., 2000 Harkany et al., 2001 Li et al., 2004a* O'Mahony et al., 1998
rat
Aβ1-40
Y
Vehicle
Aβ immuno
rat
Aβ1-40
Y
Vehicle
Aβ immuno
Decreased AChE fibre density
rat rat rat rat rat rat rat rat
Aβ1-42 Aβ1-42 Aβ1-42 Aβ1-42 Aβ1-42, Aβ25-35 Aβ1-42 Aβ1-40 Aβ1-42, Aβ25-35
N N N N N N Y N
Vehicle Vehicle Vehicle Vehicle Vehicle Vehicle Vehicle Vehicle
Retrosplenial granular Ctx FCtx or cingulate Ctx Medial septum Right MNB Right MNB Right MNB Right MNB MNB Hipp bilateral Right MNB
Decreased ACh release (in vivo), and ChAT cell count Decreased ACh release (in vivo), and ChAT cell count in NB Decreased ChAT immuno, and ACh release by K+ Decreased ChAT neurones (cell counts)
None None None None None None None ThS
Decreased ChAT immuno cell count Decreased AChE and ChAT activity in FCtx Decreased AChE fibre density in Ctx Decreased AChE and ChAT activity Decreased AChE fibre density Decreased AChE fibre density Decreased AChE fibre density Decreased AChE fibre density
Reference
Species
Aβ sequence
Cholinergic System Abe et al., 1991
rat
Abraham et al., 2000 Choi et al., 2001* Dudas et al., 2002
rat mouse rat
Aβ12-28, Aβ2535, Aβ1-40 Aβ1-42 Aβ1-42 Aβ25-35
Emre et al., 1992
rat
Giovannelli et al., 1995
Physiological solvent?
N
CR
Type of analysis
Decreased ACh release (in vivo); unchanged ChAT assay Decreased AChE fibres Unchanged ACh levels Unchanged ChAT immuno cell count in Hipp, and ChAT and AChE activity in Hipp Decreased number of AChE cells
Table 3A. Effect of Aβ injection on neuronal subpopulations. (Continued) Reference
Species
Aβ sequence
Physiologic al solvent?
Scali et al., 1999 Sigurdsson et al., 1995 Sigurdsson et al., 1997a
rat rat rat
Aβ1-40 Aβ25-35 Aβ25-35
N Y or N N
Yamaguchi & Kawashima, 2001 Yamaguchi et al., 2002
rat
Aβ25-35
rat
Yan et al., 2001* Winkler et al., 1994* Noradrenergic System Chen et al., 1996 Emre et al., 1992 Gonzalo-Ruiz et al., 2003* Song et al., 2001* Serotonergic System Chen et al., 1996 Gonzalo-Ruiz et al., 2003 Harkany et al., 2001
Controls
Site of injection
Assay to detect Aβ
Type of analysis
Right NB VP/SI Am
CR CR CR
Decreased Ach levels Unchanged ChAT activity Unchanged ChAT activity
N
Saline Vehicle Vehicle, revAβ2535 Vehicle
Left ventricle
None
Aβ25-35
N
Vehicle
Left ventricle
None
mice rat
Aβ1-42 RatAβ1-42
Y Y
revAβ1-42 Vehicle
ICV CA1 or lateral ventricle
None Aβ immuno
Decreased ChAT activity, and ChAT cell counts Decreased ChAT activity, and ChAT cell counts Decreased Ach levels Unchanged ChAT activity in Hipp
rat rat
Aβ25-35 Aβ1-40
N N
Increased levels of NE in locus coeruleus Decreased number of DβH cells
Aβ1-40
Y
Aβ immuno
Decreased DβH neurones (cell counts)
mouse
Aβ1-42, Aβ1-40, Aβ25-35, Aβ1-28
Y
Vehicle, revAβ142
Hipp FCtx/Hipp, PCtx/Hipp Retrosplenial granular Ctx ICV
None None
rat
Vehicle Vehicle, revAβ140 Vehicle
None
Increased NE turnover
rat
Aβ25-35
N
Vehicle
Hipp
None
rat
Aβ1-40
Y
Vehicle
Aβ immuno
rat
Aβ1-42
N
Vehicle
Retrosplenial granular Ctx MNB
Increased levels of 5-HT and 5-HIAA in locus coeruleus Decreased 5-HT neurones (cell counts)
None
Decreased 5-HT fibre density, levels of 5-HT and 5-HIAA levels, and 5-HT1A receptor binding sites
Table 3A. Effect of Aβ injection on neuronal subpopulations. (Continued) Reference
Species
Amino Acid Transmitters Harkany et al., 1999a rat
Aβ sequence
Physiologic al solvent?
Controls
Site of injection
Assay to detect Aβ
Aβ1-42
N
Vehicle
Right MNB
None
Harkany et al., 2000
rat
Aβ1-42, Aβ25-35
N
Vehicle
Right MNB
None
Scali et al., 1999
rat
Aβ1-40
N
Saline
Right NB
CR
Neuropeptides Yamamoto et al., 2003
rat
Aβ25-35
Y
Vehicle
NBM bilateral
None
Interneurones Harkany et al., 1995a
rat
Aβ1-42
N
Vehicle
None
Li et al., 2004a* O'Mahony et al., 1998
rat rat
Aβ1-40 Aβ1-42, Aβ25-35
Y N
Vehicle Vehicle
Medial septum Hipp bilateral Right MNB
Walsh et al., 2002*
rat
Aβ1-42
Y
Vehicle, revAβ142
Vitreous chamber
Type of analysis
Increased levels of glutamate, aspartate and taurine Increased levels of Ca2+, taurine, aspartate and glutamate in vivo Unchanged glutamate, aspartate, taurine levels in PCtx; increased GABA levels; decreased glutamic acid decarboxylase activity in PCtx Decreased somatostatin and proSS mRNA; increased cholecystokinin, unchanged proCCK mRNA; unchanged substance P; increased activity of neuropeptide-degrading enzyme PEP but EP24.15, PSA, LAP and APB are unchanged; increased neuropeptide-processing enzymes SPC and PAM but CPE is unchanged
Unchanged parvalbumin immuno-total cell count in MS None Decreased nNOS cell counts & WB ThS Increased NADPH-diaphorase immuno intensity (in nNOS neurons) and nNOS-activity Fluorescein- Decreased number of parvalbumin-positive cells tagged Aβ
Table 3B. Effect of Aβ infusion on neuronal subpopulations. Species
Aβ sequence
Physiological solvent?
Controls
Site of infusion
Assay to detect Aβ
rat (infant, adult, or aged)
Aβ1-40
N
Vehicle
Right ventricle
None
Itoh et al., 1996*
rat
Aβ1-40
N
Vehicle
Left ventricle
None
Nabeshima & Nitta, 1994* Nag et al., 1999*
rat
Aβ1-40
N
Vehicle
Left ventricle
None
rat
Aβ1-40
N
Vehicle
Nag & Tang, 2001*
rat
Aβ1-40
N
Vehicle
Nakamura et al., 2001*
rat
Aβ1-42
N
Nitta et al., 1994* Nitta et al., 1997* Olariu et al., 2001
rat rat rat
Aβ1-40 Aβ1-40 Aβ25-35
N N N
Vehicle, revAβ1-40 Vehicle Vehicle Vehicle
Left or right Aβ immuno ventricle Left or right None ventricle Right ventricle None
Pavia et al., 2000
rat
N
scrAβ25-35
Right ventricle
None
Saez-Valero et al., 2002 Tanaka et al., 1998* Tang et al., 2002*
rat
A/TFA then Aβ25-35 A/TFA then Aβ25-35 Aβ1-40 Aβ1-40
N
scrAβ25-35
Right ventricle
None
N N
Vehicle Vehicle
Right ventricle Ventricle
None None
Reference
Cholinergic System Fukuta et al., 2001*
rat rat
Left ventricle Aβ immuno Right ventricle None Right ventricle None
Type of analysis
Decreased ChAT activity in adult rats; unchanged ChAT activity in infant and aged rats. Decreased release of ACh by nicotine or K+ (dialysis) Decreased ChAT activity; unchanged AChE activity Decreased ChAT activity Decreased ChAT activity Decreased ChAT activity and hemicholinium-3 binding Decreased ChAT activity Decreased ChAT activity Decreased ACh release by nicotine (dialysis) Increased AChE immuno-cell counts; unchanged ChAT activity Altered AChE isoform ratio; unchanged AChE activity Unchanged ChAT activity Decreased ChAT activity
Table 3B. Effect of Aβ infusion on neuronal subpopulations. (Continued) Controls
Site of infusion
Assay to detect Aβ
N
Vehicle, revAβ1-40
Right ventricle
None
Decreased ACh release by nicotine (dialysis)
N
Vehicle
CR
Decreased ChAT activity
Aβ1-40 Aβ1-42
N N
Vehicle revAβ1-40
Left ventricle, 3 injections over 5 days Right ventricle Right ventricle
None None
Decreased ChAT activity Unchanged ChAT activity
rat
Aβ1-40
N
Vehicle
Left ventricle
None
Yamada et al., 1999b*
rat
Aβ1-42
N
revAβ1-40
Right ventricle
None
Decreased release of DA by nicotine or K+ (dialysis) Unchanged levels of dopamine, DOPAC, HVA, 5-HT, 5-HIAA, NA
Neuropeptides Aguado-Llera et al., 2005
rat
Aβ25-35, Aβ1-42
N
Saline, revAβ25-35
Right ventricle
None
Nag et al., 1999*
rat
Aβ1-40
N
Vehicle
Left or right ventricle
Nag & Tang, 2001*
rat
Aβ1-40
N
Vehicle
Left or right ventricle
Tang et al., 2002*
rat
Aβ1-40
N
Vehicle
Ventricle
Reference
Species
Aβ sequence
Tran et al., 2001*
rat
Wang et al., 2001*
rat
Aβ1-40, Aβ1-42, Aβ25-35 Aβ1-40
Yamada et al., 1998* Yamada et al., 1999b* Dopaminergic System Itoh et al., 1996*
rat rat
Physiological solvent?
Type of analysis
Decreased somatostatin levels; decreased density of somatostatin receptor sst2, but sst1, sst3 or sst4 are unchanged Aβ immuno Decreased somatostatin levels and mRNA; decreased substance P but unchanged neuropeptide Y levels None Decreased somatostatin and substance P levels but unchanged neuropeptide Y levels None Decreased somatostatin levels
Table 4A. Injection of Aβ induces gliosis. Assay to detect Aβ None
Microglia (F4/80-intensity)
Aβ immuno
Microglia (CD68-total counts)
Physiological solvent? Y
Controls
Site of injection
revAβ1-42
Ctx
Y
Vehicle
N
Saline
FCtx, PCtx, ATCx Right NBM
Aβ1-40
Y
Vehicle
rat
Aβ1-42
Y
mice
Aβ1-42
Y
Li et al., 2004a* Nakagawa et al., 2004* O'Hare et al., 1999 Reyes et al., 2004*
rat rat
Aβ1-40 Aβ1-42
Y Y
rat rat
Y Y
Richardson et al., 2002* Ryu et al., 2004*
rat
Aβ1-42 Aβ1-40, rat Aβ1-40 Aβ1-42
Y
rat
Aβ1-42
Y
revAβ1-42
Right Hipp
None
Scali et al., 1999 Sigurdsson et al., 1996
rat rat
Aβ1-40 Aβ25-35
N N
Saline Vehicle, revAβ25-35
Right NB Right Am
CR None
Reference El Khoury et al., 2003* Geula et al., 1998* Giovannini et al., 2002 Gonzalo-Ruiz et al., 2003* Jantaratnotai et al., 2003* Kim et al., 2004*
Species
Aβ sequence
mice
Aβ1-42
monkey old rat
Aβ40, Aβ42 (fibrillar) Aβ1-42
rat
Type of analysis
Aβ, CR
Astrocytes (GFAP-cell counts); Microglia (OX-6, COX-2, iNOS-cell counts) Aβ immuno Astrocytes (GFAP-qualitative)
Retrosplenial granular Ctx Vehicle, Corpus callosum Aβ immuno Astrocytes (GFAP-qualitative); Microglia revAβ1-42 (OX-42, OX-6-qualitative); Oligodendrocytes (CC1-cell counts) revAβ1-42 ICV None Microglia (OX-42 and interferon-γqualitative) Vehicle Hipp bilateral None iNOS-cell counts (glia), WB Vehicle Right ventricle Aβ immuno, Microglia (OX-42-qualitative) CR Sterile water CA3 Aβ immuno Astrocytes (GFAP-qualitative) Vehicle Dentate gyrus Aβ immuno, Astrocytes (GFAP-cell counts) bilateral CR, ThS Saline CA3 bilateral Aβ immuno Astrocytes (GFAP-intensity and number) Astrocytes (GFAP-cell counts) Microglia (ED1, COX-2-cell counts) Microglia (OX-42-qualitiative) Astrocytes (GFAP-branching)
Table 4A. Injection of Aβ induces gliosis. (Continued) Species
Aβ sequence
Physiological solvent?
Controls
Site of injection
Assay to detect Aβ
Sigurdsson et al., 1997a
rat
Aβ25-35
N
Am
CR
N N
Vehicle, revAβ25-35 Vehicle Vehicle
Sigurdsson et al., 1997b Sigurdsson et al., 2000
rat rat
Aβ25-35 Aβ1-42
Am Am bilateral
Soto et al., 1998
rat
Aβ1-42
N
Vehicle
Am
Stepanichev et al., 2003b
rat
Aβ25-35
N
Vehicle
Hipp
Stephan et al., 2001
rat
Aβ40+Aβ43
N
Vehicle
Stephan et al., 2003
rat
Aβ40+Aβ43
N
Vehicle
Walsh et al., 2002*
rat
Aβ1-42
Y
Walzer et al., 2002 Weldon et al., 1998*
rat rat
Aβ25-35 Aβ1-40 (fibrillar)
N Y
Vehicle, revAβ1-42 Vehicle Vehicle
Dentate gyrus, 8x bilateral Dentate gyrus, 8x bilateral Vitreous chamber Right Am Striatum
Whitehead et al., 2005
rat
Aβ25-35
Y
Vehicle
ICV bilateral
Yamamoto et al., 2003
rat
Aβ25-35
Y
Vehicle
NBM bilateral
Yan et al., 2001*
mice
Aβ1-42
Y
revAβ1-42
ICV
Zou et al., 2003
rat
Aβ1-42
N
PBS
Entorhinal Ctx
Reference
Type of analysis
Astrocytes (GFAP-branching); Microglia (IL1β) CR Astrocytes (GFAP-branching) Aβ immuno, Microglia (IL-1β, OX-42-semiquantitative) CR Aβ immuno, Astrocytes (GFAP-qualitative) CR, ThS None Astrocytes (GFAP-qualitative); Microglia (isolectin B4-qualitative) Aβ immuno, Astrocytes (GFAP-qualitative); Microglia ThS (OX-42-qualitative) Aβ immuno, Astrocytes (GFAP-qualitative); Microglia ThS (OX-42-qualitative) FluoresceinAstrocytes (GFAP) tagged Aβ CR Astrocytes (GFAP-cell counts) Aβ immuno, Astrocytes (GFAP, iNOS-intensity); CR, ThS Microglia (OX-42-cell counts; iNOSintensity) CR Astrocytes (GFAP-cell counts); Microglia (OX-6-cell counts) None Astrocytes (GFAP immuno and increased βglucuronidase activity) None Astrocytes (GFAP-qualitative); Microglia (IL1β-qualitative) CR Astrocytes (GFAP-quantitative)
Table 4B. Injection of Aβ does not gliosis. Reference
Species
Aβ sequence
Bishop & Robinson, 2003a*
rat
Games et al., 1992*
rat
Aβ1-40, Aβ142, RatAβ1-40 Aβ1-40, Aβ138, Aβ25-35
Geula et al., 1998*
Podlisny et al., 1992*
Podlisny et al., 1993*
rat Aβ40, Aβ42 young/old, (fibrillar or monkey soluble) young monkey Aβ1-40, Aβ2535
Physiologic al solvent? Y
Y or N
Y
Y or N
Controls Vehicle
Vehicle, scrAβ140, revAβ1-40, revAβ25 -35, scrAβ25-35 Vehicle
Vehicle, revAβ140, scrAβ1-40, scrAβ25-35 Vehicle, revAβ140, scrAβ1-40, scrAβ25-35 Prolactin in vehicle
monkey
Aβ1-40, Aβ2535
Y or N
Stephenson & Clemens, 1992
rat
Aβ1-43
N
Weldon et al., 1998
rat
Aβ1-40 (soluble)
N
Vehicle
Zou et al., 2003
rat
Aβ1-42+Aβ1-40
N
PBS
Site of injection Ctx
Assay to detect Aβ Aβ immuno, EM
Type of analysis Microglia (Ferritin-total counts)
Ctx or Hipp Aβ immuno, Astrocytes (GFAP-qualitative); Microglia CR (ED1-qualitative)
FCtx, PCtx, ATCx
Aβ immuno
Microglia (CD68-total counts)
Ctx
Aβ immuno
Astrocytes (GFAP-qualitative)
Ctx
Aβ immuno
Astrocytes (GFAP-qualitative)
Corpus striatum, dorsal Hipp Striatum
Entorhinal Ctx
Aβ immuno Astrocytes (GFAP-qualitative); Microglia (ED1-qualitative) Aβ immuno, CR, ThS CR
Astrocytes (GFAP, iNOS-intensity); Microglia (OX-42-cell counts; iNOSintensity) Astrocytes (GFAP-quantitative)
Table 4C. Infusion of Aβ induces gliosis. Reference
Species
Aβ sequence
Frautschy et al., 1998*
rat
Aβ40
Physiological solvent? Y
Matsunaga et al., 2003* Netland et al., 1998
rat
Aβ1-40
N
rat
Aβ
Y
Nitta et al., 1997* Snow et al., 1994*
rat rat
Aβ1-40 Aβ1-40
N N
Tran et al., 2001*
rat
Aβ1-40, Aβ142, Aβ25-35
N
Controls Vehicle
Vehicle, revAβ1-40 Vehicle Vehicle Vehicle, saline Vehicle, revAβ1-40
Site of infusion Ventricle
Assay to detect Aβ Aβ immuno, CR, ThS
Type of analysis
Astrocytes (GFAP-area of reactivity); Microglia (phosphotyrosine-area of reactivity) FCtx or Hipp Aβ immuno Astrocytes (GFAP-qualitative); Microglia (CD11b-qualitative) Ventricle Aβ immuno, Microglia (OX-6-counts) ThS Right ventricle None Astrocytes (GFAP-qualitative) Hipp Aβ immuno, Astrocytes (GFAP-intensity); Microglia CR, ThS (ED1-intensity) Right ventricle None Astrocytes (GFAP, iNOS-qualitative); Microglia (CD11b, iNOS-qualitative); iNOS mRNA and activity
Table 4D. Infusion of Aβ does not induce gliosis. Reference *
Games et al., 1992
Species
Aβ sequence
rat
Aβ1-40, Aβ1-38, Aβ25-35
Physiologica l solvent?
N
Controls
Site of infusion
Vehicle, aCSF, revAβ1-40
Hipp
Assay to detect Aβ
Type of analysis
Aβ immuno, Astrocytes (GFAP-qualitative); Microglia CR (ED1-qualitative)
Table 5A. Behavioural impairments induced by Aβ injection. Reference
Chen et al., 1996 Choi et al., 2001*
Species Aβ sequence
Physiological solvent?
Controls
Site of injection
Assay to detect Aβ
Timing of Aβ injection
Activity analysis
Behavioural assessment
rat mouse
Aβ25-35 Aβ1-42
N Y
Vehicle Saline
Hipp ICV
None None
7-14d prior 14d prior
None None
Delobette et al., 1997
rat
N
Vehicle
Right ventricle
None
14-28d prior
None
Dornan et al., 1993
rat
Aβ25-35, Aβ1-28 Aβ25-35
Y
Vehicle
Hipp bilateral
CR
8-10d prior
Locomotor
N,N, Y,N
Vehicle
Hipp, third ventricle
None
3min after
None
No change on radial arm maze or water maze Footshock avoidance
Y
Vehicle
Hipp, Am, thalamus, caudate, mamillary bodies, septum Right MNB Right MNB
None
3min after
None
Footshock avoidance
None None
14d prior 5-12d prior
Open-field Open-field
Passive avoidance Plus maze, passive avoidance Plus maze Water maze, passive avoidance Water maze
Flood et al., 1991
mice
Flood et al., 1994
mice
Aβ1-28, Aβ18-28, Aβ12-28, Aβ12-20 Aβ12-28
Harkany et al., 1999a Harkany et al., 1999b
rat rat
Aβ1-42 Aβ1-42
N N
Vehicle Vehicle
Harkany et al., 2001 Jhoo et al., 2004
rat mice
Aβ1-42 Aβ1-42
N N
MNB ICV
None None
7d prior 3d prior
None None
Jin et al., 2004
rat
N
NB
None
10d prior
None
Li et al., 2004b*
rat
Aβ1-42, Aβ25-35 Aβ1-40
Vehicle Vehicle, revAβ1-40 Vehicle
Y
Vehicle
Hipp bilateral
None
14d prior
Malin et al., 2001
rat
Aβ1-40
N
Vehicle, revAβ1-42
Hipp, 7x bilateral
Aβ immuno
14d prior
Water maze Water maze; no change on Y-maze Water maze
Open-field Open-field, Y-maze, passive avoidance None One-trial/day reward learning
Table 5A. Behavioural impairments induced by Aβ injection. (Continued) Reference
Species Aβ sequence
Maurice et al., 1996
mice
Mazzola et al., 2003*
mice
McDonald et al., 1996 Miguel-Hidalgo et al., 1998 Mileusnic et al., 2004
Physiological solvent?
Controls
Site of injection
Assay to detect Aβ
Timing of Aβ injection
Activity analysis
Behavioural assessment
N
Vehicle
Right ventricle
CR
6-14d prior
None
N,Y
Vehicle
Right ventricle
None
7d prior
None
Y-maze, passive avoidance, water maze Passive avoidance
rat
Aβ25-35, Aβ1-28 Aβ25-35, Aβ1-42 Aβ1-40
N
Dorsal Hipp
None
7d after, 7d prior
None
Y-maze
rat
Aβ1-28
N
Vehicle, revAβ1-40 Vehicle
Right Hipp
None
7d or 28d prior
None
Passive avoidance
chick
Aβ12-28
Y
Vehicle
Hyperstriatum
None
None
One-trial passive avoidance
O'Hare et al., 1999*
rat
Aβ1-42
Y
Sterile water
CA3
Aβ immuno
45min after, 1d prior After training
None
Pan et al., 2004 Perez-Severiano et al., 2004 Richardson et al., 2002*
rat rat
Aβ25-35 Aβ25-35
Y Y
Vehicle Vehicle
Left ventricle Hipp bilateral
None None
None None
rat
Aβ1-42
Y
Saline
CA3 bilateral
Aβ immuno
8d prior 2d prior, then testing 35d later After training
Two-lever operant chamber alternating lever cyclic-ratio Water maze Radial arm maze
Shen et al., 2002 Sigurdsson et al., 1995
rat rat
Aβ25-35 Aβ25-35
Y Y or N
Vehicle Vehicle
Hipp bilateral VP/SI
None CR
Stepanichev et al., 2003a
rat
Aβ25-35
N
Vehicle
ICV bilateral
None
Stepanichev et al., 2004 Stephan et al., 2001
rat rat
Aβ25-35 Aβ40+Aβ43
N N
Vehicle Vehicle
ICV bilateral Dentate gyrus, 8x bilateral
None ThS, Aβ immuno
None
Two-lever operant chamber alternating lever cyclic-ratio 7d prior None Water maze 12-37d prior Open field No change on water maze or conditioned avoidance 16-20d prior; None Y-maze, social recognition, 7d after, 60d prior but no change on passive to retraining avoidance; Radial arm maze 4w prior None Radial arm maze 4w prior None Radial arm maze, water maze
Table 5A. Behavioural impairments induced by Aβ injection. (Continued) Reference
Species Aβ sequence
Physiological solvent?
Controls
Site of injection
Assay to detect Aβ
Timing of Aβ injection
Activity analysis
N
Vehicle
Dentate gyrus, 8x bilateral ICV bilateral
ThS, Aβ immuno None
4w prior
None
3d prior
None
None
3d after, 1-14d prior to reexposure 21d prior
Swimming speed None
Locomotor
Water maze
None
7-10d prior
None
None
Y-maze, passive avoidance but no change on Porsolt forced swim test for behavioural despair Staircase test
None
No change on water maze Apomorphine-induced circling behaviour
Stephan et al., 2003
rat
Aβ40+Aβ43
Sun & Alkon, 2002
rat
Aβ25-35
Terranova et al., 1996
rat
N
Vehicle, revAβ25-35 Vehicle, Medial septum revAβ1-40, scrAβ25-35 Saline, Right ventricle revAβ25-35 scrAβ25-35 ICV
Tohda et al., 2003
mouse
Aβ1-40, Aβ1-42, Aβ25-35 Aβ25-35
Urani et al., 2002
rat
Aβ25-35
N
Whitehead et al., 2005
rat
Aβ25-35
Y
Vehicle
ICV bilateral
CR
Winkler et al., 1994*
rat
RatAβ1-42
Y
Vehicle
Aβ immuno
Yagami et al., 2004*
rat
Y
5d prior
None
rat
N
Vehicle, scrAβ25-35, revAβ25-35 Vehicle
None
Yamaguchi & Kawashima, 2001 Yamaguchi et al., 2002 Yan et al., 2001*
Aβ25-35, Aβ1-40, Aβ1-42 Aβ25-35
CA1 or lateral ventricle Striatum
8d after, 7d prior to retraining 15 months prior
Left ventricle
None
4d prior
None
rat mice
Aβ25-35 Aβ1-42
N Y
Vehicle revAβ1-42
Left ventricle ICV
None None
5d prior 1-3d prior
Yan et al., 2004*
mice
Aβ1-42
Y
revAβ1-42
ICV
None
1d prior
N
Behavioural assessment
Radial arm maze, water maze Water maze Social recognition
Passive avoidance, radial arm maze Locomotor Passive avoidance None Passive avoidance, Y-maze, water maze None Passive avoidance, Y-maze
Table 5B. Behavioural impairments induced by Aβ infusion. Reference
Species Aβ sequence
Physiological solvent?
Controls
Site of infusion
Assay to detect Aβ
Timing of Aβ infusion
Activity analysis
Behavioural assessment
2w infusion began 15d prior Trained and then daily injections 20min prior to testing 2w infusion began 8-14d prior 2w infusion began 10d prior 2w infusion began 10d prior 2w infusion began 16-21d prior
None
Wooden cross maze
None
No change on lever pressing and delayed conditional discrimination
None None
Water maze, passive avoidance Water maze
None
Water maze
Open field
Spontaneous object recognition but no change on acoustic startle reflex Y-maze, water maze, passive avoidance Water maze
Ammassari-Teule et al., 2002* Cleary et al., 1995*
rat
Aβ1-42
N
revAβ1-42
Right ventricle
None
rat
Aβ1-40
N
Vehicle
CA3
ThS
Nabeshima & Nitta, 1994* Nag et al., 1999*
rat
Aβ1-40
N
Vehicle
Left ventricle
None
rat
Aβ1-40
N
Vehicle
Nag & Tang, 2001*
rat
Aβ1-40
N
Vehicle
Aβ immuno None
Nag et al., 2001*
rat
Aβ1-40
N
Vehicle
Left or right ventricle Left or right ventricle Left or right ventricle
Nakamura et al., 2001* Nitta et al., 1994*
rat
Aβ1-42
N
Right ventricle
None
rat
Aβ1-40
N
Vehicle, revAβ1-40 Vehicle
Left ventricle
Nitta et al., 1997*
rat
Aβ1-40
N
Vehicle
Right ventricle
Aβ immuno None
Olariu et al., 2001
rat
Aβ25-35
N
Vehicle
Right ventricle
None
Tanaka et al., 1998*
rat
Aβ1-40
N
Vehicle
Right ventricle
None
None
3d infusion began None 20-25d prior 2w infusion began None 8-12d prior 2w infusion began None 8-14d prior 2w infusion began Locomoto 7-16d prior r 34d infusion began 10d prior
None
Water maze, passive avoidance Y-maze, elevated-plus maze, water maze, passive avoidance Water maze, passive avoidance but no change on Y-maze
Table 5B. Behavioural impairments induced by Aβ infusion. (Continued) Reference
Species Aβ sequence
Physiological solvent? N
Controls
Site of infusion
Vehicle
Ventricle
Assay to detect Aβ None
Timing of Aβ Activity Behavioural infusion analysis assessment 2w infusion began None Water maze 10d prior 10d infusion began Arm entry Radial eight-arm maze 6d prior
Tang et al., 2002*
rat
Aβ1-40
Tran et al., 2001*
rat
N
Vehicle, revAβ1-40
Right ventricle
None
Urani et al., 2004*
rat
Aβ1-40, Aβ1-42, Aβ25-35 Aβ1-40
N
revAβ1-40
Right ventricle
None
2w infusion began 14d prior
None
Wang et al., 2001*
rat
Aβ1-40
N
Vehicle
Left ventricle
CR
None
Yamada et al., 1998* Yamada et al., 1999a* Yamada et al., 1999b* Yamada et al., 1999c*
rat
Aβ1-40
N
Vehicle
Right ventricle
None
rat
Aβ1-42
N
revAβ1-40
Right ventricle
None
rat
Aβ1-42
N
revAβ1-40
Right ventricle
None
rat
Aβ1-42
N
revAβ1-40
Right ventricle
None
3 injections over 8d, last injection was 12d prior 2w infusion began 10-17d prior 2w infusion began 7-18d prior 2w infusion began 7-18d prior 2w infusion began 7-16d prior
No change on conditioned fear stress procedure Water maze
Locomotor Y-maze, water maze, passive avoidance Locomotor Y-maze, water maze, passive avoidance Locomotor Y-maze, water maze, passive avoidance Locomotor Y-maze, water maze
Table 6A. Effects of Aβ injection on synapse function. Controls
Site of injection
Assay to detect Aβ
Type of analysis
ICV
None
Decreased LTP in vivo after HFS for Aβ25-35 only
N N
Vehicle, revAβ2535 Vehicle Vehicle
ICV ICV
None None
N N
Vehicle Vehicle
Right ventricle Right ventricle
None
Aβ1-40 Aβ40+Aβ43
N N
Vehicle Vehicle
ICV None Dentate gyrus, Aβ immuno, 8x bilateral ThS
rat
Aβ40+Aβ43
N
Vehicle
Tohda et al., 2003
mouse
Aβ25-35
N
Trubetskaya et al., 2003
rat
Aβ25-35
N
Saline, revAβ2535 Vehicle
Dentate gyrus, Aβ immuno, 8x bilateral ThS Right ventricle None
Decreased LTP in vivo after HFS Decreased LTP in vivo after HFS for Aβ1-40 only; no change in baseline transmission Induction of LTD in vivo after HFS Decreased LTP in vivo after HFS; no change in baseline transmission Decreased LTP in vivo after HFS Decreased LTP in vivo after tetanus; no change in baseline transmission; no change in synaptophysin immuno Decreased LTP in vivo after tetanus; no change in baseline transmission No change in synaptophysin immuno-quantitative
Reference
Physiological solvent?
Species
Aβ sequence
Freir et al., 2001
rat
Aβ25-35, Aβ1525
N
Freir et al., 2003 Freir & Herron, 2003
rat rat
Kim et al., 2001 Klyubin et al., 2004
rat rat
Aβ25-35 Aβ1-40, Aβ1228 Aβ1-42 Aβ1-40
Minogue et al., 2003 Stephan et al., 2001
rat rat
Stephan et al., 2003
ICV bilateral
None
Increased LTP in vivo after tetanus; increased size of baseline evoked potential in vivo
Table 6B. Effects of Aβ infusion on synapse function. Reference
Species
Itoh et al., 1999*
rat
Aβ sequence Aβ1-40
Physiological solvent? N
Controls Vehicle
Site of infusion Ventricle
Assay to detect Aβ None
Type of analysis Decreased LTP in hippocampal slices obtained after infusion
Table 7A. Effect of Aβ injection on markers of oxidative stress.
rat
Aβ sequence Aβ1-42
Physiological solvent? N
Saline
Site of injection Right NB
Assay to detect Aβ None
rat
Aβ1-42
N
Vehicle
Right MNB
None
Jhoo et al., 2004
mice
Aβ1-42
N
Vehicle, revAβ1-40
ICV
None
Li et al., 2004b*
rat
Aβ1-40
Y
Vehicle
Hipp bilateral
None
Perez-Severiano et al., 2004
rat
Aβ25-35
Y
Vehicle
Hipp bilateral
None
Rosales-Corral et al., 2004* Shen et al., 2002
rat
Aβ1-40
Y
CA1
rat
Aβ25-35
Y
Vehicle, revAβ1-40 Vehicle
Hipp bilateral
Aβ immuno, CR None
Stepanichev et al., 2004
rat
Aβ25-35
N
Vehicle
ICV bilateral
None
Reference Boyd-Kimball et al., 2005 Harkany et al., 1999b
Species
Controls
Type of analysis Increased protein carbonyls by 2D gel with oxyblot analysis Increased Cu/Zn-SOD activity; decreased MnSOD activity Increased Cu/Zn-SOD, Mn-SOD, GPx, and glutathione reductase activity; increased levels of protein carbonyls and malondialdehyde. Increased malondialdehyde content; unchanged SOD activity Increased ROS content and lipid peroxidation; unchanged Cu/Zn-SOD, Mn-SOD and GPx activity Increased nitrites and lipid peroxidation products; decreased GPx activity Increased lipid peroxidation; decreased SOD and GPx activity; decreased glutathione levels Increased lipid peroxidation and superoxide generation.
Table 7B. Effect of Aβ infusion on markers of oxidative stress. Species
Aβ sequence
Kim et al., 2003*
rat
Aβ1-42
Physiological solvent? N
Yamada et al., 1999a*
rat
Aβ1-42
N
Reference
Controls Vehicle, revAβ1-40 revAβ1-40
Site of injection Right ventricle
Assay to detect Aβ None
Right ventricle
None
Type of analysis Decreased immuno intensity for MnSOD, glutathione, GPx, glutathione-Stransferase Unchanged lipid peroxidation levels
Table 8A. Miscellaneous markers that were examined after injection of Aβ. Reference *
Baltrons et al., 2002 *
Choi et al., 2001
*
Ghribi et al., 2001 Giovannini et al., 2002
*
Li et al., 2004b Minogue et al., 2003 *
Mohajeri et al., 2002 Pan et al., 2004
*
Reyes et al., 2004
*
Aβ sequence
rat
Aβ1-40
Physiological solvent? Y
mouse
Aβ1-42
Y
Saline
rabbit
Aβ1-42
Y
Vehicle
Cistern
None
Increased NF-kB (neurones)-cell count and WB
rat
Aβ1-42
N
Saline
Right NBM
Aβ, CR
rat
Aβ1-40
Y
Vehicle
Hipp bilateral
None
Phospho-p38, MAPK immuno but unchanged phosphoERK and phospho-SAPK/JNK immuno; increased IL1β in homogenates Decreased membrane fluidity
rat mice
Aβ1-40 Aβ42
N Y
None None
Increased IL-1β levels Increased neprilysin levels (WB) and mRNA
rat
Aβ25-35
Y
Vehicle ICV Vehicle, PCtx revAβ42, BSA Vehicle Left ventricle
None
rat
Aβ1-40, RatAβ140 Aβ1-40
Y
Vehicle
Increased mRNA and protein levels of voltage-gated K+ channels Kv2.1, Kv1.4, Kv4.2, but not Kv1.5, Kv4.3 Unchanged laminin expression (injury response)
Y
mouse Aβ1-42, Aβ1-40, Aβ25-35, Aβ1-28 mouse Aβ1-16, Aβ1-40, Aβ1-42, Aβ1740, Aβ25-35, Aβ17-42 mouse Aβ1-42
Y Y
Vehicle, revAβ1-40 Vehicle, revAβ1-42 Vehicle
Y N
rat
Rosales-Corral et al., 2004 *
Song et al., 2001
*
Szczepanik et al., 2001
*
Szczepanik & Ringheim, 2003 Urani et al., 2002
Species
rat
Aβ25-35
Controls Vehicle
Site of injection Hipp, cerebellar vermis ICV
Dentate gyrus bilateral CA1
Assay to detect Aβ None None
Type of analysis Decreased soluble guanylyl cyclase expression in astrocytes Mitochondrial pyruvate dehydrogenase content
ICV
Aβ immuno, CR, ThS Aβ immuno, CR None
ICV
None
Increased levels of IL-1α, IL-1β, IL-6, MCP-1, TNFα in homogenates
Vehicle
ICV
None
scrAβ25-35
ICV
None
Increased IL-1α, IL-1β, MCP-1 but TNF-α unchanged in homogenates Decreased levels of progesterone but unchanged pregnenolone and dehydroepiandrosterone in Hipp
Increased levels of IL-1β, IL-6, TNF-α Increased plasma levels of IL-6, IL-1β
Table 8A. Miscellaneous markers that were examined after injection of Aβ. Reference
Species
Whitehead et al., 2005 * Yagami et al., 2004
rat rat
*
rat
Zand et al., 2005
Physiologica Controls Site of injection l solvent? Aβ25-35 Y Vehicle ICV bilateral Aβ25-35, Aβ1Y Vehicle, scrAβ25Striatum 40, Aβ1-42 35, revAβ25-35 Aβ1-42 Y revAβ1-42 Dentate gyrus Aβ sequence
Assay to detect Aβ CR None None
Type of analysis Increased NFkB, TNF-α-intensity Increased thromboxane A2 content Increased laminin-positive blood vessels-counts; Increased VEGF in astrocytes and microgliaqualitative
Table 8B. Miscellaneous markers that were examined after infusion of Aβ. Reference
Aguado-Llera et al., 2005
Species
Aβ sequence
rat
Aβ25-35, Aβ142
Physiological solvent?
Controls
Site of injection
Assay to detect Aβ
N
Saline, revAβ25-35
Right ventricle
None
Fukuta et al., rat (infant, adult and aged) 2001* Olariu et al., 2001 rat
Aβ1-40
N
Vehicle
Right ventricle
None
Aβ25-35
N
Vehicle
Right ventricle
None
Olariu et al., 2002*
rat
Aβ1-40
N
revAβ1-40
Right ventricle
None
Reyes et al., 2004*
rat
Aβ1-40
Y
Vehicle
Dorsal Hipp
Tang et al., 2000*
rat
N
rat
N
Vehicle, revAβ1-40 revAβ1-40
Right ventricle
Urani et al., 2004*
Aβ1-40, Aβ142, Aβ25-35 Aβ1-40
Aβ immuno, CR, ThS None
Right ventricle
None
Zhang et al., 2004*
rat
Aβ1-40
N
Vehicle
Left ventricle, 3 injections over 5 days
None
Type of analysis
Decreased p-Akt but unchanged levels of IGF-1-levels and MAP-K; unchanged αi subunits of G-proteins Increased NGF levels in Hipp in adult rats, but unchanged in infant and aged rats Decreased activity and binding affinity of PKC Decreased activity and binding affinity of PKC Unchanged laminin expression (injury response) Increased BDNF mRNA but no change in NGF or neurotrophin-3 mRNA Decreased levels of progesterone but unchanged pregnenolone and dehydroepiandrosterone in Hipp Decreased APPs and PKC levels
30
Glenda M. Bishop and Stephen R. Robinson
Solvents are an important consideration because they can affect the properties of Aβ. For example, Aβ is highly soluble in acetonitrile but precipitates out of solution if salts are present [Waite et al., 1992], indicating that the solvent can change the secondary structure of Aβ and potentially alter its physiological properties. That paper showed that when Aβ dissolved in acetonitrile and trifluoacetic acid (A/TFA) was injected into rat hippocampus it was very toxic, when dissolved in water it was less toxic, and no more toxic than the solvent when dissolved in phosphate-buffered saline (PBS) and cyclodextrin. One reason for the toxicity of acetonitrile is that it can be converted to cyanide in microsomes [Freeman & Hayes, 1988], which then compromises cellular metabolism [Goldberg et al., 1987]. Thus when Aβ dissolved in acetonitrile is delivered into the brain the Aβ will act upon cells that are under stress and have a reduced viability due to the solvent. The toxicity of Aβ observed under these circumstances may not necessarily be indicative of its toxicity to unstressed cells. It should be noted that when the solvent vehicle alone was injected into the hippocampus, A/TFA was the most toxic, water had some toxicity and PBS had only minimal toxicity [Waite et al., 1992]. This finding demonstrates that solvents themselves can cause neuronal degeneration and confirms the need to include vehicle control injections when assessing the toxicity of Aβ in vivo. Surprisingly, not all studies have controlled for vehicle effects but have instead made comparisons to untreated tissue that has not even suffered the mechanical damage associated with the injection procedure. Physiological solvents can be employed in most injection procedures, but organic solvents are favoured when performing constant infusions of Aβ via mini-osmotic pumps because this reduces the likelihood of the pumps becoming clogged. A model that can constantly infuse Aβ over long periods of time while still using a physiological solvent is possible however, as shown by Frautschy and colleagues who used HEPES buffer to dissolve Aβ for a 4-week infusion [Frautschy et al., 1998]. A useful additional control that has been included in some studies is the injection of reverse or scrambled forms of Aβ (see Figure 2), or the inclusion of rodent isoforms of the peptide to control for non-specific “peptide effects”, particularly with respect to the tendency of Aβ to form large, sticky deposits that displace nearby tissue. The rodent variants of Aβ are particularly useful controls because the primary peptide sequence differs from human Aβ by only three amino acids [Shivers et al., 1988]. Rodent Aβ is an ‘endogenous’ peptide for both rats and mice, and thus can serve as a peptide control, but can also control for the aggregational properties of full-length human Aβ peptide that the reverse or scrambled sequences are often unable to achieve. It is also worth considering that injection or infusion of Aβ into the lateral ventricles allows the peptide to interact with other agents contained within the CSF, such as metal ions, cytokines and proteins. In vitro studies have shown that Aβ interacts with acetylcholinesterase, iron, zinc, and aluminium; all change the properties of Aβ, altering its solubility, causing it to fibrillise and precipitate out of solution [Alvarez et al., 1998; Bush et al., 1995; Bush et al., 1994; Mantyh et al., 1993]. In addition, Aβ has been reported to be more toxic to cultured cells when mixed with some of these substances than when it is on its own [Alvarez et al., 1998; Schubert & Chevion, 1995]. This is an important consideration because when Aβ is discretely injected into brain tissue it has limited opportunity to interact with other proteins or molecules, except those within the immediate vicinity, whereas Aβ
Insights on Alzheimer’s Disease from the Intracerebral Injection and Infusion …
31
injected or infused into the lateral ventricles has a greater opportunity to interact with agents that can alter its properties.
Figure 2. Aβ peptide. The Aβ peptide contains 39-43 amino acids. It is normally present as Aβ1-40 or Aβ1-42, which contain 40 or 42 amino acids respectively. Rat Aβ varies from human Aβ by three amino acid substitutions at residues 5, 10, and 13. Truncated forms of Aβ are sometimes used, especially Aβ25-35, which contains only residues 25-35 of full-length Aβ. Reverse Aβ1-40 (revAβ1-40, or Aβ40-1) is often used as a control for Aβ1-40. RevAβ1-40 contains the same amino acids as Aβ1-40, but in the opposite order with the amino and carboxy groups to amino acid residues 40 and 1, respectively. Scrambled peptides contain the same amino acids as the selected peptide, but the amino acids are randomly arranged within the peptide.
Given the difficulty involved in comparing the results of studies that used differing methodologies to deliver Aβ, a stricter set of secondary exclusion criteria were employed to select a subset of studies that had used the most rigorous experimental designs: (1) a physiological solvent must have been used to dissolve Aβ. Artificial CSF, saline, PBS, HEPES buffer or cell culture media were defined as physiological solvents, while A/TFA, dimethyl sulfoxide (DMSO) or water were defined as non-physiological solvents; (2) there had to be a control condition where either the vehicle, a physiological solvent, or a reverse or scrambled form of Aβ was injected or infused for comparison; (3) a physiological full-length variant of Aβ had to be examined, which was defined as Aβ1-40, Aβ1-42 or Aβ1-43. Truncated forms of Aβ, such as Aβ25-35, can assist our understanding of particular amino acid sequences within the full-length peptide [e.g. Giulian et al., 1996; Yankner et al., 1990], but they are not physiological since they have never been detected in vivo. The studies that met these stricter criteria have been indicated in the summary tables with an asterisk (*). These secondary criteria were applied to studies that had injected Aβ, however nearly all of the studies that had infused Aβ into the brain used non-physiological solvents to prevent Aβ from clogging the pump. Consequently infusion studies that met criteria (2) and (3), such that they had appropriate control infusions and that they used full-length sequences of Aβ, are also indicated by an asterisk. In the following sections, the overall trends in each summary table are first discussed, and then the trends pertaining to the highlighted studies are further dissected for analysis. A full discussion of the data associated with each category could easily fill a chapter of this book, so we have been restricted by space limitations to a brief discussion of the most pertinent findings associated with each category. Nonetheless, we hope that the details
32
Glenda M. Bishop and Stephen R. Robinson
included in the tables will serve as a resource which will allow the interested reader to follow up on aspects that we have not had the leisure to discuss.
Aβ-induced Neuronal Degeneration In this category of analysis, the presence or absence of neuronal degeneration can be considered an absolute finding, so for ease of understanding the results, we have separated the studies which observed neuronal degeneration (Tables 2A and 2C) from those that did not (Tables 2B and 2D). The studies that injected Aβ are listed in the first two tables (2A and 2B) and those which infused Aβ are in the second two tables (2C and 2D). It is important to note that three studies assessed neuronal degeneration using either different animals [Geula et al., 1998], different solvents [Waite et al., 1992], or different Aβ sequences [Zou et al., 2003], which resulted in both positive and negative effects in terms of neuronal degeneration. We have treated these findings as separate sets of data, and have listed them in both Tables 2A and 2B. 58 studies assessed neuronal degeneration resulting from injection of Aβ into the brain, which generated 61 sets of data. Most used Nissl or haematoxylin and eosin (H&E) stains to determine either the presence of dead neurones at injection sites or the remaining number of viable neurones. Some studies assessed the presence of tau phosphorylation or used highly specific markers of cell death such as TUNEL or Fluoro-Jade. In recent years, some studies have used Western blot (WB) analysis of apoptotic markers or ELISA cell detection kits. If all of the data sets are considered as if they are equivalent, then 59% detected neuronal degeneration after injection of Aβ. If however, we limit the comparison to the more rigorous physiological studies (asterisks), then only 49% of data sets found that injection of Aβ into the brain induces neuronal degeneration. Further analysis shows that only 22% of studies that injected Aβ into the cerebral cortex, and 29% of studies that injected Aβ into hippocampus, were able to detect increased neuronal degeneration. This analysis suggests that the injection of physiological variants of Aβ into the regions of the brain most commonly affected by AD does not result in a significant degree of neuronal loss. In contrast, Aβ was reported to induce neuronal degeneration in 60% of studies that injected it into the lateral ventricles (or cistern), and in each of the studies that injected Aβ into the striatum, corpus callosum or vitreous chamber of the eye. In order to be certain that the effects observed after injection of Aβ are due to the peptide, it is necessary to confirm that at least some Aβ has deposited near the site of injection. Of the papers surveyed, the most common methods used to detect Aβ deposition were the histological stains Congo red (CR) or Thioflavin-S (ThS), or immunohistochemistry using antibodies raised against Aβ. It is interesting that only 45% of the data sets reporting Aβ toxicity ascertained that Aβ was present at the site of injection, whereas 92% of the data sets reporting a lack of toxicity confirmed Aβ deposition. Thus a much greater proportion of the studies reporting a lack of Aβ toxicity were certain of the success of their injections than those that had reported toxicity. 8 out of 9 infusion studies met the secondary criteria of the more rigorous studies, allowing for the fact that infusion studies generally require the use of non-physiological
Insights on Alzheimer’s Disease from the Intracerebral Injection and Infusion …
33
solvents to keep Aβ dissolved for the duration of the infusion (see Tables 2C and 2D). 38% of these studies found that infusion of Aβ into the brain induces neuronal degeneration. Further analysis showed that neither of the studies which infused Aβ into the hippocampus reported neuronal degeneration, whereas half of those that infused Aβ into the lateral ventricles did. This supports the observation from injection studies that deposition of physiological variants of Aβ into a brain region commonly affected by AD does not result in significant death of neurones. It should be noted that only one infusion study used a physiological solvent to dissolve Aβ [Frautschy et al., 1998]. That study reported that Aβ killed cortical neurones after 4weeks of infusion into the lateral ventricle. The constant infusion of Aβ allows the peptide to gradually accumulate, which may be the way that Aβ deposits in AD. In an attempt to further increase the deposition of Aβ, Frautschy and coworkers have co-infused the protease inhibitors leupeptin or aprotinin with Aβ1-40 to increase the deposition of Aβ in the thalamus, cortex and hippocampus compared to infusion of Aβ alone [Frautschy et al., 1998]. These authors found that increased Aβ deposition does not guarantee increased toxicity since co-infusion with aprotinin decreased the amount of apoptosis, even though it increased the amount of Aβ deposition. On balance, the preceding observations indicate that Aβ deposits do not consistently cause a significant amount of neuronal degeneration after either injection or infusion into the brain, particularly when deposited in discrete regions such as the cerebral cortex or hippocampus. Furthermore, the amount of Aβ that has been deposited does not appear to be correlated with the resulting degree of neuronal degeneration. This outcome is similar to the observations from transgenic mouse models, which reported that high levels of Aβ deposition did not correlate with the extent of neuronal death [Irizarry et al., 1997a; Irizarry et al., 1997b].
Effects of Aβ on Neuronal Subpopulations The studies that have injected or infused Aβ and examined the effects on neuronal subpopulations are described in Tables 3A and 3B, respectively. Due to the central involvement of the cholinergic system in AD [e.g. Henke & Lang, 1983; Perry et al., 1978], this subpopulation of neurones has been the most widely studied after injection or infusion of Aβ. Reported impairments include decreased levels of acetylcholine (ACh), decreased activity of choline acetyltransferase (ChAT), or decreased numbers of cells or fibres containing ChAT or acetylcholinesterase (AChE), respectively. 80% of studies that have examined the cholinergic system after injection of Aβ have reported impairments in at least one aspect of cholinergic metabolism (Table 3A). Of the 6 studies that meet our physiological criteria, 67% reported decreased cholinergic functioning after injection of Aβ. A similar outcome was obtained after infusion of Aβ, with 86% of studies that used full-length Aβ sequences and appropriate control infusions indicating a decrease in cholinergic function. One of these studies reported decreased ChAT activity but no change in AChE activity after infusion of Aβ into the left ventricle of rats [Nabeshima & Nitta, 1994], while another
34
Glenda M. Bishop and Stephen R. Robinson
reported that ChAT activity decreased after infusion of Aβ1-40 into the lateral ventricle of adult rats, but not when infused into infant or aged rats [Fukuta et al., 2001]. Giovannelli and colleagues showed that Aβ could temporarily impair cholinergic metabolism without actually killing cholinergic neurones [Giovannelli et al., 1998]. They reported that four months after injection of Aβ1-40 into the nucleus basalis (NB) there was decreased expression of ChAT in the NB and decreased ACh release from parietal cortex, yet two months later the levels had returned to normal. They also showed that neuronal death did not occur at any time point after Aβ injection (see Table 2B). These results demonstrate that functional changes can occur in the brain, and persist for several months after Aβ administration, without the Aβ causing any neuronal loss or permanent deficits. Other neurotransmitter systems that have been examined include the noradrenergic, dopaminergic and serotonergic systems, amino acid transmitters such as glutamate and GABA, and neuropeptides such as substance P, neuropeptide Y and somatostatin. The effect of Aβ on interneurones has also been investigated by examining the expression of neuronal nitric oxide synthase (nNOS) and parvalbumin. While few of these studies meet our physiological criteria, they indicate that injection of Aβ decreases the number of labelled noradrenergic and serotonergic neurones, and interneurones. Infusion studies appear to have placed greater emphasis on neuropeptides. Although none used physiological solvents, these studies indicate that infusion of Aβ may decrease the levels of somatostatin and substance P, but leave the levels of neuropeptide Y unaffected. It is not clear whether infusion of Aβ alters the dopaminergic system, since one study reported that Aβ1-40 decreased the release of dopamine [Itoh et al., 1996], while another reported that Aβ1-42 did not alter the levels of dopamine or its metabolites [Yamada et al., 1999b]. This discrepancy may be related to the length of Aβ used. In summary, Aβ appears to impair the function of pathways that use acetylcholine, serotonin, noradrenaline, somatostatin or substance P, and decreases the expression of nNOS and parvalbumin in interneurones. At least some of these effects are transient and it is not known whether these changes are due to the direct actions of Aβ, or to secondary effects such as cytokine release by activated neuroglia. It is not yet clear whether Aβ impairs the function of pathways that use dopamine or amino acid transmitters.
Aβ-induced Gliosis Astrocytes will normally form a scar around a site of damage in order to isolate it from the surrounding tissue, and microglia are recruited to phagocytose cellular debris and any other agents that are not normally present in healthy tissue. However, microglia and astrocytes can become activated by mild stimuli that do not cause neuronal loss. For example, microglia routinely respond to the presence of exogenous agents within the extracellular space, such as the Aβ that is deposited by injection or infusion [Halliday et al., 2000]. Astrocytes are sensitive to alterations in pH or osmotic pressure, and pro-inflammatory cytokines that have been released from neurones or microglia [Halliday et al., 2000]. Similar to the previous section (neuronal degeneration), the findings in this category of analysis can be considered absolute, thus the data has been separated into those that observed
Insights on Alzheimer’s Disease from the Intracerebral Injection and Infusion …
35
gliosis (Tables 4A and 4C) and those that did not (Tables 4B and 4D). The studies that injected Aβ are in Tables 4A and 4B and those that infused Aβ are in 4C and 4D. It is important to note that three studies assessed gliosis using either different animals [Geula et al., 1998], different solvents to derive different secondary structures [Weldon et al., 1998], or different Aβ sequences [Zou et al., 2003], giving both positive and negative effects. These findings have been treated as individual sets of data. 78% of the data sets that injected Aβ and assessed the reactivity of astrocytes using immunohistochemistry for glial fibrillary acidic protein (GFAP) reported an increased astrocytic reactivity (see Tables 4A and 4B). The physiological studies showed a similar pattern with 73% observing an induction of GFAP staining after injection of Aβ. Further analysis of these studies indicated a regional difference in that 75% of the studies which injected Aβ into the hippocampus, but only 25% of the studies that injected Aβ into the cerebral cortex, reported an induction of GFAP staining. One study each injected Aβ into the lateral ventricles, striatum, corpus callosum or vitreous chamber and all reported GFAP induction. Infusion of Aβ generated very similar results (see Tables 4C and 4D) with 83% of the more rigorous studies reporting an induction of GFAP. A smaller proportion (67%) reported an induction when Aβ was infused into the hippocampus while the one study that infused Aβ into the cerebral cortex and the three studies that infused Aβ into the lateral ventricles all reported an induction. In the one infusion study that met all three of our physiological criteria, it was reported that GFAP expression was induced around the injection cannula after Aβ infusion into the lateral ventricle [Frautschy et al., 1998]. Microglial reactivity can be assessed with a variety of markers, but most commonly researchers have used antibodies raised against immune-related markers such as CD11b (including the clone OX-42) and interleukin-1β (IL-1β), as well as specific markers for microglia such as lectins or phosphotyrosine. 76% of data sets have reported that injection of Aβ into the brain induces a microglial reaction. A similar pattern is observed with the physiological studies with 73% reporting microglial reactivity. In contrast to the findings for astrocytes, microgliosis has been observed in 40% of studies that injected Aβ into the cerebral cortex, and 50% of studies which injected Aβ into the hippocampus. Microgliosis was also observed in one study each that injected Aβ into the corpus callosum or vitreous chamber of the eye, and in the three studies which injected Aβ into the lateral ventricles. The results from infusion studies (see Tables 4C and 4D) were similar, with 80% of the more rigorous studies reporting an induction of microglia by Aβ. Again, 67% of studies that infused Aβ into the hippocampus observed microgliosis, as well as the one study which infused Aβ into the cerebral cortex and the two that infused Aβ into the lateral ventricles. In the only infusion study which met all three physiological criteria, it was reported that the numbers of phosphotyrosine-positive microglia were increased in the region of the injection cannula after infusion of Aβ1-40 into the lateral ventricle, and this was further enhanced if the Aβ was co-infused with protease inhibitors [Frautschy et al., 1998]. On balance, the majority of studies indicate that Aβ activates astrocytes and microglia, particularly when injected or infused into the lateral ventricles or hippocampus. There appears to be little difference in the responsiveness of astrocytes and microglia to injected or infused Aβ, except that astrocytes in the cerebral cortex may be more resistant to activation by Aβ than their hippocampal counterparts.
36
Glenda M. Bishop and Stephen R. Robinson
Aβ-induced Behavioural Dysfunction The studies that have injected or infused Aβ and examined the effects on behaviour are described in Tables 5A and 5B, respectively. 92% of studies that have injected Aβ into the brain and then assessed behavioural functions, such as the ability to learn, have found that Aβ has deleterious effects on at least one behavioural test (see Table 5A). The physiological studies follow a similar pattern, with 89% reporting behavioural impairments on at least one test. Behavioural impairments were observed after Aβ was injected into the hippocampus in 75% of studies, the lateral ventricles in 80% of studies, and the striatum in one study. It is worth noting that one of these studies reported an impairment on the water maze, yet also reported a lack of impairment on the Y-maze, while using the same Aβ injection paradigm [Choi et al., 2001]. The most commonly used behavioural tests were the Morris water maze, the Y-maze and passive avoidance tasks. These tests can either examine the ability to learn or the ability to retrieve memories, depending on when the tests are applied in relation to when the Aβ is injected. For instance, if Aβ is administered prior to training, then performance on the task measures the ability of Aβ to influence the acquisition and consolidation of new memories. If the Aβ is administered after training, then performance on the task measures the capacity of Aβ to influence retrieval processes. Aβ was injected prior to training on all studies that used the water maze, Y-maze or passive avoidance tests, and problems in acquisition were reported in 67%, 75% and 100% of the studies that met the physiological criteria, respectively. Only 2 studies injected Aβ after training, both of which found impairments using a two-lever operant chamber, indicating an amnestic effect of Aβ. Infusion of Aβ into rat brain demonstrated similar findings, with 89% of studies reporting impairments on at least one behavioural test (see Tables 5C and 5D). Although these infusion studies used non-physiological solvents, most used the naturally occurring variants of Aβ, with 95% using either Aβ1-40 and/or Aβ1-42. By contrast, only 49% of injection studies used either Aβ1-40 and/or Aβ1-42, and one study examined rat Aβ1-42. It is worth noting that two studies reported impairments on at least one test, as well as a lack of impairment on other tests while using the same Aβ infusion paradigm [Nag et al., 2001; Tanaka et al., 1998]. The one infusion study that targeted the hippocampus did not report a behavioural impairment [Cleary et al., 1995], however 94% of those that infused Aβ into the lateral ventricles did. These studies infused Aβ into the lateral ventricles prior to training, thereby demonstrating the capacity of Aβ to impair acquisition in both discriminative and spatial learning tasks. In summary, an overwhelming proportion of studies reported impairments on at least one behavioural task, regardless of whether the Aβ was injected or infused into the brain. The strength of this result might be taken as clear evidence that Aβ does have amnestic properties. Caution is needed however, because we have no way of knowing how many other studies were not published because they obtained a negative result. In this context it is noteworthy that half of the negative outcomes reported in Table 5 were published in association with positive outcomes on another task. A further consideration is that spatial learning and passive avoidance tasks may have limited relevance to the behavioural dysfunction seen in AD. Other
Insights on Alzheimer’s Disease from the Intracerebral Injection and Infusion …
37
measures such as social recognition [Stepanichev et al., 2003a; Terranova et al., 1996] may have greater utility.
Aβ-induced Synaptic Dysfunction It has been suggested that neuronal dysfunction in AD may be related to changes in synapse number and function rather than to outright neuronal degeneration [Selkoe, 2002]. The first set of studies that examined synapse function after injection of Aβ were published in 2001, and a total of 10 studies have been included in the present analysis (see Table 6A). Unfortunately, all of these studies used non-physiological solvents. If we consider only the studies that used full-length Aβ and appropriate vehicle controls, there were 6 studies which investigated whether injection of Aβ into either the lateral ventricles or the dentate gyrus affects the induction of long-term potentiation (LTP) by neurones in the CA1. Five of these studies reported that Aβ impairs the induction of LTP after either high-frequency stimulation (HFS) or tetanic stimulation, and the other study reported an enhancement of long-term depression (LTD) after high-frequency stimulation [Kim et al., 2001]. A further study reported increased induction in LTP after tetanic stimulation following injection of a nonphysiological variant of Aβ [Trubetskaya et al., 2003]. While these results support the notion that Aβ can influence synaptic plasticity, the use of non-physiological solvents may have influenced the outcome. Only one study that injected full-length Aβ used immunohistochemistry to detect changes in the numbers of synapses. This study found no changes in the pattern of immunolabelling for the presynaptic terminal protein, synaptophysin, after Aβ injection [Tohda et al., 2003], suggesting that Aβ does not influence synaptogenesis or the maintenance of existing synapses. Only one study has infused Aβ (Table 6B) and then examined LTP [Itoh et al., 1999]. In contrast to the studies that injected Aβ, this study infused Aβ for 10-11 days and then collected slices of the hippocampus to perform an in vitro investigation of LTP. They found that LTP was decreased after tetanic stimulation when compared to the induction of LTP in hippocampal slices from vehicle-infused animals [Itoh et al., 1999]. While this is not strictly an in vivo study, it has been included in the present analysis since it is the only one that has examined LTP after Aβ infusion. There is clearly a need for more studies in this area, particularly physiological studies that examine hippocampal synaptic function after injection or infusion of Aβ. Nonetheless, the limited data available indicate that Aβ decreases LTP independently of synapse number.
Aβ-induced Oxidative Stress Structural oxidative damage to lipids or proteins is indicated by the presence of lipid peroxidation products such as malondialdehyde, or protein carbonyls, respectively. The presence of oxidative stress is also indicated by an increase in the activity or protein level of enzymes involved in generating free radicals, such as superoxide dismutase (SOD), or a
38
Glenda M. Bishop and Stephen R. Robinson
decrease in the enzymes that are involved in neutralising free radicals, such as glutathione peroxidase (GPx) or glutathione reductase. Of the 8 studies that have investigated oxidative stress following Aβ injection, only two meet the criteria for physiological methodology (see Table 7A). Both studies reported an increase in lipid peroxidation products after injection of Aβ into the hippocampus. It was also reported that Aβ decreased the activity of GPx, an enzyme used to detoxify hydrogen peroxide [Rosales-Corral et al., 2004]. This result is consistent with a study that infused Aβ (Table 7B) into the lateral ventricle and observed a decrease in the extent of immunohistochemical label for GPx [Kim et al., 2003]. While the other injection studies in this category used non-physiological solvents, these studies consistently show that Aβ induces lipid peroxidation and protein carbonyl formation. It also appears that injection of Aβ may increase the activity of SOD, which may be a responsive mechanism to increased generation of superoxide after injection of Aβ [Stepanichev et al., 2004]. On balance, it appears likely that injection or infusion of Aβ into the brain does induce oxidative stress at the site of Aβ deposition. This may be due to the formation of free radicals by the peptide [e.g. Harris et al., 1995], to the production of reactive oxygen species (ROS) by activated glial cells, or simply due to increased rates of oxidative metabolism in cells exposed to Aβ. Further studies are required to investigate these possibilities.
Other Markers affected by Injection or Infusion of Aβ Researchers have examined aspects of brain function that go beyond the standard repertoire of assessment. These wide-ranging observations have been summarised in Tables 8A and 8B. For instance, injection of Aβ has been reported to decrease membrane fluidity [Li et al., 2004b], increase the expression of vascular endothelial growth factor (VEGF) in microglia and astrocytes [Zand et al., 2005] and increase the expression of the Aβ-degrading protein neprilysin and its mRNA [Mohajeri et al., 2002]. The levels of cytokines such as IL1α, IL-1β, IL-6, MCP-1 and TNFα have been found to be increased after injection of Aβ into the hippocampus or lateral ventricle [Rosales-Corral et al., 2004; Szczepanik et al., 2001; Szczepanik & Ringheim, 2003]. Infusion of Aβ has been reported to increase the expression of NGF in adult rats, but not in infant or aged rats [Fukuta et al., 2001]. It has also been reported that infusion of Aβ increases the mRNA levels of BDNF, but does not change those of NGF or neurotrophin-3 [Tang et al., 2000]. Infusion of Aβ into the lateral ventricle decreases hippocampal levels of progesterone, but does not alter hippocampal levels of pregnenolone and dehydroepiandrosterone [Urani et al., 2004]. These disparate studies indicate that Aβ exerts a wide variety of effects on the living brain; further investigation is required to verify these results, and to place them into a physiological context. In summary, Aβ appears to be capable of exerting effects on processes that lie outside of the parameters normally associated with toxicity. Further examination of such effects will help to elucidate the precise actions that Aβ has on neural cells in the living brain. Some in vivo and in vitro studies have begun to provide support for a physiological role for Aβ in the brain [see Bishop & Robinson, 2004b]. Evidence reviewed in this section, particularly the
Insights on Alzheimer’s Disease from the Intracerebral Injection and Infusion …
39
increased expression of growth factors following Aβ injection or infusion [Fukuta et al., 2001; Tang et al., 2000; Zand et al., 2005], provides further support for the notion that this peptide may also have beneficial effects.
Altering the Effects of Aβ with Other Agents While this chapter has focussed on studies that have injected or infused pure forms of Aβ into the brain, several studies have combined Aβ with other agents in an attempt to increase its rate of deposition or decrease its rate of clearance. For instance, some groups have prevented breakdown of the injected deposit with β-sheet breakers [Soto et al., 1998] and others have injected AlCl3 into the lateral ventricle prior to infusion of Aβ in order to increase its aggregation [e.g. Hashimoto et al., 2002; Oka et al., 1999]. Such procedures may result in the formation of a complex with very different properties to the original peptide. For example, co-infusion of Aβ with the protease inhibitor leupeptin into rat lateral ventricles not only increases the deposition of Aβ in the rat brain, it also greatly increases its toxicity and the microglial response [Frautschy et al., 1998]. By contrast, co-infusion of Aβ with perlecan into rat hippocampus increases the length of time that Aβ remains deposited at the injection site, yet this increased deposition is reported to have no effect on microglial reactivity when compared to infusion of Aβ alone [Snow et al., 1994]. Other studies that have seen little or no effect of Aβ on the brain have mixed the peptide with other toxic substances in the hope of making Aβ toxic. For instance, when Aβ is coinjected with ibotenic acid, an NMDA agonist, there is a significant increase in neuronal degeneration as seen by Nissl staining and a reduction in MAP-2-positive neurones [Morimoto et al., 1998]. Similarly, the present authors have observed that co-injection of Aβ1-42 with either iron or zinc increases the amount of neuronal death at cortical injection sites [Bishop & Robinson, 2003b; Bishop & Robinson, 2004a]. While co-injection of Aβ with another agent can increase the toxicity of Aβ, some researchers have instead primed the injection site with another agent and then infused or injected the Aβ peptide. An example of this is seen when A/TFA is injected into the lateral ventricle prior to Aβ infusion in order to compromise the viability of neurones and make them more vulnerable to any neurotoxicity of Aβ [Pavia et al., 2000]. After this priming, Aβ was then injected 15 minutes later and then injected daily for a period of 7 days [Pavia et al., 2000; Saez-Valero et al., 2002]. Surprisingly, neither of these studies observed detrimental effects on the cholinergic system after repeated Aβ injections, but instead saw an increased number of AChE-positive cortical fibres and neurones [Pavia et al., 2000] or a change in the isoforms of AChE [Saez-Valero et al., 2002]. Another reason for co-injecting agents with Aβ is to ameliorate the deleterious effects of Aβ on neurones. For example, when substance P was co-injected with Aβ1-40 into rat cerebral cortex, there was a decrease in the extent of neuronal loss compared to that caused by injection of Aβ alone [Kowall et al., 1991]. However in a similar study where substance P was instead co-injected with Aβ25-35 into rat hippocampus, no change was observed in the amount of neuronal death when compared to Aβ25-35 alone [Rush et al., 1992]. Another method of decreasing Aβ toxicity is the systemic administration of pharmaceutical
40
Glenda M. Bishop and Stephen R. Robinson
compounds. For instance, administration of the NMDA antagonist MK-801 for 4 days after Aβ1-42 injection into the NB improved both AChE and ChAT activity and decreased Aβinduced anxiety, whereas treatment with vitamins C and E only improved ChAT activity [Harkany et al., 1999b]. Both treatment regimes improved the loss of MnSOD activity, but only the vitamins decreased the elevated Cu/ZnSOD activity. A different approach was taken by Netland and colleagues (1998) who reported that the microglial reactivity induced by Aβ could be reduced by administering the anti-inflammatory agent indomethacin twice daily to rats during their 14-day infusion of Aβ. Similarly, co-infusion of Aβ with indomethacin decreased microglial reactivity [Netland et al., 1998]. Propentofylline has been reported to improve behavioural deteriorations after infusion of Aβ, yet could not return ChAT activity to normal [Yamada et al., 1998]. In adrenalectomised rats, their decreased corticosterone levels increased the toxicity of Aβ1-42 injections to the NB, while replacement of corticosterone in the low to middle dosage range protected against the toxicity of Aβ1-42 [Abraham et al., 2000]. The data described above demonstrate the ease with which the effects of Aβ can be altered by subtle changes of experimental design. Furthermore, these studies show that injection and infusion models can be used to study interactions between Aβ and other agents that are present within plaques, as well as to test treatments that may ameliorate the negative effects of Aβ.
Conclusion In this chapter we have shown that injection/infusion models of AD are able to extend our understanding of aspects of AD pathogenesis in ways that are not possible with other techniques. Compared with transgenic mouse models, these in vivo techniques have superior temporal and spatial resolution, and they allow greater flexibility for investigating the physiological effects of different isoforms and fragments of Aβ. Perhaps their greatest advantage, yet the least exploited, is the capacity to deliver human isoforms of Aβ into primate brain. The collective results of Aβ injection/infusion studies clearly indicate strong and diverse bioactive effects of Aβ in vivo. When taken together, the studies have demonstrated that Aβ does not induce neuronal degeneration in the majority of cases, and that there is a regional variability in the susceptibility of neurones to Aβ toxicity. While neuronal death was not a prominent effect of Aβ, subtle changes were evident in a variety of neurotransmitter systems. Indeed, it appeared that the cholinergic system may be more vulnerable than other neurotransmitter systems such as the glutamatergic pathways. Aβ was quite proficient at increasing the reactivity of astrocytes and microglia, although the responsiveness varied across brain regions. A reasonable body of evidence indicates that Aβ can elicit behavioural changes, particularly the acquisition of memory on spatial and discriminative learning tasks, and these impairments are paralleled by a higher threshold for induction of LTP. There was also an indication of changes in markers of oxidative stress. The results reviewed in this chapter have highlighted some fundamental issues confronting AD research at the present time. While these issues have already been raised by findings from transgenic mouse models, it appears to us that injection/infusion models offer
Insights on Alzheimer’s Disease from the Intracerebral Injection and Infusion …
41
the greatest promise of their resolution. The most important of these issues relates to the varied effects that Aβ exerts on the brain and behaviour. It is critical to determine whether all of these effects are a direct result of Aβ deposition, or whether some of them are secondary effects brought about by a cascade of events. A cascade might be initiated for example, by the strongly pro-inflammatory nature of Aβ, which targets C1q receptors on microglia [Daly and Kotwal, 1998; Jiang et al., 1994; Rogers et al., 1992]. The resultant phagocytic response would lead to the release of cytokines and pro-oxidants which in turn would activate astrocytes and impair their homeostatic control of synaptic function. Most of the effects of Aβ reported in this chapter could be consequences of such a cascade. It would be difficult to detect such cascades in transgenic mice because the continuous production and deposition of Aβ would obscure the temporal sequence of events. With injection/infusion models however, it should be possible to establish whether such a series of events occurs, and then to use pharmacological interventions to block steps in this cascade. Aβ is produced continuously by the brain throughout life, and this ubiquity suggests that it has a physiological role. Several roles have been proposed, including the modulation of synaptic function [for reviews see Bishop and Robinson, 2004b; Robinson and Bishop, 2002]. A challenge facing researchers is to determine which of the effects of Aβ seen in animal models are pathological and which are physiologically relevant. Investigation of this issue has been limited by the need to administer abnormally high concentrations of Aβ in order to cause its deposition in the brain. For example, in order to obtain plaques, transgenic mouse models express mutant human APP, and presumably Aβ, at concentrations that are 510 times higher than are present under normal physiological conditions [Games et al., 1995; Hsiao et al., 1996]. Similarly, most injection/infusion models have delivered concentrations of Aβ that are intended to resemble those found in Aβ plaques (approximately 1-10mM [Selkoe et al., 1986]), rather than the levels normally found in the CSF, which are 6-9 orders of magnitude lower (approximately 50-500pM [Ida et al., 1996]). Nonetheless, injection/infusion models have the capacity to deliver Aβ into selected regions of the brain at concentrations which more closely approximate those found normally. Such approaches, particularly when combined with behavioural or electophysiological measures, will assist us to distinguish the beneficial effects from the deleterious effects of this peptide. At the outset of this chapter we noted that no consensus had yet been reached from injection/infusion models concerning the effects of Aβ on the living brain. A goal of the present chapter was to categorise studies according to the investigative approach used, in the hope that this would reduce the degree of variability in the results. While this approach was useful, substantial variability remained, even when the comparison was restricted to studies that had used physiological forms of Aβ, physiological solvents and rigorous control conditions. In Table 2 for example, 11 physiological studies reported that Aβ injection kills significant numbers of neurones while 12 reported that it does not. It is tempting to dismiss the results of discordant studies as being due to methodological differences but the real challenge is to determine why in some instances Aβ is toxic to neurones, whereas in almost identical paradigms, it is not. The solution to this conundrum may well hold the key to understanding the pathogenesis of AD.
42
Glenda M. Bishop and Stephen R. Robinson
Acknowledgements We wish to acknowledge the support of a Dementia Grant from Alzheimer’s Australia Research Foundation Limited and a National Health and Medical Research Council Peter Doherty Fellowship to GB (ID: 284393).
References Abe, K., Tanzi, R. E. and Kogure, K. (1991) Selective induction of Kunitz-type protease inhibitor domain-containing amyloid precursor protein mRNA after persistent focal ischemia in rat cerebral cortex. Neurosci Lett, 125, 172-174. Abraham, I., Harkany, T., Horvath, K. M., Veenema, A. H., Penke, B., Nyakas, C. and Luiten, P. G. (2000) Chronic corticosterone administration dose-dependently modulates Aβ(1-42)- and NMDA-induced neurodegeneration in rat magnocellular nucleus basalis. J Neuroendocrinol, 12, 486-494. Aguado-Llera, D., Arilla-Ferreiro, E., Campos-Barros, A., Puebla-Jimenez, L. and Barrios, V. (2005) Protective effects of insulin-like growth factor-I on the somatostatinergic system in the temporal cortex of β-amyloid-treated rats. J Neurochem, 92, 607-615. Alvarez, A., Alarcon, R., Opazo, C., Campos, E. O., Munoz, F. J., Calderon, F. H., Dajas, F., Gentry, M. K., Doctor, B. P., De Mello, F. G. and Inestrosa, N. C. (1998) Stable complexes involving acetylcholinesterase and amyloid-β peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J Neurosci, 18, 3213-3223. Ammassari-Teule, M., Middei, S., Passino, E. and Restivo, L. (2002) Enhanced procedural learning following β-amyloid protein (1-42) infusion in the rat. Neuroreport, 13, 16791682. Arias, C., Montiel, T., Quiroz-Baez, R. and Massieu, L. (2002) β-amyloid neurotoxicity is exacerbated during glycolysis inhibition and mitochondrial impairment in the rat hippocampus in vivo and in isolated nerve terminals: implications for Alzheimer's disease. Exp Neurol, 176, 163-174. Baltrons, M. A., Pedraza, C. E., Heneka, M. T. and Garcia, A. (2002) β-amyloid peptides decrease soluble guanylyl cyclase expression in astroglial cells. Neurobiol Dis, 10, 139149. Bhagat, Y. A., Obenaus, A., Richardson, J. S. and Kendall, E. J. (2002) Evolution of βamyloid induced neuropathology: magnetic resonance imaging and anatomical comparisons in the rodent hippocampus. Magma, 14, 223-232. Bishop, G. M. and Robinson, S. R. (2003a) Deposits of fibrillar Aβ do not cause neuronal loss or ferritin expression in adult rat brain. J Neural Transm, 110, 381-400. Bishop, G. M. and Robinson, S. R. (2003b) Human Aβ1-42 reduces iron-induced toxicity in rat cerebral cortex. J Neurosci Res, 73, 316-323. Bishop, G. M. and Robinson, S. R. (2004a) The amyloid paradox: amyloid-β-metal complexes can be neurotoxic and neuroprotective. Brain Pathol, 14, 448-452.
Insights on Alzheimer’s Disease from the Intracerebral Injection and Infusion …
43
Bishop, G. M. and Robinson, S. R. (2004b) Physiological roles of amyloid-β and implications for its removal in Alzheimer's disease. Drugs Aging, 21, 621-630. Boyd-Kimball, D., Sultana, R., Fai Poon, H., Lynn, B. C., Casamenti, F., Pepeu, G., Klein, J. B. and Butterfield, D. A. (2005) Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid β-peptide (1-42) into rat brain: Implications for Alzheimer's disease. Neuroscience, 132, 313-324. Brining, S. K., Jones, C. R. and Chang, M. C. (1996) Effects of chronic β-amyloid treatment on fatty acid incorporation into rat brain. Neurobiol Aging, 17, 301-309. Bush, A. I., Moir, R. D., Rosenkranz, K. M. and Tanzi, R. E. (1995) Zinc and Alzheimer's disease. Science, 268, 1921-1923. Bush, A. I., Pettingell, W. H., Multhaup, G., d Paradis, M., Vonsattel, J. P., Gusella, J. F., Beyreuther, K., Masters, C. L. and Tanzi, R. E. (1994) Rapid induction of Alzheimer Aβ amyloid formation by zinc. Science, 265, 1464-1467. Chambers, C. B., Sigurdsson, E. M., Hejna, M. J., Lorens, S. A., Lee, J. M. and Muma, N. A. (2000) Amyloid-β injection in rat amygdala alters tau protein but not mRNA expression. Exp Neurol, 162, 158-170. Chen, S. Y., Wright, J. W. and Barnes, C. D. (1996) The neurochemical and behavioral effects of β-amyloid peptide(25-35). Brain Res, 720, 54-60. Choi, S. H., Park, C. H., Koo, J. W., Seo, J. H., Kim, H. S., Jeong, S. J., Lee, J. H., Kim, S. S. and Suh, Y. H. (2001) Memory impairment and cholinergic dysfunction by centrally administered Aβ and carboxyl-terminal fragment of Alzheimer's APP in mice. FASEB J, 15, 1816-1818. Cleary, J., Hittner, J. M., Semotuk, M., Mantyh, P. and O'Hare, E. (1995) β-amyloid(1-40) effects on behavior and memory. Brain Res, 682, 69-74. Clemens, J. A. and Stephenson, D. T. (1992) Implants containing β-amyloid protein are not neurotoxic to young and old rat brain. Neurobiol Aging, 13, 581-586. Daly, J. and Kotwal, G. J. (1998) Pro-inflammatory complement activation by the Aβ peptide of Alzheimer's disease is biologically significant and can be blocked by vaccinia virus complement control protein. Neurobiol Aging, 19, 619-627. Delobette, S., Privat, A. and Maurice, T. (1997) In vitro aggregation facilities β-amyloid peptide-(25-35)-induced amnesia in the rat. Eur J Pharmacol, 319, 1-4. Dornan, W. A., Kang, D. E., McCampbell, A. and Kang, E. E. (1993) Bilateral injections of βA(25-35) + IBO into the hippocampus disrupts acquisition of spatial learning in the rat. Neuroreport, 5, 165-168. Dudas, B., Cornelli, U., Lee, J. M., Hejna, M. J., Walzer, M., Lorens, S. A., Mervis, R. F., Fareed, J. and Hanin, I. (2002) Oral and subcutaneous administration of the glycosaminoglycan C3 attenuates Aβ(25-35)-induced abnormal tau protein immunoreactivity in rat brain. Neurobiol Aging, 23, 97-104. Durell, S. R., Guy, H. R., Arispe, N., Rojas, E. and Pollard, H. B. (1994) Theoretical models of the ion channel structure of amyloid β-protein. Biophys J, 67, 2137-2145. El Khoury, J. B., Moore, K. J., Means, T. K., Leung, J., Terada, K., Toft, M., Freeman, M. W. and Luster, A. D. (2003) CD36 mediates the innate host response to β-amyloid. J Exp Med, 197, 1657-1666.
44
Glenda M. Bishop and Stephen R. Robinson
Emre, M., Geula, C., Ransil, B. J. and Mesulam, M. M. (1992) The acute neurotoxicity and effects upon cholinergic axons of intracerebrally injected β-amyloid in the rat brain. Neurobiol Aging, 13, 553-559. Flood, J. F., Morley, J. E. and Roberts, E. (1991) Amnestic effects in mice of four synthetic peptides homologous to amyloid β protein from patients with Alzheimer disease. Proc Natl Acad Sci U S A, 88, 3363-3366. Flood, J. F., Morley, J. E. and Roberts, E. (1994) An amyloid β-protein fragment, Aβ[12-28], equipotently impairs post-training memory processing when injected into different limbic system structures. Brain Res, 663, 271-276. Frautschy, S. A., Horn, D. L., Sigel, J. J., Harris-White, M. E., Mendoza, J. J., Yang, F., Saido, T. C. and Cole, G. M. (1998) Protease inhibitor coinfusion with amyloid β-protein results in enhanced deposition and toxicity in rat brain. J Neurosci, 18, 8311-8321. Freeman, J. J. and Hayes, E. P. (1988) Microsomal metabolism of acetonitrile to cyanide. Effects of acetone and other compounds. Biochem Pharmacol, 37, 1153-1159. Freir, D. B., Costello, D. A. and Herron, C. E. (2003) Aβ25-35-induced depression of longterm potentiation in area CA1 in vivo and in vitro is attenuated by verapamil. J Neurophysiol, 89, 3061-3069. Freir, D. B. and Herron, C. E. (2003) Nicotine enhances the depressive actions of Aβ1-40 on long-term potentiation in the rat hippocampal CA1 region in vivo. J Neurophysiol, 89, 2917-2922. Freir, D. B., Holscher, C. and Herron, C. E. (2001) Blockade of long-term potentiation by βamyloid peptides in the CA1 region of the rat hippocampus in vivo. J Neurophysiol, 85, 708-713. Fukuta, T., Nitta, A., Itoh, A., Furukawa, S. and Nabeshima, T. (2001) Difference in toxicity of β-amyloid peptide with aging in relation to nerve growth factor content in rat brain. J Neural Transm, 108, 221-230. Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., Guido, T., Hagoplan, S., Johnson-Wood, K., Khan, K., Lee, M., Leibowitz, P., Lieberburg, I., Little, S., Masliah, E., McConlogue, L., Montoya-Zavala, M., Mucke, L., Paganini, L., E., P., Power, M., Schenk, D., Seubert, P., Snyder, B., Soriano, F., Tan, H., Vitale, J., Wadsworth, S., Wolozin, B. and Zhao, J. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F βamyloid precursor protein. Nature, 373, 523-527. Games, D., Khan, K. M., Soriano, F. G., Keim, P. S., Davis, D. L., Bryant, K. and Lieberburg, I. (1992) Lack of Alzheimer pathology after β-amyloid protein injections in rat brain. Neurobiol Aging, 13, 569-576. Geula, C., Wu, C. K., Saroff, D., Lorenzo, A., Yuan, M. and Yankner, B. A. (1998) Aging renders the brain vulnerable to amyloid β-protein neurotoxicity. Nat Med, 4, 827-831. Ghribi, O., Herman, M. M., DeWitt, D. A., Forbes, M. S. and Savory, J. (2001) Aβ(1-42) and aluminum induce stress in the endoplasmic reticulum in rabbit hippocampus, involving nuclear translocation of gadd 153 and NF-κB. Brain Res Mol Brain Res, 96, 30-38. Ghribi, O., Herman, M. M., Pramoonjago, P., Spaulding, N. K. and Savory, J. (2004) GDNF regulates the Aβ-induced endoplasmic reticulum stress response in rabbit hippocampus
Insights on Alzheimer’s Disease from the Intracerebral Injection and Infusion …
45
by inhibiting the activation of gadd 153 and the JNK and ERK kinases. Neurobiol Dis, 16, 417-427. Ghribi, O., Herman, M. M. and Savory, J. (2003) Lithium inhibits Aβ-induced stress in endoplasmic reticulum of rabbit hippocampus but does not prevent oxidative damage and tau phosphorylation. J Neurosci Res, 71, 853-862. Giordano, T., Pan, J. B., Monteggia, L. M., Holzman, T. F., Snyder, S. W., Krafft, G., Ghanbari, H. and Kowall, N. W. (1994) Similarities between β amyloid peptides 1-40 and 40-1: effects on aggregation, toxicity in vitro, and injection in young and aged rats. Exp Neurol, 125, 175-182. Giovannelli, L., Casamenti, F., Scali, C., Bartolini, L. and Pepeu, G. (1995) Differential effects of amyloid peptides β-(1-40) and β-(25-35) injections into the rat nucleus basalis. Neuroscience, 66, 781-792. Giovannelli, L., Scali, C., Faussone-Pellegrini, M. S., Pepeu, G. and Casamenti, F. (1998) Long-term changes in the aggregation state and toxic effects of β-amyloid injected into the rat brain. Neuroscience, 87, 349-357. Giovannini, M. G., Scali, C., Prosperi, C., Bellucci, A., Vannucchi, M. G., Rosi, S., Pepeu, G. and Casamenti, F. (2002) β-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis, 11, 257274. Giulian, D., Haverkamp, L. J., Yu, J. H., Karshin, W., Tom, D., Li, J., Kirkpatrick, J., Kuo, L. M. and Roher, A. E. (1996) Specific domains of β-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J Neurosci, 16, 6021-6037. Glenner, G. G. and Wong, C. W. (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun, 120, 885-890. Goldberg, M. P., Weiss, J. H., Pham, P. C. and Choi, D. W. (1987) N-methyl-D-aspartate receptors mediate hypoxic neuronal injury in cortical culture. J Pharmacol Exp Ther, 243, 784-791. Gonzalo-Ruiz, A., Gonzalez, I. and Sanz-Anquela, J. M. (2003) Effects of β-amyloid protein on serotoninergic, noradrenergic, and cholinergic markers in neurons of the pontomesencephalic tegmentum in the rat. J Chem Neuroanat, 26, 153-169. Gonzalo-Ruiz, A., Sanz, J. M., Arevalo, J., Geula, C. and Gonzalo, P. (2005) Amyloid β peptide-induced cholinergic fibres loss in the cerebral cortex of the rat is modified by diet high in lipids and by age. J Chem Neuroanat, 29, 31-48. Halliday, G., Robinson, S. R., Shepherd, C. and Kril, J. (2000) Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms. Clin Exp Pharmacol Physiol, 27, 1-8. Harkany, T., Abraham, I., Laskay, G., Timmerman, W., Jost, K., Zarandi, M., Penke, B., Nyakas, C. and Luiten, P. G. (1999a) Propionyl-IIGL tetrapeptide antagonizes β-amyloid excitotoxicity in rat nucleus basalis. Neuroreport, 10, 1693-1698. Harkany, T., Abraham, I., Timmerman, W., Laskay, G., Toth, B., Sasvari, M., Konya, C., Sebens, J. B., Korf, J., Nyakas, C., Zarandi, M., Soos, K., Penke, B. and Luiten, P. G. (2000) β-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci, 12, 2735-2745.
46
Glenda M. Bishop and Stephen R. Robinson
Harkany, T., De Jong, G. I., Soos, K., Penke, B., Luiten, P. G. and Gulya, K. (1995a) βamyloid (1-42) affects cholinergic but not parvalbumin-containing neurons in the septal complex of the rat. Brain Res, 698, 270-274. Harkany, T., Lengyel, Z., Soos, K., Penke, B., Luiten, P. G. and Gulya, K. (1995b) Cholinotoxic effects of β-amyloid (1-42) peptide on cortical projections of the rat nucleus basalis magnocellularis. Brain Res, 695, 71-75. Harkany, T., Mulder, J., Sasvari, M., Abraham, I., Konya, C., Zarandi, M., Penke, B., Luiten, P. G. and Nyakas, C. (1999b) N-Methyl-D-aspartate receptor antagonist MK-801 and radical scavengers protect cholinergic nucleus basalis neurons against β-amyloid neurotoxicity. Neurobiol Dis, 6, 109-121. Harkany, T., O'Mahony, S., Keijser, J., Kelly, J. P., Konya, C., Borostyankoi, Z. A., Gorcs, T. J., Zarandi, M., Penke, B., Leonard, B. E. and Luiten, P. G. (2001) β-amyloid(1-42)induced cholinergic lesions in rat nucleus basalis bidirectionally modulate serotonergic innervation of the basal forebrain and cerebral cortex. Neurobiol Dis, 8, 667-678. Harris, M. E., Hensley, K., Butterfield, D. A., Leedle, R. A. and Carney, J. M. (1995) Direct evidence of oxidative injury produced by the Alzheimer's β-amyloid peptide (1-40) in cultured hippocampal neurons. Exp Neurol, 131, 193-202. Hartley, D. M., Walsh, D. M., Ye, C. P., Diehl, T., Vasquez, S., Vassilev, P. M., Teplow, D. B. and Selkoe, D. J. (1999) Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci, 19, 8876-8884. Hashimoto, M., Hossain, S., Shimada, T., Sugioka, K., Yamasaki, H., Fujii, Y., Ishibashi, Y., Oka, J. and Shido, O. (2002) Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J Neurochem, 81, 1084-1091. Henke, H. and Lang, W. (1983) Cholinergic enzymes in neocortex, hippocampus and basal forebrain of non-neurological and senile dementia of Alzheimer-type patients. Brain Res, 267, 281-291. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F. and Cole, G. (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science, 274, 99-102. Ida, N., Hartmann, T., Pantel, J., Schroder, J., Zerfass, R., Forstl, H., Sandbrink, R., Masters, C. L. and Beyreuther, K. (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem, 271, 22908-22914. Irizarry, M. C., McNamara, M., Fedorchak, K., Hsiao, K. and Hyman, B. T. (1997a) APPSw transgenic mice develop age-related Aβ deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol, 56, 965-973. Irizarry, M. C., Soriano, F., McNamara, M., Page, K. J., Schenk, D., Games, D. and Hyman, B. T. (1997b) Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci, 17, 7053-7059. Itoh, A., Akaike, T., Sokabe, M., Nitta, A., Iida, R., Olariu, A., Yamada, K. and Nabeshima, T. (1999) Impairments of long-term potentiation in hippocampal slices of β-amyloidinfused rats. Eur J Pharmacol, 382, 167-175.
Insights on Alzheimer’s Disease from the Intracerebral Injection and Infusion …
47
Itoh, A., Nitta, A., Nadai, M., Nishimura, K., Hirose, M., Hasegawa, T. and Nabeshima, T. (1996) Dysfunction of cholinergic and dopaminergic neuronal systems in β-amyloid protein-infused rats. J Neurochem, 66, 1113-1117. Jantaratnotai, N., Ryu, J. K., Kim, S. U. and McLarnon, J. G. (2003) Amyloid β peptideinduced corpus callosum damage and glial activation in vivo. Neuroreport, 14, 14291433. Jen, L. S., Hart, A. J., Jen, A., Relvas, J. B., Gentleman, S. M., Garey, L. J. and Patel, A. J. (1998) Alzheimer's peptide kills cells of retina in vivo. Nature, 392, 140-141. Jhoo, J. H., Kim, H. C., Nabeshima, T., Yamada, K., Shin, E. J., Jhoo, W. K., Kim, W., Kang, K. S., Jo, S. A. and Woo, J. I. (2004) β-amyloid (1-42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex. Behav Brain Res, 155, 185-196. Jiang, H., Burdick, D., Glabe, C. G., Cotman, C. W. and Tenner, A. J. (1994) β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J Immunol, 152, 5050-5059. Jin, D. Q., Park, B. C., Lee, J. S., Choi, H. D., Lee, Y. S., Yang, J. H. and Kim, J. A. (2004) Mycelial extract of Cordyceps ophioglossoides prevents neuronal cell death and ameliorates β-amyloid peptide-induced memory deficits in rats. Biol Pharm Bull, 27, 1126-1129. Kim, H. C., Yamada, K., Nitta, A., Olariu, A., Tran, M. H., Mizuno, M., Nakajima, A., Nagai, T., Kamei, H., Jhoo, W. K., Im, D. H., Shin, E. J., Hjelle, O. P., Ottersen, O. P., Park, S. C., Kato, K., Mirault, M. E. and Nabeshima, T. (2003) Immunocytochemical evidence that amyloid β (1-42) impairs endogenous antioxidant systems in vivo. Neuroscience, 119, 399-419. Kim, H. S., Cho, J. Y., Kim, D. H., Yan, J. J., Lee, H. K., Suh, H. W. and Song, D. K. (2004) Inhibitory effects of long-term administration of ferulic acid on microglial activation induced by intracerebroventricular injection of β-amyloid peptide (1-42) in mice. Biol Pharm Bull, 27, 120-121. Kim, J. H., Anwyl, R., Suh, Y. H., Djamgoz, M. B. and Rowan, M. J. (2001) Use-dependent effects of amyloidogenic fragments of β-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J Neurosci, 21, 1327-1333. Klyubin, I., Walsh, D. M., Cullen, W. K., Fadeeva, J. V., Anwyl, R., Selkoe, D. J. and Rowan, M. J. (2004) Soluble Arctic amyloid β protein inhibits hippocampal long-term potentiation in vivo. Eur J Neurosci, 19, 2839-2846. Koh, J. Y., Yang, L. L. and Cotman, C. W. (1990) β-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res, 533, 315320. Kowall, N. W., Beal, M. F., Busciglio, J., Duffy, L. K. and Yankner, B. A. (1991) An in vivo model for the neurodegenerative effects of β amyloid and protection by substance P. Proc Natl Acad Sci U S A, 88, 7247-7251. Kowall, N. W., McKee, A. C., Yankner, B. A. and Beal, M. F. (1992) In vivo neurotoxicity of beta-amyloid [β(1-40)] and the β(25-35) fragment. Neurobiol Aging, 13, 537-542.
48
Glenda M. Bishop and Stephen R. Robinson
Li, L. X., Dai, J. P., Ru, L. Q., Yin, G. F. and Zhao, B. (2004a) Effects of tanshinone on neuropathological changes induced by amyloid β-peptide(1-40) injection in rat hippocampus. Acta Pharmacol Sin, 25, 861-868. Li, Y., Qin, H. Q., Chen, Q. S. and Wang, J. J. (2004b) Behavioral and neurochemical effects of the intrahippocampal co-injection of β-amyloid protein 1-40 and ibotenic acid in rats. Int J Neurosci, 114, 1521-1531. Malin, D. H., Crothers, M. K., Lake, J. R., Goyarzu, P., Plotner, R. E., Garcia, S. A., Spell, S. H., Tomsic, B. J., Giordano, T. and Kowall, N. W. (2001) Hippocampal injections of amyloid β-peptide 1-40 impair subsequent one-trial/day reward learning. Neurobiol Learn Mem, 76, 125-137. Mantyh, P. W., Ghilardi, J. R., Rogers, S., DeMaster, E., Allen, C. J., Stimson, E. R. and Maggio, J. E. (1993) Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide. J Neurochem, 61, 1171-1174. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L. and Beyreuther, K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A, 82, 4245-4249. Matsunaga, W., Shirokawa, T. and Isobe, K. (2003) Specific uptake of Aβ1-40 in rat brain occurs in astrocyte, but not in microglia. Neurosci Lett, 342, 129-131. Maurice, T., Lockhart, B. P. and Privat, A. (1996) Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction. Brain Res, 706, 181193. Mazzola, C., Micale, V. and Drago, F. (2003) Amnesia induced by β-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur J Pharmacol, 477, 219-225. McDonald, M. P., Overmier, J. B., Bandyopadhyay, S., Babcock, D. and Cleary, J. (1996) Reversal of β-amyloid-induced retention deficit after exposure to training and state cues. Neurobiol Learn Mem, 65, 35-47. Miguel-Hidalgo, J. J., Vecino, B., Fernandez-Novoa, L., Alvarez, A. and Cacabelos, R. (1998) Neuroprotective role of S12024 against neurodegeneration in the rat dentate gyrus. Eur Neuropsychopharmacol, 8, 203-208. Mileusnic, R., Lancashire, C. L. and Rose, S. P. (2004) The peptide sequence Arg-Glu-Arg, present in the amyloid precursor protein, protects against memory loss caused by Aβ and acts as a cognitive enhancer. Eur J Neurosci, 19, 1933-1938. Minogue, A. M., Schmid, A. W., Fogarty, M. P., Moore, A. C., Campbell, V. A., Herron, C. E. and Lynch, M. A. (2003) Activation of the c-Jun N-terminal kinase signaling cascade mediates the effect of amyloid-β on long term potentiation and cell death in hippocampus: a role for interleukin-1β? J Biol Chem, 278, 27971-27980. Mohajeri, M. H., Wollmer, M. A. and Nitsch, R. M. (2002) Aβ42-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo. J Biol Chem, 277, 35460-35465. Morimoto, K. and Oda, T. (2003) Kainate exacerbates β-amyloid toxicity in rat hippocampus. Neurosci Lett, 340, 242-244. Morimoto, K., Yoshimi, K., Tonohiro, T., Yamada, N., Oda, T. and Kaneko, I. (1998) Coinjection of β-amyloid with ibotenic acid induces synergistic loss of rat hippocampal neurons. Neuroscience, 84, 479-487.
Insights on Alzheimer’s Disease from the Intracerebral Injection and Infusion …
49
Nabeshima, T. and Nitta, A. (1994) Memory impairment and neuronal dysfunction induced by β-amyloid protein in rats. Tohoku J Exp Med, 174, 241-249. Nag, S. and Tang, F. (2001) The effect of age on the response of the rat brains to continuous β-amyloid infusion. Brain Res, 889, 303-307. Nag, S., Tang, F. and Yee, B. K. (2001) Chronic intracerebroventricular exposure to βamyloid(1-40) impairs object recognition but does not affect spontaneous locomotor activity or sensorimotor gating in the rat. Exp Brain Res, 136, 93-100. Nag, S., Yee, B. K. and Tang, F. (1999) Reduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of β-amyloid (1-40). Brain Res Bull, 50, 251-262. Nakagawa, Y., Yuzuriha, T. and Iwaki, T. (2004) Active clearance of human amyloid β1-42 peptide aggregates from the rat ventricular system. Neuropathology, 24, 194-200. Nakamura, S., Murayama, N., Noshita, T., Annoura, H. and Ohno, T. (2001) Progressive brain dysfunction following intracerebroventricular infusion of β1-42-amyloid peptide. Brain Res, 912, 128-136. Nelson, P. T. and Saper, C. B. (1996) Injections of okadaic acid, but not β-amyloid peptide, induce Alz-50 immunoreactive dystrophic neurites in the cerebral cortex of sheep. Neurosci Lett, 208, 77-80. Netland, E. E., Newton, J. L., Majocha, R. E. and Tate, B. A. (1998) Indomethacin reverses the microglial response to amyloid β-protein. Neurobiol Aging, 19, 201-204. Nitta, A., Fukuta, T., Hasegawa, T. and Nabeshima, T. (1997) Continuous infusion of βamyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration. Jpn J Pharmacol, 73, 51-57. Nitta, A., Itoh, A., Hasegawa, T. and Nabeshima, T. (1994) β-Amyloid protein-induced Alzheimer's disease animal model. Neurosci Lett, 170, 63-66. O'Hare, E., Weldon, D. T., Mantyh, P. W., Ghilardi, J. R., Finke, M. P., Kuskowski, M. A., Maggio, J. E., Shephard, R. A. and Cleary, J. (1999) Delayed behavioral effects following intrahippocampal injection of aggregated Aβ(1-42). Brain Res, 815, 1-10. Oka, J., Suzuki, E., Goto, N. and Kameyama, T. (1999) Endogenous GLP-1 modulates hippocampal activity in β-amyloid protein-treated rats. Neuroreport, 10, 2961-2964. Olariu, A., Tran, M. H., Yamada, K., Mizuno, M., Hefco, V. and Nabeshima, T. (2001) Memory deficits and increased emotionality induced by β-amyloid (25-35) are correlated with the reduced acetylcholine release and altered phorbol dibutyrate binding in the hippocampus. J Neural Transm, 108, 1065-1079. Olariu, A., Yamada, K., Mamiya, T., Hefco, V. and Nabeshima, T. (2002) Memory impairment induced by chronic intracerebroventricular infusion of β-amyloid (1-40) involves downregulation of protein kinase C. Brain Res, 957, 278-286. O'Mahony, S., Harkany, T., Rensink, A. A., Abraham, I., De Jong, G. I., Varga, J. L., Zarandi, M., Penke, B., Nyakas, C., Luiten, P. G. and Leonard, B. E. (1998) β-amyloidinduced cholinergic denervation correlates with enhanced nitric oxide synthase activity in rat cerebral cortex: reversal by NMDA receptor blockade. Brain Res Bull, 45, 405411.
50
Glenda M. Bishop and Stephen R. Robinson
Pan, Y., Xu, X., Tong, X. and Wang, X. (2004) Messenger RNA and protein expression analysis of voltage-gated potassium channels in the brain of Aβ(25-35)-treated rats. J Neurosci Res, 77, 94-99. Pavia, J., Alberch, J., Alvarez, I., Toledano, A. and de Ceballos, M. L. (2000) Repeated intracerebroventricular administration of β-amyloid(25-35) to rats decreases muscarinic receptors in cerebral cortex. Neurosci Lett, 278, 69-72. Perez-Severiano, F., Salvatierra-Sanchez, R., Rodriguez-Perez, M., Cuevas-Martinez, E. Y., Guevara, J., Limon, D., Maldonado, P. D., Medina-Campos, O. N., Pedraza-Chaverri, J. and Santamaria, A. (2004) S-Allylcysteine prevents amyloid-β peptide-induced oxidative stress in rat hippocampus and ameliorates learning deficits. Eur J Pharmacol, 489, 197202. Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H. and Perry, R. H. (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J, 2, 1457-1459. Pike, C. J., Cummings, B. J. and Cotman, C. W. (1992) β-amyloid induces neuritic dystrophy in vitro: similarities with Alzheimer pathology. Neuroreport, 3, 769-772. Pike, C. J., Walencewicz, A. J., Glabe, C. G. and Cotman, C. W. (1991) In vitro aging of βamyloid protein causes peptide aggregation and neurotoxicity. Brain Res, 563, 311-314. Podlisny, M. B., Stephenson, D. T., Frosch, M. P., Lieberburg, I., Clemens, J. A. and Selkoe, D. J. (1992) Synthetic amyloid β-protein fails to produce specific neurotoxicity in monkey cerebral cortex. Neurobiol Aging, 13, 561-567. Podlisny, M. B., Stephenson, D. T., Frosch, M. P., Tolan, D. R., Lieberburg, I., Clemens, J. A. and Selkoe, D. J. (1993) Microinjection of synthetic amyloid β-protein in monkey cerebral cortex fails to produce acute neurotoxicity. Am J Pathol, 142, 17-24. Reyes, A. E., Chacon, M. A., Dinamarca, M. C., Cerpa, W., Morgan, C. and Inestrosa, N. C. (2004) Acetylcholinesterase-Aβ complexes are more toxic than Aβ fibrils in rat hippocampus: effect on rat β-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss. Am J Pathol, 164, 2163-2174. Richardson, R. L., Kim, E. M., Shephard, R. A., Gardiner, T., Cleary, J. and O'Hare, E. (2002) Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Aβ(1-42) injections in the rat. Brain Res, 954, 1-10. Robinson, S. R. and Bishop, G. M. (2002) Aβ as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. Neurobiol Aging, 23, 1051-1072. Rogers, J., Cooper, N. R., Webster, S., Schultz, J., McGeer, P. L., Styren, S. D., Civin, W. H., Brachova, L., Bradt, B., Ward, P. and Lieberburg, I. (1992) Complement activation by βamyloid in Alzheimer disease. Proc Natl Acad Sci U S A, 89, 10016-10020. Roher, A. E., Ball, M. J., Bhave, S. V. and Wakade, A. R. (1991) β-amyloid from Alzheimer disease brains inhibits sprouting and survival of sympathetic neurons. Biochem Biophys Res Commun, 174, 572-579. Rosales-Corral, S., Tan, D. X., Reiter, R. J., Valdivia-Velazquez, M., Acosta-Martinez, J. P. and Ortiz, G. G. (2004) Kinetics of the neuroinflammation-oxidative stress correlation in rat brain following the injection of fibrillar amyloid-β onto the hippocampus in vivo. J Neuroimmunol, 150, 20-28.
Insights on Alzheimer’s Disease from the Intracerebral Injection and Infusion …
51
Rush, D. K., Aschmies, S. and Merriman, M. C. (1992) Intracerebral β-amyloid(25-35) produces tissue damage: is it neurotoxic? Neurobiol Aging, 13, 591-594. Ryu, J. K., Franciosi, S., Sattayaprasert, P., Kim, S. U. and McLarnon, J. G. (2004) Minocycline inhibits neuronal death and glial activation induced by β-amyloid peptide in rat hippocampus. Glia, 48, 85-90. Saez-Valero, J., de Ceballos, M. L., Small, D. H. and de Felipe, C. (2002) Changes in molecular isoform distribution of acetylcholinesterase in rat cortex and cerebrospinal fluid after intracerebroventricular administration of amyloid β-peptide. Neurosci Lett, 325, 199-202. Scali, C., Prosperi, C., Giovannelli, L., Bianchi, L., Pepeu, G. and Casamenti, F. (1999) β(140) amyloid peptide injection into the nucleus basalis of rats induces microglia reaction and enhances cortical gamma-aminobutyric acid release in vivo. Brain Res, 831, 319321. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D. and Seubert, P. (1999) Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400, 173-177. Schubert, D. and Chevion, M. (1995) The role of iron in beta amyloid toxicity. Biochem Biophys Res Commun, 216, 702-707. Selkoe, D. J. (2002) Alzheimer's disease is a synaptic failure. Science, 298, 789-791. Selkoe, D. J., Abraham, C. R., Podlisny, M. B. and Duffy, L. K. (1986) Isolation of lowmolecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J Neurochem, 46, 1820-1834. Shen, Y. X., Xu, S. Y., Wei, W., Sun, X. X., Liu, L. H., Yang, J. and Dong, C. (2002) The protective effects of melatonin from oxidative damage induced by amyloid β-peptide 2535 in middle-aged rats. J Pineal Res, 32, 85-89. Shivers, B. D., Hilbich, C., Multhaup, G., Salbaum, M., Beyreuther, K. and Seeburg, P. H. (1988) Alzheimer's disease amyloidogenic glycoprotein: expression pattern in rat brain suggests a role in cell contact. EMBO J, 7, 1365-1370. Sigurdsson, E. M., Hejna, M. J., Lee, J. M. and Lorens, S. A. (1995) β-Amyloid 25-35 and/or quinolinic acid injections into the basal forebrain of young male Fischer-344 rats: behavioral, neurochemical and histological effects. Behav Brain Res, 72, 141-156. Sigurdsson, E. M., Lee, J. M., Dong, X. W., Hejna, M. J. and Lorens, S. A. (1997a) Bilateral injections of amyloid-β 25-35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects. Neurobiol Aging, 18, 591608. Sigurdsson, E. M., Lee, J. M., Dong, X. W., Hejna, M. J. and Lorens, S. A. (1997b) Laterality in the histological effects of injections of amyloid-β 25-35 into the amygdala of young Fischer rats. J Neuropathol Exp Neurol, 56, 714-725. Sigurdsson, E. M., Lorens, S. A., Hejna, M. J., Dong, X. W. and Lee, J. M. (1996) Local and distant histopathological effects of unilateral amyloid-β 25-35 injections into the amygdala of young F344 rats. Neurobiol Aging, 17, 893-901.
52
Glenda M. Bishop and Stephen R. Robinson
Sigurdsson, E. M., Permanne, B., Soto, C., Wisniewski, T. and Frangione, B. (2000) In vivo reversal of amyloid-β lesions in rat brain. J Neuropathol Exp Neurol, 59, 11-17. Smyth, M. D., Kesslak, J. P., Cummings, B. J. and Cotman, C. W. (1994) Analysis of brain injury following intrahippocampal administration of β-amyloid in streptozotocin-treated rats. Neurobiol Aging, 15, 153-159. Snow, A. D., Sekiguchi, R., Nochlin, D., Fraser, P., Kimata, K., Mizutani, A., Arai, M., Schreier, W. A. and Morgan, D. G. (1994) An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A β-amyloid in rat brain. Neuron, 12, 219-234. Song, D. K., Im, Y. B., Jung, J. S., Cho, J., Suh, H. W. and Kim, Y. H. (2001) Central βamyloid peptide-induced peripheral interleukin-6 responses in mice. J Neurochem, 76, 1326-1335. Soto, C., Sigurdsson, E. M., Morelli, L., Kumar, R. A., Castano, E. M. and Frangione, B. (1998) β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med, 4, 822-826. Stein-Behrens, B., Adams, K., Yeh, M. and Sapolsky, R. (1992) Failure of β-amyloid protein fragment 25-35 to cause hippocampal damage in the rat. Neurobiol Aging, 13, 577-579. Stepanichev, M. Y., Moiseeva, Y. V., Lazareva, N. A., Onufriev, M. V. and Gulyaeva, N. V. (2003a) Single intracerebroventricular administration of amyloid-β (25-35) peptide induces impairment in short-term rather than long-term memory in rats. Brain Res Bull, 61, 197-205. Stepanichev, M. Y., Zdobnova, I. M., Yakovlev, A. A., Onufriev, M. V., Lazareva, N. A., Zarubenko, II and Gulyaeva, N. V. (2003b) Effects of tumor necrosis factor-α central administration on hippocampal damage in rat induced by amyloid β-peptide (25-35). J Neurosci Res, 71, 110-120. Stepanichev, M. Y., Zdobnova, I. M., Zarubenko, II, Moiseeva, Y. V., Lazareva, N. A., Onufriev, M. V. and Gulyaeva, N. V. (2004) Amyloid-β(25-35)-induced memory impairments correlate with cell loss in rat hippocampus. Physiol Behav, 80, 647-655. Stephan, A., Laroche, S. and Davis, S. (2001) Generation of aggregated β-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J Neurosci, 21, 5703-5714. Stephan, A., Laroche, S. and Davis, S. (2003) Learning deficits and dysfunctional synaptic plasticity induced by aggregated amyloid deposits in the dentate gyrus are rescued by chronic treatment with indomethacin. Eur J Neurosci, 17, 1921-1927. Stephenson, D. T. and Clemens, J. A. (1992) In vivo effects of β-amyloid implants in rodents: lack of potentiation of damage associated with transient global forebrain ischemia. Brain Res, 586, 235-246. Sun, M. K. and Alkon, D. L. (2002) Impairment of hippocampal CA1 heterosynaptic transformation and spatial memory by β-amyloid(25-35). J Neurophysiol, 87, 2441-2449. Szczepanik, A. M., Rampe, D. and Ringheim, G. E. (2001) Amyloid-β peptide fragments p3 and p4 induce pro-inflammatory cytokine and chemokine production in vitro and in vivo. J Neurochem, 77, 304-317.
Insights on Alzheimer’s Disease from the Intracerebral Injection and Infusion …
53
Szczepanik, A. M. and Ringheim, G. E. (2003) IL-10 and glucocorticoids inhibit Aβ(1-42)and lipopolysaccharide-induced pro-inflammatory cytokine and chemokine induction in the central nervous system. J Alzheimers Dis, 5, 105-117. Takata, K., Kitamura, Y., Tsuchiya, D., Kawasaki, T., Taniguchi, T. and Shimohama, S. (2003) Heat shock protein-90-induced microglial clearance of exogenous amyloid-β1-42 in rat hippocampus in vivo. Neurosci Lett, 344, 87-90. Tanaka, T., Yamada, K., Senzaki, K., Narimatsu, H., Nishimura, K., Kameyama, T. and Nabeshima, T. (1998) NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by β-amyloid protein in rats. Eur J Pharmacol, 352, 135-142. Tang, F., Nag, S., Shiu, S. Y. and Pang, S. F. (2002) The effects of melatonin and Ginkgo biloba extract on memory loss and choline acetyltransferase activities in the brain of rats infused intracerebroventricularly with β-amyloid 1-40. Life Sci, 71, 2625-2631. Tang, Y., Yamada, K., Kanou, Y., Miyazaki, T., Xiong, X., Kambe, F., Murata, Y., Seo, H. and Nabeshima, T. (2000) Spatiotemporal expression of BDNF in the hippocampus induced by the continuous intracerebroventricular infusion of β-amyloid in rats. Brain Res Mol Brain Res, 80, 188-197. Terranova, J. P., Kan, J. P., Storme, J. J., Perreaut, P., Le Fur, G. and Soubrie, P. (1996) Administration of amyloid β-peptides in the rat medial septum causes memory deficits: reversal by SR 57746A, a non-peptide neurotrophic compound. Neurosci Lett, 213, 7982. Tohda, C., Tamura, T. and Komatsu, K. (2003) Repair of amyloid β(25-35)-induced memory impairment and synaptic loss by a Kampo formula, Zokumei-to. Brain Res, 990, 141147. Tran, M. H., Yamada, K., Olariu, A., Mizuno, M., Ren, X. H. and Nabeshima, T. (2001) Amyloid β-peptide induces nitric oxide production in rat hippocampus: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors. FASEB J, 15, 1407-1409. Trubetskaya, V. V., Stepanichev, M. Y., Onufriev, M. V., Lazareva, N. A., Markevich, V. A. and Gulyaeva, N. V. (2003) Administration of aggregated β-amyloid peptide (25-35) induces changes in long-term potentiation in the hippocampus in vivo. Neurosci Behav Physiol, 33, 95-98. Urani, A., Romieu, P., Roman, F. J. and Maurice, T. (2002) Enhanced antidepressant effect of sigma1 (σ1) receptor agonists in β25-35-amyloid peptide-treated mice. Behav Brain Res, 134, 239-247. Urani, A., Romieu, P., Roman, F. J., Yamada, K., Noda, Y., Kamei, H., Manh Tran, H., Nagai, T., Nabeshima, T. and Maurice, T. (2004) Enhanced antidepressant efficacy of sigma1 receptor agonists in rats after chronic intracerebroventricular infusion of βamyloid-(1-40) protein. Eur J Pharmacol, 486, 151-161. Waite, J., Cole, G. M., Frautschy, S. A., Connor, D. J. and Thal, L. J. (1992) Solvent effects on beta protein toxicity in vivo. Neurobiol Aging, 13, 595-599. Walsh, D. T., Montero, R. M., Bresciani, L. G., Jen, A. Y., Leclercq, P. D., Saunders, D., AN, E. L.-A., Gbadamoshi, L., Gentleman, S. M. and Jen, L. S. (2002) Amyloid-β peptide is toxic to neurons in vivo via indirect mechanisms. Neurobiol Dis, 10, 20-27.
54
Glenda M. Bishop and Stephen R. Robinson
Walzer, M., Lorens, S., Hejna, M., Fareed, J., Hanin, I., Cornelli, U. and Lee, J. M. (2002) Low molecular weight glycosaminoglycan blockade of β-amyloid induced neuropathology. Eur J Pharmacol, 445, 211-220. Wang, R., Zhang, H. Y. and Tang, X. C. (2001) Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by β-amyloid protein-(1-40) in rat. Eur J Pharmacol, 421, 149-156. Weldon, D. T., Rogers, S. D., Ghilardi, J. R., Finke, M. P., Cleary, J. P., O'Hare, E., Esler, W. P., Maggio, J. E. and Mantyh, P. W. (1998) Fibrillar β-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci, 18, 2161-2173. Whitehead, S. N., Hachinski, V. C. and Cechetto, D. F. (2005) Interaction between a rat model of cerebral ischemia and β-amyloid toxicity: inflammatory responses. Stroke, 36, 107-112. Winkler, J., Connor, D. J., Frautschy, S. A., Behl, C., Waite, J. J., Cole, G. M. and Thal, L. J. (1994) Lack of long-term effects after β-amyloid protein injections in rat brain. Neurobiol Aging, 15, 601-607. Yagami, T., Takahara, Y., Ishibashi, C., Sakaguchi, G., Itoh, N., Ueda, K., Nakazato, H., Okamura, N., Hiramatsu, Y., Honma, T., Arimura, A., Sakaeda, T. and Katsuura, G. (2004) Amyloid β protein impairs motor function via thromboxane A2 in the rat striatum. Neurobiol Dis, 16, 481-489. Yamada, K., Tanaka, T., Han, D., Senzaki, K., Kameyama, T. and Nabeshima, T. (1999a) Protective effects of idebenone and alpha-tocopherol on β-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in β-amyloidinduced neurotoxicity in vivo. Eur J Neurosci, 11, 83-90. Yamada, K., Tanaka, T., Mamiya, T., Shiotani, T., Kameyama, T. and Nabeshima, T. (1999b) Improvement by nefiracetam of β-amyloid-(1-42)-induced learning and memory impairments in rats. Br J Pharmacol, 126, 235-244. Yamada, K., Tanaka, T., Senzaki, K., Kameyama, T. and Nabeshima, T. (1998) Propentofylline improves learning and memory deficits in rats induced by β-amyloid protein-(1-40). Eur J Pharmacol, 349, 15-22. Yamada, K., Tanaka, T., Zou, L. B., Senzaki, K., Yano, K., Osada, T., Ana, O., Ren, X., Kameyama, T. and Nabeshima, T. (1999c) Long-term deprivation of oestrogens by ovariectomy potentiates β-amyloid-induced working memory deficits in rats. Br J Pharmacol, 128, 419-427. Yamaguchi, Y. and Kawashima, S. (2001) Effects of amyloid-β-(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. Eur J Pharmacol, 412, 265-272. Yamaguchi, Y., Matsuno, T. and Kawashima, S. (2002) Antiamnesic effects of azaindolizinone derivative ZSET845 on impaired learning and decreased ChAT activity induced by amyloid-β 25-35 in the rat. Brain Res, 945, 259-265. Yamamoto, M., Chikuma, T. and Kato, T. (2003) Changes in the levels of neuropeptides and their metabolizing enzymes in the brain regions of nucleus basalis magnocellularislesioned rats. J Pharmacol Sci, 92, 400-410.
Insights on Alzheimer’s Disease from the Intracerebral Injection and Infusion …
55
Yan, J. J., Cho, J. Y., Kim, H. S., Kim, K. L., Jung, J. S., Huh, S. O., Suh, H. W., Kim, Y. H. and Song, D. K. (2001) Protection against β-amyloid peptide toxicity in vivo with longterm administration of ferulic acid. Br J Pharmacol, 133, 89-96. Yan, J. J., Kim, D. H., Moon, Y. S., Jung, J. S., Ahn, E. M., Baek, N. I. and Song, D. K. (2004) Protection against β-amyloid peptide-induced memory impairment with long-term administration of extract of Angelica gigas or decursinol in mice. Prog Neuropsychopharmacol Biol Psychiatry, 28, 25-30. Yankner, B. A., Duffy, L. K. and Kirschner, D. A. (1990) Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science, 250, 279282. Zand, L., Ryu, J. K. and McLarnon, J. G. (2005) Induction of angiogenesis in the β-amyloid peptide-injected rat hippocampus. Neuroreport, 16, 129-132. Zhang, H. Y., Yan, H. and Tang, X. C. (2004) Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-α in intracerebroventricular β-amyloid(1-40) infused rats and human embryonic kidney 293 Swedish mutant cells. Neurosci Lett, 360, 21-24. Zou, K., Kim, D., Kakio, A., Byun, K., Gong, J. S., Kim, J., Kim, M., Sawamura, N., Nishimoto, S., Matsuzaki, K., Lee, B., Yanagisawa, K. and Michikawa, M. (2003) Amyloid β-protein (Aβ)1-40 protects neurons from damage induced by Aβ1-42 in culture and in rat brain. J Neurochem, 87, 609-619.
In: New Research on Alzheimer’s Disease Editor: Eileen M. Welsh, pp. 57-85
ISBN 1-59454-939-7 © 2006 Nova Science Publishers, Inc.
Chapter II
The Role of Phospholipase A2 in Alzheimer's Disease Wagner F. Gattaz∗, Evelin L. Schaeffer and Orestes V. Forlenza Laboratory of Neuroscience, Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, S.P., Brazil
Abstract Phospholipase A2 (PLA2) is a key enzyme in phospholipid metabolism. In the brain, PLA2 is involved in the liberation of membrane choline for acetylcholine synthesis, as well as in the processing of the amyloid precursor protein to form the beta-amyloid, the major component of senile plaques in Alzheimer's disease (AD). In previous postmortem studies we reported on decreased PLA2 activity in the frontal and in the parietal cortex of patients with AD, suggesting reduced phospholipid metabolism in the disease. Interestingly, we found also a reduction of PLA2 activity in platelet membranes of AD patients, suggesting that reduced phospholipid turnover may also be observed in peripheral cells of AD patients. In an in vivo study we investigated the intracerebral phospholipid metabolism in 16 patients with probable AD and 18 age-matched controls through 31P-Magnetic Resonance Spectroscopy of the pre-frontal cortex. Cognitive assessment was performed by the CAMDEX schedule. PME resonance was significantly higher and PDE was lower among AD than controls. PME correlated negatively with cognitive performance. Higher PME indicates reduced breakdown of membrane phospholipids, which is in line with reduced PLA2 activity. Our findings in the prefrontal cortex suggest that reduced membrane phospholipid turnover may be a widespread cerebral phenomenon in AD brains, since the pre-frontal cortex is a region
∗
Corresponding author: Wagner F. Gattaz, Laboratory of Neuroscience (LIM-27), Department & Institute of Psychiatry, Faculty of Medicine, University of São Paulo, Rua Doutor Ovídio Pires de Campos 785, 05403-010 São Paulo - S.P. – Brasil; (E-mail:
[email protected] / phone & fax: +55.11.3069 8010)
58
Wagner F. Gattaz, Evelin F. Schaeffer and Orestes V. Forlenza not as severely affected by the neurodegenerative process as temporal and parietal areas, specially in early stages of dementia. To investigate further the implications of reduced PLA2 in the neurobiology of AD, we carried out a series of in vitro and animal experiments, to respectively test the effects of the inhibition of PLA2 on neuronal homeostasis in cultured neurons, and in memory formation in rats. In primary cultures of cortical and hippocampal neurons, the inhibition of PLA2 precluded neurite outgrowth, and the sustained inhibition of the enzyme in mature cultures lead to loss of viability. These findings reinforce the involvement of PLA2 enzymes in neurodevelopment and neurodegeneration. In early stages of AD there is an impairment of episodic short-term (STM) and long-term memory (LTM). In rat hippocampal slices, PLA2 has been implicated in mechanisms of synaptic plasticity involved in memory formation. Using adult Wistar rats, we investigated the effects of injections of PLA2 inhibitors into rat hippocampus on the formation of STM and LTM of a one-trial step-down inhibitory avoidance task. Infusion of the PLA2 inhibitors impaired both STM and LTM in a dosedependent manner. Additionally, because memory function is largely dependent on the fluidity of brain membranes, we investigated the effects of in vivo PLA2 inhibition on the fluidity of hippocampal membranes from rats subjected to inhibitory avoidance training. Hippocampal tissue from rats injected with PLA2 inhibitor showed reduced membrane fluidity, and this reduction was highly correlated with PLA2 inhibition. Taken together, our findings suggest that reduced PLA2 activity, probably reducing membrane phospholipids breakdown, may contribute to the memory impairment in AD.
Introduction Phospholipase A2 Enzymes Phospholipase A2 (PLA2) is a family of hydrolytic enzymes that catalyze the cleavage of fatty acids from the sn-2 position of phospholipids from both plasma and intracellular membranes to liberate free fatty acids and lysophospholipids (Dennis, 1994; Balsinde et al., 1999). Numerous PLA2 subtypes have been identified and characterized. They have been classified into several groups on the basis of their structure, cellular localization, requirement for Ca2+, and substrate specificity. The PLA2 subtypes are classified into three main groups: extracellular or secreted Ca2+-dependent PLA2 (sPLA2); cytosolic Ca2+-dependent PLA2 (cPLA2); and intracellular Ca2+-independent PLA2 (iPLA2) (Six and Dennis, 2000; Winstead et al., 2000; Kudo and Murakami, 2002; Chakraborti, 2003). The mRNA and/or the activity of sPLA2, cPLA2, and iPLA2 groups were detected in human and rodent brains (Yoshihara and Watanabe, 1990; Sharp and White, 1993; Chen et al., 1994; Owada et al., 1994; Larsson et al., 1998; Molloy et al., 1998; Underwood et al., 1998; Kishimoto et al., 1999; Larsson Forsell et al., 1999; Pickard et al., 1999; Song et al., 1999; Yang et al., 1999; Gelb et al., 2000; Mancuso et al., 2000; Suzuki et al., 2000; Tanaka et al., 2000). The sPLA2 enzymes are characterized by low molecular mass (~13-18 kDa), a requirement for millimolar Ca2+ concentrations for catalytic activity, and a broad specificity for phospholipids with different polar head groups and fatty acid chains at the sn-2 position (Farooqui et al., 1999). The 85 kDa cPLA2 shows a marked selectivity for phospholipids containing AA at the sn-2 position
The Role of Phospholipase A2 in Alzheimer's Disease
59
of phosphatidylcholine. Activation of cPLA2 is regulated by nanomolar or micromolar intracellular Ca2+ concentrations (Yoshihara and Watanabe, 1990; Underwood et al., 1998). The iPLA2 enzymes have high molecular mass (~88 kDa), do not require Ca2+ for catalytic activity, and show a preference, although slight, for AA over other fatty acids at the sn-2 position of phosphatidylcholine (Larsson et al., 1998; Mancuso et al., 2000; Tanaka et al., 2000). The heterogeneous nature of the PLA2 family means that subtype-specific methods need to be employed so as to distinguish the activity of one particular molecular form of the enzyme from another (Gattaz et al., 1995; Ross et al., 1997; Schaeffer and Gattaz, 2005).
PLA2 in Neuronal Homeostasis A wide range of physiological processes in which phospholipid metabolism plays a central role is regulated by PLA2 enzymes. For instance, cleavage of membrane phosphatidylcholine by PLA2 generates lysophosphatidylcholine and free arachidonic acid (AA) (Farooqui et al., 1997). The former is involved in the release of choline for the synthesis of acetylcholine (Maire and Wurtman, 1985; Blusztajn et al., 1987), whereas the latter causes a long-lasting facilitation of excitatory synaptic transmission after the induction of long-term potentiation (LTP) in the CA1 region of rat hippocampal slices (Nishizaki et al., 1999) and in pyramidal neurons of rat cerebral cortex (Nishikawa et al., 1994). LTP is a form of activity-dependent synaptic plasticity that is proposed as a basis of memory formation (Bliss and Collingridge, 1993). PLA2 metabolites participate in a wide variety of homeostatic functions, and the relationship between membrane fatty acid modification and neurite outgrowth has been evaluated in several recent tissue culture models (Ikemoto et al., 1997). PLA2-activated downstream pathways appear to have a general role in maintaining the ability of neurites to respond rapidly to external stimuli, possibly via regulating the ability of the cytoskeleton to remodel (Smalheiser et al., 1996). Arachidonic acid, one of the major products of PLA2 metabolism, has been implicated in the modulation of ion-channel conductance, the release of neurotransmitters (Kim & Clapham, 1989; Hwang et al., 1990; Miller et al, 1992) and neuritogenesis. In cultures of cerebellar neurones, arachidonic acid was shown to be involved in the intracellular signalling pathway leading to axonal growth, in a process dependent on the activation of calcium channels (Williams et al., 1994). Accordingly, neurite outgrowth was also stimulated in COX-2-overexpressing cells (Kadoyama et al., 2001). Finally, PLA2 inhibitors delayed the initial outgrowth of neurites on laminin, and exogenous arachidonic acid, conversely, enhanced neurite outgrowth (Smalheiser et al., 1996). In addition, in vitro studies have implicated PLA2 in the regulation of beta-amyloid precursor protein (APP) processing. Hence, PLA2 inhibition in cell cultures decreased the secretion of APP, whereas its activation potently increased APP secretion (Emmerling et al., 1993; Nitsch et al., 1997). In cultured cells, increased secretion of APP has been found to reduce the production of the beta-amyloid peptide (Caporaso et al., 1992; Fukushima et al., 1993; Fluhrer et al., 2002), the major component of amyloid plaques in Alzheimer’s disease (AD) (Alzheimer et al., 1995). AA was also found to increase APP secretion (Emmerling et al., 1996). Finally, the AA metabolites leukotrienes and 5-HPETE, generated by 5-
60
Wagner F. Gattaz, Evelin F. Schaeffer and Orestes V. Forlenza
lipoxygenase, and the metabolites prostaglandins and tromboxanes, generated by cyclooxygenase, are potent mediators of inflammation (Musser and Kreft, 1992; Yoshikai, 2001).
Phospholipid Metabolism and Neuropsychiatric Disorders Since PLA2 is the primary enzyme involved in the breakdown of membrane phosphomonoesters, abnormalities of PLA2 metabolism (possibly related to disease and/or to the processes involved in ageing) may affect membrane phospholipid turnover and arachidonic acid production in such a way as to cause cytoarchitectural changes and increased β-amyloid deposition within the brain. Research into biochemical processes affecting membrane composition and fluidity have generated models that fit relatively well in the pathophysiology of certain neurodegenerative diseases. Data from the 1990’ suggested decreased PLA2 activity in Alzheimer’s disease (Gattaz et al., 1995, Gattaz et al., 1996). Abnormalities of PLA2 metabolism have also been described in other neuropsychiatric diseases such as schizophrenia (Gattaz et al., 1987, Gattaz et al., 1990, Noponen et al., 1996, Ross et al., 1997), multiple sclerosis (Simonato, 1993), temporal-lobe epilepsy (Woelk & Peiler-Ichikawa, 1974, Visioli et al., 1994), and dyslexia (MacDonell et al., 2000). Accordingly to the “phospholipid hypothesis”, membrane changes play a primary role in the aetiology of neuropsychiatric disorders. Abnormal regulation of highly unsaturated fatty acid metabolism, mainly at the sn-2 position of phospholipid molecules, results in modifications of the neuronal membrane structure, affecting intracellular signalling from neurotransmitter- and ion channel-related functions (Horrobin, 1998).
PLA2 and Alzheimer’s Disease Rationale Because a wide range of physiological processes in which phospholipid metabolism plays a central role are regulated by phospholipase A2 (PLA2) enzymes, it is reasonable to hypothesise that abnormalities in PLA2-related functions may result in multiple pathological effects, ranging from intracellular signalling to neurotransmission. Choline, the precursor of acetylcholine, is released in cholinergic neurones by the PLA2 cleavage of membrane phosphatidylcholine (Blusztajn et al., 1987). PLA2 is involved in arachidonic acid (AA) release from membrane phospholipids, and thereby in the synthesis of major mediators of the inflammatory response, which secondarily participates in the maturation of neuritic plaques. It has also been reported that PLA2 appears to be involved in regulating the processing of amyloid precursor protein (APP) in cell culture (Emmerling et al., 1993). Thus, in cultured CHO-m1 cells, treatment with AA stimulated the secretory pathway of APP metabolism (Emmerling et al., 1996). It has also been demonstrated in cell culture models that PLA2 activation by mellitin led to an increase in the secretion of the APPs, whilst inhibition of PLA2 was reported to stop carbachol-stimulated production of APPs from CHO-m1 cells
The Role of Phospholipase A2 in Alzheimer's Disease
61
(Emmerling et al., 1993). In neurodegeneration models, it has been shown that arachidonic acid participates in the polymerization of hyperphosphorylated tau into neurofibrillary tangles, a critical step in the pathophysiology of dementia (Lukiw and Bazan, 2000).
Post-Mortem Studies Post-mortem studies have shown that PLA2 activity is decreased in AD brain (Gattaz et al., 1995ª, Gattaz et al., 1996). A reduction in cPLA2 activity in frontal and parietal cortices of AD patients was associated with an earlier onset of dementia, earlier age at death, and higher counts of senile plaques and neurofibrillary tangles. In the investigation of abnormalities in phospholipid metabolism, Skinner et al. (1989) demonstrated a marked reduction in the proportion of docosahexanoate in the parietal cortex of AD patients, and reduced total free fatty acid content in prefrontal areas. Since docosahexanoate is one of the main free fatty acids released following by PLA2 deacylation of membrane phospholipids, such finding is highly compatible with the reduction of PLA2 activity found in AD brains. Anisotropy studies have additionally demonstrated abnormal membrane fluidity in hippocampal synaptosomes of AD patients, which is also related with abnormal phospholipid turnover (Eckert et al., 2000). Finally, lower calcium-independent PLA2 (iPLA2) activity was identified in the prefrontal cortex of frontal-variant AD patients (Talbot et al., 2000). Taken together, such findings suggest that aberrations in the synthesis and degradation of membrane phospholipids are metabolic events that occur in AD.
Spectroscopy Studies The intracerebral availability of phospholipid precursors and metabolites, as well as the occurrence of high-energy phosphates, can be estimated by the analysis of the 31P spectral curve within a discrete brain area with the aid of magnetic resonance spectroscopy (MRS). Phosphomonoesters (PME) and phosphodiesters (PDE) are respectively the precursors and breakdown products of membrane phospholipids, and the ratio between both provides information on membrane phospholipid turnover. 31P-MRS studies of AD patients reported altered PME and PDE resonance in temporoparietal areas, which reflects changes in the biophysical state of membrane phospholipids (Pettegrew et al., 1988; Brown et al., 1989; Smith et al., 1993; Pettegrew et al., 1995). Pettegrew et al. (1988; 1995) found elevated PME levels in cortical areas of patients with mild AD, and increased PDE levels in severe AD, hypothesising that PME changes occur early in the disease, whereas PDE changes occur later. The authors further proposed that changes in membrane phospholipid and high-energy phosphate metabolism might precede the onset of dementia. Brown et al. (1989) showed that PME, PME/PDE ratio, and inorganic phosphate levels were elevated in temporoparietal areas of AD patients as compared to controls, although in another series addressing brain energy metabolism no significant difference between AD and controls was observed for either PME or PDE (Brown et al., 1993). Gonzalez et al. (1996) reported a 50% increase in PME/PDE
62
Wagner F. Gattaz, Evelin F. Schaeffer and Orestes V. Forlenza
ratio, but no changes in phosphocreatine, beta-nucleoside triphosphate (beta-NTP), and inorganic phosphate levels in AD brains. Correlations with morphologic data further suggested that elevations in PME levels precede the appearance of senile plaques in early stages of AD, whereas elevations in PDE levels, reflecting degeneration of neural membranes, correlate with the appearance of plaques in late stages of the disease (Pettegrew et al., 1988). In autopsy specimens of parietal gray matter from subjects with severe AD, spectroscopy abnormalities correlated with the density of neurofibrillary tangles (Smith et al., 1993). In a recent study conducted in our group (Forlenza et al., 2005), we investigated the intracerebral phospholipid metabolism in Alzheimer’s disease patients with the aid of 31PMRS, in a case control study comprising 18 patients with mild or moderate probable Alzheimer’s disease, and 16 healthy non-demented age-matched volunteers. Patients were recruited and assessed at the Alzheimer’s disease outpatient unit at the Institute of Psychiatry, University of Sao Paulo, and MRS scans were performed at the Division of Neruroimaging, Heart Institute, University of São Paulo. We used a 1.5T magnetic resonance imager addressing a 40mm3 voxell in the left pre-frontal cortex. Major outcome measures were mean relative peak areas of phosphate-rich cerebral metabolites within the 31P spectra of patients and controls, namely phosphomonoesters (PME), phosphodiesters (PDE), adenosinetriphosphate (alpha, beta, and gamma-ATP), phosphocreatine, and inorganic phosphate. Spectroscopy data were further correlated with parameters indicative of cognitive performance, as ascertained by the cognitive subscale of the Cambridge Examination for Mental Disorders of the Elderly (CAMCOG). The PME resonance and the PME/PDE ratio were increased in Alzheimer’s disease patients as compared to controls (p<0.05) (Figure 1). PME resonance was negatively correlated with global cognitive performance as shown by the total Mini-mental State Examination (rs=-0.36; p=0.05) and CAMCOG scores (rs=0.49; p=0.007), as well as with discrete neuropsychological functions, namely memory (rs=0.53; p=0.004), visual perception (rs=-0.54; p=0.003), orientation (rs=-0.36; p=0.05), and abstract thinking (rs=-0.48; p=0.01) (Figure 2). Other spectroscopy parameters were not significantly different between the two groups. We provided evidence of reduced membrane phospholipid breakdown in the pre-frontal cortex of mild and moderately demented Alzheimer’s disease patients. These abnormalities were correlated with neuropsychological deficits that are characteristic of Alzheimer’s disease, and reinforce the hypothesis that disordered cerebral phospholipid metabolism may play an etiological role in Alzheimer’s dementia, and further support the contention that alterations in brain membrane abnormalities can be non-invasively detected by 31P-MRS at early stages of clinical manifestations of the disease. Further research is needed in order to define whether this finding should be regarded as an etiological factor, or rather as an epiphenomenon of the neurodegenerative process.
The Role of Phospholipase A2 in Alzheimer's Disease
63
(A) PME % 20 16 12 8 4 0
Control
Alzheimer
(B) PDE % 50 45 40 35 30 25 20
Control
Alzheimer
(C) PME/PDE ratio 1.00
0.75
0.50
0.25
0.00
Control
Alzheimer
Figure 1. In vivo intracerebral availability of phospholipid precursors (PME) and metabolites (PDE), as determined by 31P-Magnetic resonance spectroscopy. Figures 1A and 1B represent the distribution of Alzheimer’s disease and control subjects according to percent areas of PME or PDE resonance, respectively; Figure 1C represent PME/PDE ratio.
Wagner F. Gattaz, Evelin F. Schaeffer and Orestes V. Forlenza
64
A
B 32
100
MMSE
CAMCOG
120
80
60
40
20
rs = - 0.487 p = 0.007 2
4
6
8
10
12
14
24
16
rs = - 0.364 p = 0.05
8
16
2
4
6
PME
C
10
12
14
16
D Visual perception
30
rs = - 0.534 p = 0.004
Memory
8
PME
20
10
0 2
4
6
8
PME
10
12
14
16
12
rs = - 0.542 p = 0.003
10
8
6
4
2 0 2
4
6
8
10
12
14
16
PME
Figure 2. Negative correlations between prefrontal cortex phosphomonoesters (PME) and neuropsychological parameters. (A): CAMCOG: Cognitive subscale of the Cambridge Examination for Mental Disorders of the Elderly (total scores); (B): MMSE: Mini-mental State Examination (total scores); (C): Memory and (D): Visual Perception tasks of the CAMCOG schedule.
Platelet PLA2 Activity in AD: A Peripheral Correlate of Cerebral Phospholipid Abnormalities? Platelets and neurones possess certain membrane and receptor properties in common; platelets may therefore provide a useful model system in investigations of brain metabolic abnormalities in AD (Zubenko et al., 1999). The activity of cPLA2 in the brain may be indirectly assessed by measuring the activity of the enzyme in platelets. In the search for peripheral correlates of cerebral enzymatic abnormalities, several studies have focused on PLA2 activity in platelet membranes, where a reduction in PLA2 activity can also be detected in AD (Gattaz et al., 1996). In a recent study, we replicated previous findings of reduced platelet PLA2 activity in AD, and further demonstrated that such abnormality is correlated with the neuropsychological symptoms of the disease (Gattaz et al., 2004). We investigated PLA2 activity in platelets from 21 AD patients as compared to 17 healthy elderly controls and 11 individuals with mild cognitive impairment (MCI). Subjects were cognitively assessed by the
The Role of Phospholipase A2 in Alzheimer's Disease
65
Mini-Mental State Examination (MMSE) and the CAMDEX schedule. Platelet PLA2 activity was determined by radio-enzymatic assay, which mainly detected a calcium-independent form of the enzyme present also in the brain (iPLA2). PLA2 activity was significantly lower in AD than in controls (p<0.001). Mean PLA2 activity in MCI individuals was between the values of AD patients and controls, with a subgroup showing PLA as low as the lowest AD patients, but the differences from MCI were not significant from AD and control groups (Figure 3). 50
PLA2 activity
(pmoles/mg protein/min)
40
30
20
10
0
AD
MCI
Control
Figure 3. PLA2 activity is decreased in patients with AD and MCI. Platelet PLA2 activity in individuals with Alzheimer’s disease (AD) (n=21), mild cognitive impairment (MCI) (n=11), and cognitively normal age-matched controls (n=17) was determined by radio-enzymatic assays (pmol / mg protein / minute). Significance levels: AD vs. controls: p<0.001.
Lower PLA2 activity was significantly correlated with a worse cognitive performance both at the MMSE (p=0.001) and the cognitive sub-scale of the CAMDEX inventory (p=0.002). Both reduced PLA2 activity and the correlation with impaired cognition were also reported in brain tissue of AD patients, suggesting thus that the present determinations in platelets may be related to a reduction in the brain. Further longitudinal studies in course will investigate whether those MCI individuals with the lowest PLA2 values in platelets would be at a higher risk to develop AD during a longitudinal follow up.
PLA2, Neuroplasticity and Memory Formation PLA2 in Neurodevelopment and in Neurodegeneration Whilst the importance of PLA2 in eicosanoid metabolism and signal transduction has been well established, much remains to be learned of its function and regulation within the brain. It has been shown in tissue culture models that neurite outgrowth and differentiation of neuroblastoma cells involve the participation of arachidonic acid (Williams et al., 1994).
66
Wagner F. Gattaz, Evelin F. Schaeffer and Orestes V. Forlenza
PLA2 is implicated in neurodevelopmental processes and in the early development of the nervous system. In embryonic rat brain, PLA2 activity peaks by the 12th gestational day, and progressive declines towards birth, maintaining basal levels in the post-natal period (Yoshihara et al., 1992; Forlenza et al., 2002). In primary cultures of embryonic rat cortical neurons, cPLA2 activity peaks on the 4th day in culture, and decreases after six days of incubation, when the cultures become mature. PLA2 activation in early developmental stages of cultures suggests its involvement in processes related to cell survival and development, particularly membrane recovering and neurite outgrowth (Forlenza et al., 2002). A
B
C
D
E
F
G
H
Figure 4. Inhibition of PLA2 precludes neurite outgrowth . Primary cultures of rat cortical neurons at the 7th DIC, continuously treated with MAFP or BEL starting from the 4th DIC. Trypan blue staining. Cultures were imaged at 200x-manignification (Nikon TE300) corresponding to different experimental conditions: A – MAFP control (no treatment); B – treatment with MAFP 10µM; C – treatment with MAFP 100µM; D – treatment with MAFP 250µM; E – BEL control (no treatment); F – treatment with BEL 1µM; G – treatment with BEL 10µM; H – treatment with BEL 50µM.
The Role of Phospholipase A2 in Alzheimer's Disease
67
Cortical neurons - MTT assay
% of viable cells
120 100 80 60 40 20 0 Treatment with MAFP
Control
MAFP10µM
MAFP100µM
MAFP250µM
A
% of viable cells
Cortical neurons - M TT assay
150 100 50 0 Treatm ent w ith Bel
Control
BEL1µM
BEL10µM
BEL50µM
B Figure 5. Neurotoxic effect of MAFP and BEL in primary cultures of cortical neurons. MTT cellular viability assay in 7DIC neurons submitted to continuous treatment with MAFP (A) or BEL (B) started at the 4th DIC. Bars represent mean values of PLA2 activity (± standard deviation, SD), of at least 3 independent determinations and respective controls, in picomols per milligram of protein per minute (pM/mg protein/min). Significance levels: * p<0.05; ** p<0.01; *** p<0.001.
In a recent study conducted in our lab, we addressed the effects of the pharmacological modulation of PLA2 in primary cultures of rat cortical neurons. Inhibition curves were obtained in 4 day-in-culture neurons treated for 30 minutes with either the dual PLA2 inhibitor methyl arachidonyl fluorophosphonate (MAFP), or the iPLA2 inhibitor bromoenol lactone (BEL). Full in vitro inhibition was achieved with 100 and 250µM of MAFP, or 10 and 20µM of BEL. Conversely, a dose-dependent activation of PLA2 was obtained with 1020µg/ml of mellitin. PLA2 inhibition with MAFP or BEL was not acutely toxic for cultured
68
Wagner F. Gattaz, Evelin F. Schaeffer and Orestes V. Forlenza
neurons. However, early and sustained inhibition of the enzyme precluded the development of neurites, and resulted in long-term loss of neuronal viability (Figure 4) (Mendes et al., 2005). When treatments with MAFP and BEL were applied to mature cultures of cortical and hippocampal neurons, i.e., after five days in culture, the inhibition of PLA2 was neurotoxic, as shown by a significant reduction in the number of viable neurons and neurite bearing cells (Figure 5) (Forlenza et al., in preparation).
Intracerebral PLA2 Inhibition in Rats and Affects Memory Formation and Membrane Fluidity In early AD there is an impairment of declarative episodic short-term (STM) and longterm memory (LTM) in correlation with reduced activity in hippocampus and cerebral cortex (Perani et al., 1993; Desgranges et al., 1998; Elgh et al., 2002). The biochemical cascade of memory has been extensively studied in the CA1 region of the dorsal hippocampus of rats in connection with one-trial step-down inhibitory avoidance task, which involves learning not to step-down from a platform in order to avoid a mild foot-shock. This task has a declarative component (increased avoidance latency), which crucially involves the hippocampus. In this paradigm the formation of STM (< 3 h) and LTM (at least 24 h) involves immediate posttraining activation of NMDA (and NMDA-mediated Ca2+ influx), AMPA, and metabotropic glutamate receptors, and modulation by muscarinic cholinergic receptors (Izquierdo and Medina, 1997; Izquierdo et al., 1997, 1999). It has been proposed that STM and LTM processes are mediated by mechanisms of synaptic plasticity referred to as short-term (STP) and long-term potentiation (LTP), respectively (Bliss and Collingridge, 1993; Izquierdo and Medina, 1997). Both cPLA2 and iPLA2 have been implicated in LTP induction in rat hippocampus. Hence, PLA2 inhibition in rat hippocampal slices prevented LTP induction in the CA1 region mediated by an NMDA-sensitive mechanism, and decreased [3H]AMPA binding observed after LTP induction (Bernard et al., 1994). In vivo LTP induction in rat hippocampus activated PLA2, which consequently reduced phosphatidylcholine and increased free AA levels (Clements et al., 1991). In addition, PLA2 inhibition in rat hippocampal slices blocked the NMDA-mediated release of lysophosphatidylcholine and, consequently, of choline (precursor of acetylcholine) (Weichel et al., 1999). Taken together, these data suggest an involvement of cPLA2 in LTP, due to their effects on glutamatergic and cholinergic systems. AA, which is formed by PLA2 activity, has also been implicated in LTP formation. Hence, Ca2+-sensitive LTP induction in rat hippocampal slices was facilitated by AA treatment (Nishizaki et al., 1999). In addition, selective iPLA2 inhibition in rat hippocampal slices prevented LTP induction in the CA1 region, which was restored by AA treatment (Wolf et al., 1995; Fujita et al., 2001). Besides the findings implicating PLA2 in LTP, some studies have suggested an involvement of the enzyme in memory function. For instance, injections of PLA2 inhibitors into the chick intermediate medial hyperstriatum ventrale impaired the learning of a passive avoidance task (Hölscher and Rose, 1994). Additionally, intraperitoneal injections of a PLA2 inhibitor in rats impaired spatial learning tested in the Morris water
The Role of Phospholipase A2 in Alzheimer's Disease
69
maze (Hölscher et al., 1995). Finally, intraperitoneal injections of a selective iPLA2 inhibitor in mice also impaired spatial learning (Fujita et al., 2000). A recent study examining brain phospholipid metabolism in the cPLA2 knockout mouse has suggested that altered AA metabolism influences membrane fluidity (Rosenberger et al., 2003). Membrane fluidity has also been implicated in LTP. Hence, treatment of aged rats with polyunsaturated fatty acids, which are known to increase membrane fluidity (Stubbs and Smith, 1984), reversed the age-related impairments in LTP (McGahon et al., 1999). Moreover, some studies showed that reduced fluidity of rat hippocampal membranes impaired memory (Hong, 1995; Clarke et al., 1999), whereas increased fluidity improved memory (Müller et al., 1997; Scheuer et al., 1999). Previous studies from our group showed reduced PLA2 activity in post-mortem brains of patients with AD, and this reduction correlated with the severity of dementia (Gattaz et al., 1995). In addition, reduced cPLA2 and iPLA2 activities were found in post-mortem hippocampus of AD patients (Ross et al., 1998). These data are in line with the in vivo NMR spectroscopy findings of decreased phospholipid metabolism in AD brains (Brown et al., 1989; Pettegrew et al., 1995), as well as with the finding on reduced membrane fluidity in post-mortem hippocampus of AD patients (Eckert et al., 2000). In face of these data, we performed a series of animal experiments to investigate the effects of injections of PLA2 inhibitors directly into rat hippocampus on the acquisition of STM and LTM, using as behavioural paradigm the step-down inhibitory avoidance task. Additionally, we investigated the effects of in vivo PLA2 inhibition on the fluidity of hippocampal membranes from rats subjected to inhibitory avoidance training. Male Wistar rats (2.5-3 months old) were intraperitoneally anaesthetized, placed in a stereotaxic frame, and bilaterally implanted with cannulae in the CA1 region of the dorsal hippocampus at stereotaxic coordinates anterior – 4.3 mm from bregma, lateral ± 4.0 mm from midline, and ventral 3.4 mm from dura (Paxinos and Watson, 1998). After recovering, the rats received intrahippocampal acute injections of a vehicle (DMSO/saline) or of one of three different PLA2 inhibitors dissolved in the vehicle: (a) methyl arachidonyl fluorophosphonate (MAFP), an irreversible dual cPLA2 and iPLA2 inhibitor (Balsinde and Dennis, 1996; Lio et al., 1996), (b) palmitoyl trifluoromethylketone (PACOCF3), a reversible dual cPLA2 and iPLA2 inhibitor (Ackermann et al., 1995; Balsinde and Dennis, 1997), or (c) bromoenol lactone (BEL), an irreversible selective iPLA2 inhibitor (Ackermann et al., 1995). Based on the findings showing that intracerebral injections of PLA2 inhibitors before but not after training produced amnesia for a passive avoidance task in chicks (Hölscher and Rose, 1994), and that treatment of rat hippocampal slices with a PLA2 inhibitor before tetanic stimulation prevented the induction of LTP but treatment after tetanic stimulation did not affect the maintenance phase of LTP (Fujita et al., 2001), in our study we decided to investigate the effects of the PLA2 inhibitors when injected before training in inhibitory avoidance task. Pre-training injections would be presumed to primarily affect the acquisition phase of memory formation (Izquierdo, 1989). At 30 min after injections into the CA1 region of (a) vehicle (n = 13) or 1 µM MAFP (n = 14) or 10 µM MAFP (n = 17), of (b) vehicle (n = 14) or 10 µM PACOCF3 (n = 11) or 100 µM PACOCF3 (n = 13), or of (c) vehicle (n = 14) or 1 µM BEL (n = 11) or 10 µM BEL (n = 12), the rats were submitted to one-session of step-down inhibitory avoidance training.
70
Wagner F. Gattaz, Evelin F. Schaeffer and Orestes V. Forlenza
Briefly, the animals were placed on a platform in an inhibitory avoidance box whose floor was an electrified grid. In training sessions, immediately after stepping-down, placing the four paws on the grid, the animals received a 0.4 mA, 4.0 s scrambled foot-shock. Latencies to step-down were measured. Rats were tested for retention after 1.5 h and after 24 h, for STM and LTM, respectively. In test sessions, the animals were placed again on the platform and step-down latencies were measured up to a ceiling of 180 s, and no foot-shock was given. (a) Training session latencies were similar in animals injected with vehicle or with 1 µM or 10 µM MAFP (p > 0.1). After training, in animals injected with vehicle, latencies for STM and LTM significantly increased by 9 and 11-fold, respectively (p = 0.001). Injections of 10 µM MAFP (but not of 1 µM; p > 0.5) significantly prevented the increments of latencies for STM and LTM (p < 0.02, as compared to vehicle) (Figure 6A). (b) Training session latencies were similar in animals injected with vehicle or with 10 µM or 100 µM PACOCF3 (p > 0.1). After training, in animals injected with vehicle, latencies for STM and LTM significantly increased by 7 and 8-fold, respectively (p = 0.001). Injections of 100 µM PACOCF3 (but not of 10 µM; p > 0.5) significantly prevented the increments of latencies for STM and LTM (p < 0.02, as compared to vehicle) (Figure 6B). (c) Training session latencies were similar in animals injected with vehicle or with 1 µM or 10 µM BEL (p > 0.2). After training, in animals injected with vehicle, latencies for STM and LTM significantly increased by 11-fold (p = 0.001). Injections of 10 µM BEL (but not of 1 µM; p > 0.5) significantly prevented the increments of latencies for STM and LTM (p < 0.001 and p < 0.01, respectively, as compared to vehicle) (Figure 6C) (Schaeffer and Gattaz, 2005). As pre-training injections of MAFP, PACOCF3, and BEL impaired memory acquisition, we investigated whether the amnesic effects of the PLA2 inhibitors in inhibitory avoidance task were due to their action on general activity (locomotor and exploratory activities) during training performance. At 30 min after injections into the CA1 region of (a) vehicle or 10 µM MAFP, of (b) vehicle or 100 µM PACOCF3, or of (c) vehicle or 10 µM BEL (n = 10 per group), the rats were submitted to 3 min of free exploration of inhibitory avoidance apparatus. Crossings of three imaginary lines on the floor of inhibitory avoidance apparatus were counted. We found that the number of crossings was similar in animals injected with vehicle or with 10 µM MAFP, 100 µM PACOCF3, or 10 µM BEL (p > 0.1) (data not shown), indicating that the impairing effects of the pre-training injections of the PLA2 inhibitors were not caused by gross behavioral alterations on training performance (Schaeffer and Gattaz, 2005). After behavioral procedures, histological analyses were carried out to verify the injection placements and to investigate whether the observed effects of PLA2 inhibition on test session latencies in inhibitory avoidance task were a consequence of neuronal death. Rats injected with vehicle (n = 8) or with 10 µM MAFP (n = 6), 100 µM PACOCF3 (n = 6), or 10 µM BEL (n = 6) were deeply anaesthetized, transcardially perfused with saline and fixed with a 10% formaldehyde solution. The brains were withdrawn and fixed in the same fixative, embedded in paraffin, cut into consecutive 5 µm sections with a microtome, and placed on glass slides. The sections were stained with haematoxylin-eosin for histological localization of the injection sites as well as for histological analysis of neuronal death in the injection sites. Using a light microscope at 400X magnification, neuronal death was determined as the decrease in the percentage of purple-stained cell nuclei by haematoxylin-eosin in a delimited
The Role of Phospholipase A2 in Alzheimer's Disease
71
area of 2.0 mm2 corresponding to the injection sites in the CA1 region. In the remaining rats submitted to behavioural procedures a 10% trypan blue solution was injected into the brain sites implanted with cannulae. After 30 min the animals were killed by decapitation and the brains were withdrawn, fixed in a 10% formaldehyde solution, and cut manually for histological localization of the injection sites. Injections spread with a radius of 1.0-1.5 mm3 in each cannula-implanted site. On the whole, injections were found to be correct in 94% of the animals. We found that injections of the PLA2 inhibitors did not cause neuronal death as compared to vehicle (10 µM MAFP, p = 0.1; 100 µM PACOCF3 and 10 µM BEL, p > 0.5) (data not shown) (Schaeffer and Gattaz, 2005). Additionally, we investigated the degree of inhibition of PLA2 activity in the CA1 region of another group of rats injected with PLA2 inhibitors. Hence, at 30 min after injections into the CA1 region of (a) vehicle (n = 8) or 1 µM MAFP (n = 6) or 10 µM MAFP (n = 9), of (b) vehicle (n = 9) or 10 µM PACOCF3 (n = 9) or 100 µM PACOCF3 (n = 8), or of (c) vehicle or 1 µM or 10 µM BEL (n = 8 per group), the rats were submitted to inhibitory avoidance task as described above, but they were killed by decapitation immediately after receiving the footshock in order to dissect the CA1 region for PLA2 activity determination around the time of training. The brains were rapidly withdrawn and about 2.0 mm3 of the CA1 region corresponding to the injection sites were bilaterally dissected, homogenized in 5 mM TrisHCl (pH 7.4, 4°C), and stored at –70°C until use. PLA2 activity was determined by a radioenzymatic assay. Briefly, as enzyme substrate we used L-α-1-palmitoyl-2-arachidonylphosphatidylcholine labelled with [1-14C] in the arachidonyl tail at the sn-2 position (arachidonyl-1-14C-PC). We determined optimal assay conditions ([Ca2+] and pH value) for measuring cPLA2 plus iPLA2 activities in CA1 tissue homogenates of rats injected with MAFP or PACOCF3, and for measuring only iPLA2 activity in CA1 tissue homogenates of rats injected with BEL (data not shown). Hence, the assay samples (500 µl) contained 100 mM Tris-HCl (pH 8.5 for cPLA2 plus iPLA2; pH 7.5 for iPLA2), 1 µM CaCl2 (for cPLA2 plus iPLA2) or 100 µM EDTA (for iPLA2), 300 µg of protein from homogenates, and 0.06 µCi arachidonyl-1-14C-PC. After an incubation time of 30 min at 37°C the reaction was stopped and the liberated [1-14C]AA was extracted. The radioactivity of [1-14C]AA was measured in a liquid scintillation counter and used for calculating the PLA2 activity, which is expressed in pmol⋅mg protein⋅min– 1. The activity of cPLA2 plus iPLA2 in post-mortem CA1 region was significantly reduced by 28% by injections of 10 µM MAFP (p < 0.01) and by 26% by injections of 100 µM PACOCF3 (p = 0.002), but was not significantly reduced by injections of 1 µM MAFP (p > 0.2) or 10 µM PACOCF3 (p > 0.05), as compared to vehicle. The activity of iPLA2 in post-mortem CA1 region was significantly reduced by 17% by injections of 10 µM BEL (p = 0.002), but was not significantly reduced by injections of 1 µM BEL (p > 0.2), as compared to vehicle (Figure 7) (Schaeffer and Gattaz, 2005). As inhibition of hippocampal PLA2 activity impaired memory acquisition of inhibitory avoidance task, we carried out biochemical assays to evaluate directly whether the inhibitory avoidance is accompanied by changes in hippocampal PLA2 activity around the time of training. Nonimplanted male Wistar rats (2.5-3 months old) were divided into three groups: (a) naïve controls (n = 8), killed by decapitation immediately after withdrawal from their home cages; (b) shocked animals (n = 8), placed directly over the electrified grid, given a 0.4
Wagner F. Gattaz, Evelin F. Schaeffer and Orestes V. Forlenza 180
A
150 120 90 60
*
*
30
training
1.5 h (STM)
24 h (LTM)
180 latency to step-down (s)
10 uM
1 uM
vehicle
10 uM
1 uM
vehicle
10 uM
1 uM
0 vehicle
latency to step-down (s)
72
B
150 120 90 60
*
30
* 100 uM
10 uM
vehicle
100 uM
10 uM
1.5 h (STM)
24 h (LTM)
180
C
150 120 90 60 30
**
**
training
1.5 h (STM)
10 uM
1 uM
vehicle
10 uM
1 uM
vehicle
10 uM
1 uM
0 vehicle
latency to step-down (s)
training
vehicle
100 uM
10 uM
vehicle
0
24 h (LTM)
Figure 6. Acute PLA2 inhibition in rat CA1 region impairs acquisition of short- and long-term memory. Step-down latencies (seconds) are given as median (interquartile interval). Injections of 1 µM MAFP (A) (n = 14), 10 µM PACOCF3 (B) (n = 11), or 1 µM BEL (C) (n = 11) did not significantly prevent the increments of latencies for STM and LTM as compared to vehicle (n = 15, 15, 16, respectively). Injections of 10 µM MAFP (A) (n = 17), 100 µM PACOCF3 (B) (n = 13), or 10 µM BEL (C) (n = 12) significantly prevented the increments of latencies for STM and LTM as compared to vehicle (*p < 0.05 and **p < 0.01).
The Role of Phospholipase A2 in Alzheimer's Disease
73
PLA2 activity (pmol.mg/min)
mA, 4.0 s scrambled foot-shock, and immediately killed by decapitation; and (c) animals trained in the step-down inhibitory avoidance task (n = 10) as described above, and killed by decapitation immediately after receiving the foot-shock. Brain tissue preparation and PLA2 assay were carried out as described above. In this experiment, PLA2 assay was prepared using Tris-HCl pH 8.5 and 1 µM CaCl2. We found that inhibitory avoidance training increased significantly PLA2 activity during acquisition (14%; p = 0.002, as compared to naïve values). Additionally, inhibitory avoidance training increased significantly PLA2 activity as compared to shocked values (13%; p = 0.003), indicating that increments in PLA2 activity were specifically caused by the inhibitory avoidance training. Shocked animals had similar values of PLA2 activity as naïve controls (p > 0.5) (Figure 8) (Schaeffer and Gattaz, 2005). 8
**
6
**
**
4
2
MAFP
PACOCF3
10 uM
1 uM
vehicle
100 uM
10 uM
vehicle
10 uM
1 uM
vehicle
0
BEL
Figure 7. Dose-dependent inhibition of PLA2 activity in rat CA1 region. PLA2 activity (pmol⋅mg protein⋅min– 1) is given as mean (± standard deviation). Injections of 1 µM MAFP (n = 6), 10 µM PACOCF3 (n = 9), or 1 µM BEL (n = 8) did not significantly reduce PLA2 activity as compared to vehicle (n = 8, 9, 8, respectively). Injections of 10 µM MAFP (n = 9), 100 µM PACOCF3 (n = 8), or 10 µM BEL (n = 8) significantly reduced PLA2 activity as compared to vehicle (**p < 0.01).
Because memory function is largely dependent on the fluidity of brain membranes (Hong, 1995; Müller et al., 1997; Clarke et al., 1999; Scheuer et al., 1999), we investigated the effects of in vivo PLA2 inhibition on the fluidity of hippocampal membranes from rats subjected to inhibitory avoidance training. At 30 min after injections into the CA1 region of vehicle or 100 µM PACOCF3 (n = 24 per group), the rats were placed on the platform in the inhibitory avoidance box; when stepping-down the animals received a 0.4 mA, 4.0 s scrambled foot-shock. Rats were killed after 2.5 min, which was the time found to produce significant AA release mediated by PLA2 activity after in vivo LTP induction (Clements et al., 1991). The CA1 region at the injection sites was bilaterally dissected, homogenized (pools of 3 rats) in 5 mM Tris-HCl (pH 7.4, 4°C), and aliquots for PLA2 activity determination were separated and frozen at –70°C. The rest of homogenates was additionally diluted in 5 mM Tris-HCl (pH 7.4, 4°C) and centrifuged at 48,000 g for 20 min at 4°C (2x). The final membrane pellet was resuspended in 5 mM Tris-HCl (pH 7.4, 4°C) and aliquots for membrane fluidity determination were frozen at –20°C. Membrane fluidity was determined
74
Wagner F. Gattaz, Evelin F. Schaeffer and Orestes V. Forlenza
PLA2 activity (pmol.mg/min)
by anisotropy measurements. Briefly, we used the non-polar fluorescence probe 1,6diphenyl-1,3,5-hexatriene (DPH), which provides a measurement of anisotropy from the hydrophobic core of membranes. DPH anisotropy is inversely correlated with the fluidity of this membrane region. The assay samples (2 ml) containing 5 mM Tris-HCl (pH 7.4), 30 µg of protein from membrane suspensions, and 33 µM DPH were incubated for 45 min at 37°C. The steady-state anisotropy was measured in a Photon Technology International – PTI spectrofluorometer, using excitation and emission wavelengths of 360 nm and 450 nm, respectively. As expected, PACOCF3 significantly inhibited PLA2 activity in CA1 homogenates as compared to vehicle (p < 0.01; Figure 9A). Moreover, CA1 membranes from rats injected with PACOCF3 showed significantly reduced fluidity at the hydrophobic core, as indicated by increased DPH anisotropy, as compared to vehicle (p < 0.01; Figure 9B). Membrane fluidity was highly correlated with PLA2 activity in animals injected with PACOCF3 (r = 0.76, p < 0.03; Figure 10A) or with vehicle (r = 0.84, p < 0.01; Figure 10B) (Schaeffer et al., 2005). 6.0 5.5
**
5.0 4.5 4.0 3.5 naive
shocked
trained
Figure 8. Effect of inhibitory avoidance training on PLA2 activity in rat CA1 region. PLA2 activity (pmol⋅mg protein⋅min– 1) is given as mean (± standard deviation). Animals trained in inhibitory avoidance task (n = 10) showed significant increase in PLA2 activity around the time of training as compared to naïve and shocked animals (n = 8 per group). Shocked animals had similar values of PLA2 activity as naïve controls (**p < 0.01).
The findings described above show that the inhibition of PLA2 activity in the CA1 region of the dorsal hippocampus of rats impaired the acquisition of STM and LTM of step-down inhibitory avoidance task. It should be noticed that impairment of memory was only observed when the concentrations of the inhibitors were enough to cause a significant inhibition of PLA2 activity. Memory impairment was not due to effects of the inhibition of PLA2 activity on locomotion and exploratory behaviour during training performance. Moreover, memory impairment did not result from neuronal death in the CA1 region after inhibition of PLA2 activity, suggesting thus a functional effect of PLA2 on memory neurochemistry. Our data confirm the previous findings showing that inhibitors of PLA2 impaired learning in chicks, rats, and mice (Hölscher and Rose, 1994; Hölscher et al., 1995; Fujita et al., 2000), and extend them by demonstrating that injections of PLA2 inhibitors directly into the hippocampus impaired memory acquisition of rats. The diversity of PLA2 family and its
The Role of Phospholipase A2 in Alzheimer's Disease
75
PLA2 activity (pmol.mg/min)
varied regulatory and functional properties emphasize the importance of considering different groups of PLA2 when investigating their physiological and pathological roles. The present findings show that the selective inhibition of iPLA2 activity by BEL in hippocampal CA1 region of rats impaired the acquisition of STM and LTM of inhibitory avoidance task. This result confirms and extends the previous finding showing that intraperitoneal injections of BEL in mice impaired spatial learning tested in the Morris water maze (Fujita et al., 2000). In our study we optimized some assay conditions for PLA2 activity determination. During these assays we found a dominant activity of iPLA2 in the dorsal hippocampus of rats towards 1palmitoyl-2-[1-14C]arachidonyl-phosphatidylcholine. The remaining PLA2 activity, likely of cPLA2 because of the assay conditions used (micromolar Ca2+ concentration), was about 11fold lower than the iPLA2 activity (data not shown). This finding is in line with previous data showing low levels of mRNA of cPLA2 (Molloy et al., 1998; Kishimoto et al., 1999) and a dominant iPLA2 activity over cPLA2 activity in rat hippocampus (Yang et al., 1999). Despite the low levels of mRNA and low activity of cPLA2, there are some evidences for an involvement of cPLA2 in LTP induction in rat hippocampus (Bernard et al., 1994; Weichel et al., 1999). The development of selective cPLA2 inhibitors is required for a better understanding of the involvement of cPLA2 in memory processes.
5
A
4
**
3 2 1 0 vehicle
PACOCF3
0,220
B
**
Anisotropy (DPH)
0,215 0,210 0,205 0,200 0,195 0,190 ve hicle
PACOCF3
Figure 9. PLA2 activity and anisotropy measurements in post-mortem CA1 region of rats. PLA2 activity (pmol⋅mg protein⋅min–1) and DPH anisotropy are given as mean (± standard deviation). All determinations were done in triplicate. Injections of 100 µM PACOCF3 (n = 8) significantly decreased PLA2 activity (A) and reduced membrane fluidity at the hydrophobic core, as indicated by increased DPH anisotropy (B), as compared to vehicle (n = 8) (**p < 0.01).
76
Wagner F. Gattaz, Evelin F. Schaeffer and Orestes V. Forlenza
PLA2 activity (pmol.mg/min)
5
A
4
r = -.76
3 2 1 0 0,200
0,205
0,210
0,215
0,220
0,225
Anisotropy (DPH)
B
PLA2 activity (pmol.mg/min)
5,0
r = -.84 4,5
4,0
3,5
3,0 0,194
0,196
0,198
0,200
0,202
0,204
0,206
Anisotropy (DPH)
Figure 10. Correlation between PLA2 activity and anisotropy in post-mortem CA1 region of rats. PLA2 activity (pmol⋅mg protein⋅min–1) and DPH anisotropy are given as the mean value from triplicate determinations. PLA2 activity correlated negatively with anisotropy (= positively with fluidity) at the hydrophobic core in rats injected with PACOCF3 (A; r = -.76, p < 0.03) or with vehicle (B; r = -.84, p < 0.01).
With the current experimental design (i.e. pre-training injections) our findings suggest that PLA2 inhibition blocked memory acquisition. Because STM and LTM are acquired at the same moment, one could argue that blocking acquisition there is no point to analyze the effects of drugs on both STM and LTM. However, it has been clearly shown that STM and LTM for the inhibitory avoidance task are established through partially independent molecular pathways in the hippocampus and related brain areas (Izquierdo et al., 1998). A recent study evaluating possible differential effects of drug injections before acquisition and during the early consolidation period of STM and LTM of inhibitory avoidance supports the view that consolidations of STM and LTM for inhibitory avoidance are parallel, independent processes (Quevedo et al., 2004). Further studies are required to clarify whether acquisition of STM and LTM would involve different mechanisms.
The Role of Phospholipase A2 in Alzheimer's Disease
77
It is noteworthy that in our study PLA2 activity increased in the CA1 region of rat hippocampus immediately after inhibitory avoidance training. Such increase may be caused by NMDA-stimulated Ca2+ influx (Yoshihara and Watanabe, 1990; Bernard et al., 1994; Underwood et al., 1998) and by phosphorylation mediated by mitogen-activated protein kinase and protein kinase C (Lin et al., 1993; Nemenoff et al., 1993) if considering an involvement of cPLA2. In the case of iPLA2, increased activity may also be mediated by protein kinase C-directed phosphorylation (Underwood et al., 1998; Akiba et al., 1999). Activation of PLA2 may result in increased glutamate binding to AMPA (Bernard et al., 1994) and metabotropic receptors (Collins et al., 1995). All these biochemical mechanisms (NMDA, AMPA, and metabotropic receptors, MAPK, PKC) in the hippocampus participate in the early stages of memory formation of inhibitory avoidance task in rats (Bianchin et al., 1994; Bernabeu et al., 1995; Cammarota et al., 1995, 2000; Alonso et al., 2002). The findings from anisotropy measurements suggest that apart from PLA2 cleaving membrane phospholipids generating arachidonic acid (Farooqui et al., 1997) – an important mediator in synaptic plasticity underlying memory processing (Nishizaki et al., 1999; Fujita et al., 2001) – it also influences membrane fluidity at the hydrophobic core. The increment of hydrophobic core fluidity of rat hippocampal membranes was found to improve memory function (Müller et al., 1997; Scheuer et al., 1999). In our experiments we used crude preparations of hippocampal membranes that probably contains plasma membranes as well as intracellular membranes. The inhibition of cPLA2 and iPLA2 by PACOCF3 (Ackermann et al., 1995; Balsinde and Dennis, 1997) in our study may reduce fluidity of both plasma and intracellular membranes, since cPLA2 translocates to nuclear and endoplasmic reticulum membranes where it releases AA (Schievella et al., 1995; Gijón et al., 1999; Hirabayashi et al., 1999; Perisic et al., 1999), and iPLA2 was found to release AA from the plasma membrane (Mizuno-Kamiya et al., 2001). At the plasma membrane, the effect of increased membrane fluidity on memory improvement (Müller et al., 1997; Scheuer et al., 1999) may be mediated by increased densities of NMDA and muscarinic receptors (Muccioli et al., 1996; Scheuer et al., 1999), which are both involved in memory formation (Izquierdo et al., 1997). Additionally, an increment in nuclear membrane fluidity was found to increase mRNA nucleocytoplasmic transport, whereas a reduction in nuclear membrane fluidity was found to decrease the mRNA efflux (Tomassoni et al., 1999). The mRNA-mediated gene expression is crucially involved in memory formation (Igaz et al., 2002, 2004). Taken together with these data, the present results suggest that the mechanism by which reduced PLA2 activity impairs memory formation involves also changes in membrane fluidity.
Conclusion The results of our study showing that PLA2 inhibition impaired memory acquisition and reduced membrane fluidity are of interest in face of previous reports from our and other laboratories showing decreased PLA2 activity in post-mortem brain, including the hippocampus, of patients with AD (Gattaz et al., 1995; Ross et al., 1998; Talbot et al., 2000), as well as reduced membrane fluidity in post-mortem hippocampus of AD patients (Eckert et al., 2000). In face of these data, we speculate that reduced membrane fluidity mediated by
78
Wagner F. Gattaz, Evelin F. Schaeffer and Orestes V. Forlenza
decreased PLA2 activity may contribute to memory impairment in AD. Further studies should clarify whether the stimulation of PLA2 does improve memory performance in animals, which could open new avenues for the development of treatment strategies in AD.
References Ackermann, EJ; Conde-Frieboes, K; Dennis, EA. Inhibition of macrophage Ca(2+)independent phospholipase A2 by bromoenol lactone and trifluoromethyl ketones. J Biol Chem. 1995;270(1):445-450. Akiba, S; Mizunaga, S; Kume, K; Hayama, M; Sato, T. Involvement of group VI Ca2+independent phospholipase A2 in protein kinase C-dependent arachidonic acid liberation in zymosan-stimulated macrophage-like P388D1 cells. J Biol Chem. 1999; 274(28):19906-19912. Alonso, M; Viola, H; Izquierdo, I; Medina, JH. Aversive experiences are associated with a rapid and transient activation of ERKs in the rat hippocampus. Neurobiol Learn Mem. 2002;77(1):119-124. Alzheimer, A; Stelzmann, RA; Schnitzlein, HN; Murtagh, FR. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat. 1995;8(6):429-431. Balsinde, J; Balboa, MA; Insel, PA; Dennis, EA. Regulation and inhibition of phospholipase A2. Annu Rev Pharmacol Toxicol. 1999;39:175-189. Balsinde, J; Dennis, EA. Distinct roles in signal transduction for each of the phospholipase A2 enzymes present in P388D1 macrophages. J Biol Chem. 1996;271(12):6758-6765. Balsinde, J; Dennis, EA. Function and inhibition of intracellular calcium-independent phospholipase A2. J Biol Chem. 1997;272(26):16069-16072. Bernabeu, R; Izquierdo, I; Cammarota, M; Jerusalinsky, D; Medina, JH. Learning-specific, time-dependent increase in [3H]phorbol dibutyrate binding to protein kinase C in selected regions of the rat brain. Brain Res. 1995;685(1-2):163-168. Bernard, J; Lahsaini, A; Massicotte, G. Potassium-induced long-term potentiation in area CA1 of the hippocampus involves phospholipase activation. Hippocampus. 1994;4(4):447-453. Bianchin, M; Da Silva, RC; Schmitz, PK; Medina, JH; Izquierdo, I. Memory of inhibitory avoidance in the rat is regulated by glutamate metabotropic receptors in the hippocampus. Behav Pharmacol. 1994;5(3):356-359. Bliss, TV; Collingridge, GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361(6407):31-39. Blusztajn, JK; Liscovitch, M; Mauron, C; Richardson, UI; Wurtman, RJ. Phosphatidylcholine as a precursor of choline for acetylcholine synthesis. J Neural Transm Suppl. 1987b;24:247-259. Brown, GG; Garcia, JH; Gdowski, JW; Levine, SR; Helpern, JA. Altered brain energy metabolism in demented patients with multiple subcortical ischemic lesions. Working hypotheses. Arch Neurol. 1993;50(4):384-388.
The Role of Phospholipase A2 in Alzheimer's Disease
79
Brown, GG; Levine, SR; Gorell, JM; Pettegrew, JW; Gdowski, JW; Bueri, JA; Helpern, JA; Welch, KM. In vivo 31P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia. Neurology. 1989;39(11):1423-1427. Cammarota, M; de Stein, ML; Paratcha, G; Bevilaqua, LR; Izquierdo, I; Medina, JH. Rapid and transient learning-associated increase in NMDA NR1 subunit in the rat hippocampus. Neurochem Res. 2000;25(5):567-572. Cammarota, M; Izquierdo, I; Wolfman, C; Levi de Stein, M; Bernabeu, R; Jerusalinsky, D; Medina, JH. Inhibitory avoidance training induces rapid and selective changes in 3[H]AMPA receptor binding in the rat hippocampal formation. Neurobiol Learn Mem. 1995;64(3):257-264. Caporaso, GL; Gandy, SE; Buxbaum, JD; Ramabhadran, TV; Greengard, P. Protein phosphorylation regulates secretion of Alzheimer beta/A4 amyloid precursor protein. Proc Natl Acad Sci U S A. 1992;89(7):3055-3059. Chakraborti, S. Phospholipase A(2) isoforms: a perspective. Cell Signal. 2003;15(7):637-665. Chen, J; Engle, SJ; Seilhamer, JJ; Tischfield, JA. Cloning and recombinant expression of a novel human low molecular weight Ca(2+)-dependent phospholipase A2. J Biol Chem. 1994;269(4):2365-2368. Clarke, MS; Prendergast, MA; Terry, AV Jr. Plasma membrane ordering agent pluronic F-68 (PF-68) reduces neurotransmitter uptake and release and produces learning and memory deficits in rats. Learn Mem. 1999;6(6):634-649. Clements, MP; Bliss, TV; Lynchl, MA. Increase in arachidonic acid concentration in a postsynaptic membrane fraction following the induction of long-term potentiation in the dentate gyrus. Neuroscience. 1991;45(2):379-389. Collins, DR; Smith, RC; Davies, SN. Interactions between arachidonic acid and metabotropic glutamate receptors in the induction of synaptic potentiation in the rat hippocampal slice. Eur J Pharmacol. 1995;294(1):147-154. Dennis, EA. Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem. 1994;269(18):13057-13060. Desgranges, B; Baron, JC; de la Sayette, V; Petit-Taboue, MC; Benali, K; Landeau, B; Lechevalier, B; Eustache, F. The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization. Brain. 1998;121(Pt 4):611-631. Eckert, GP; Cairns, NJ; Maras, A; Gattaz, WF; Müller, WE. Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in Alzheimer's disease. Dement Geriatr Cogn Disord. 2000;11(4):181-186. Elgh, E; Sundstrom, T; Nasman, B; Ahlstrom, R; Nyberg, L. Memory functions and rCBF (99m)Tc-HMPAO SPET: developing diagnostics in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2002;29(9):1140-1148. Emmerling, MR; Dudley, DT; Dyer, RD; Carroll, RT; Doyle, PD; Davis, RE. The role of arachidonic acid in the secretion of the amyloid precursor protein (APP). Ann N Y Acad Sci. 1996;777:310-315. Emmerling, MR; Moore, CJ; Doyle, PD; Carroll, RT; Davis, RE. Phospholipase A2 activation influences the processing and secretion of the amyloid precursor protein. Biochem Biophys Res Commun. 1993;197(1):292-297.
80
Wagner F. Gattaz, Evelin F. Schaeffer and Orestes V. Forlenza
Farooqui, AA; Litsky, ML; Farooqui, T; Horrocks, LA. Inhibitors of intracellular phospholipase A2 activity: their neurochemical effects and therapeutical importance for neurological disorders. Brain Res Bull. 1999;49(3):139-153. Farooqui, AA; Yang, HC; Rosenberger, TA; Horrocks, LA. Phospholipase A2 and its role in brain tissue. J Neurochem. 1997;69(3):889-901. Fluhrer, R; Capell, A; Westmeyer, G; Willem, M; Hartung, B; Condron, MM; Teplow, DB; Haass, C; Walter, J. A non-amyloidogenic function of BACE-2 in the secretory pathway. J Neurochem. 2002;81(5):1011-1020. Forlenza, OV; Schaeffer, EL; Gattaz, WF. Phospholipase A2 activity in rat embryonic brain and in primary cultures of cortical neurons. J Neural Transm. 2002;109(5-6):623-631. Forlenza, OV; Wacker, P; Nunes, PV; Yacubian, J; Castro, CC; Otaduy, MC; Gattaz, WF. Reduced phospholipid breakdown in Alzheimer's brains: a (31)P spectroscopy study. Psychopharmacology (Berl). 2005; [Epub ahead of print]. Fujita, S; Ikegaya, Y; Nishikawa, M; Nishiyama, N; Matsuki, N. Docosahexaenoic acid improves long-term potentiation attenuated by phospholipase A(2) inhibitor in rat hippocampal slices. Br J Pharmacol. 2001;132(7):1417-1422. Fujita, S; Ikegaya, Y; Nishiyama, N; Matsuki, N. Ca2+-independent phospholipase A2 inhibitor impairs spatial memory of mice. Jpn J Pharmacol. 2000;83(3):277-278. Fukushima, D; Konishi, M; Maruyama, K; Miyamoto, T; Ishiura, S; Suzuki, K. Activation of the secretory pathway leads to a decrease in the intracellular amyloidogenic fragments generated from the amyloid protein precursor. Biochem Biophys Res Commun. 1993;194(1):202-207. Gattaz, WF; Cairns, NJ; Levy, R; Forstl, H; Braus, DF; Maras, A. Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 1996;246(3):129-131. Gattaz, WF; Forlenza, OV; Talib, LL; Barbosa, NR; Bottino, CM. Platelet phospholipase A(2) activity in Alzheimer's disease and mild cognitive impairment. J Neural Transm. 2004;111(5):591-601. Gattaz, WF; Hübner, CK; Nevalainen, TJ; Thuren, T; Kinnunen, PKJ. Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biol Psychiatry. 1990;28(6):495-501. Gattaz, WF; Köllisch, M; Thuren, T; Virtanen, JA; Kinnunen, PKJ. Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol Psychiatry. 1987;22:421-426. Gattaz, WF; Steudle, A; Maras, A. Increased platelet phospholipase A2 in schizophrenia. Schizophr Res. 1995;16:1-6. Gattaz, WF; Maras, A; Cairns, NJ; Levy, R; Forstl, H. Decreased phospholipase A2 activity in Alzheimer brains. Biol Psychiatry. 1995;37(1):13-17. Gelb, MH; Valentin, E; Ghomashchi, F; Lazdunski, M; Lambeau, G. Cloning and recombinant expression of a structurally novel human secreted phospholipase A2. J Biol Chem. 2000;275(51):39823-39826. Gijón, MA; Spencer, DM; Kaiser, AL; Leslie, CC. Role of phosphorylation sites and the C2 domain in regulation of cytosolic phospholipase A2. J Cell Biol. 1999;145(6):1219-1232.
The Role of Phospholipase A2 in Alzheimer's Disease
81
Gonzalez, RG; Guimaraes, AR; Moore, GJ; Crawley, A; Cupples, LA; Growdon, JH. Quantitative in vivo 31P magnetic resonance spectroscopy of Alzheimer disease. Alzheimer Dis Assoc Disord. 1996;10(1):46-52. Hirabayashi, T; Kume, K; Hirose, K; Yokomizo, T; Iino, M; Itoh, H; Shimizu, T. Critical duration of intracellular Ca2+ response required for continuous translocation and activation of cytosolic phospholipase A2. J Biol Chem. 1999;274(8):5163-5169. Hölscher, C; Canevari, L; Richter-Levin, G. Inhibitors of PLA2 and NO synthase cooperate in producing amnesia of a spatial task. Neuroreport. 1995;6(5):730-732. Hölscher, C; Rose, SP. Inhibitors of phospholipase A2 produce amnesia for a passive avoidance task in the chick. Behav Neural Biol. 1994;61(3):225-232. Hong, A. The neural basis of learning and memory declines in aged rats. Sheng Li Ke Xue Jin Zhan. 1995;26(3):240-242. Horrobin, DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res. 1998;30(3):193-208. Hwang, TC; Guggino, SE; Guggino, WB. Direct modulation of secretory chloride channels by arachidonic and other cis unsaturated fatty acids. Proc Natl Acad Sci USA. 1990;87(15):5706-5709. Igaz, LM; Bekinschtein, P; Vianna, MM; Izquierdo, I; Medina, JH. Gene expression during memory formation. Neurotox Res. 2004;6(3):189-204. Igaz, LM; Vianna, MR; Medina, JH; Izquierdo, I. Two time periods of hippocampal mRNA synthesis are required for memory consolidation of fear-motivated learning. J Neurosci. 2002;22(15):6781-6789. Ikemoto, A; Kobayashi, T; Watanabe, S; Okuyama, H. Membrane fatty acid modifications of PC12 cells by arachidonate or docosahexaenoate affect neurite outgrowth but not norepinephrine release. Neurochem Res. 1997;22(6):671-678. Izquierdo, I. Mechanism of action of scopolamine as an amnestic. Trends Pharmacol Sci. 1989;10(5):175-177. Izquierdo, I; Barros, DM; Mello e Souza, T; de Souza, MM; Izquierdo, LA; Medina, JH. Mechanisms for memory types differ. Nature. 1998;393(6686):635-636. Izquierdo, I; Medina, JH. Memory formation: the sequence of biochemical events in the hippocampus and its connection to activity in other brain structures. Neurobiol Learn Mem. 1997;68(3):285-316. Izquierdo, I; Medina, JH; Vianna, MR; Izquierdo, LA; Barros, DM. Separate mechanisms for short- and long-term memory. Behav Brain Res. 1999;103(1):1-11. Izquierdo, I; Quillfeldt, JA; Zanatta, MS; Quevedo, J; Schaeffer, E; Schmitz, PK; Medina, JH. Sequential role of hippocampus and amygdala, entorhinal cortex and parietal cortex in formation and retrieval of memory for IA in rats. Eur J Neurosci. 1997;9(4):786-793. Kadoyama, K; Takahashi, Y; Higashida, H; Tanabe, T; Yoshimoto, T. Cyclooxygenase-2 stimulates production of amyloid beta-peptide in neuroblastoma x glioma hybrid NG10815 cells. Biochem Biophys Res Commun. 2000;281(2):483-490. Kim, D; Clapham, DE. Potassium channels in cardiac cells activated by arachidonic acid and phospholipids. Science. 1989;244(4909):1174-1176.
82
Wagner F. Gattaz, Evelin F. Schaeffer and Orestes V. Forlenza
Kishimoto, K; Matsumura, K; Kataoka, Y; Morii, H; Watanabe, Y. Localization of cytosolic phospholipase A2 messenger RNA mainly in neurons in the rat brain. Neuroscience. 1999;92(3):1061-1077. Kudo, I; Murakami, M. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat. 2002;68-69:3-58. Larsson Forsell, PK; Kennedy, BP; Claesson, HE. The human calcium-independent phospholipase A2 gene multiple enzymes with distinct properties from a single gene. Eur J Biochem. 1999;262(2):575-585. Larsson, PK; Claesson, HE; Kennedy, BP. Multiple splice variants of the human calciumindependent phospholipase A2 and their effect on enzyme activity. J Biol Chem. 1998;273(1):207-214. Lin, LL; Wartmann, M; Lin, AY; Knopf, JL; Seth, A; Davis, RJ. cPLA2 is phosphorylated and activated by MAP kinase. Cell. 1993;72(2):269-278. Lio, YC; Reynolds, LJ; Balsinde, J; Dennis, EA. Irreversible inhibition of Ca(2+)independent phospholipase A2 by methyl arachidonyl fluorophosphonate. Biochim Biophys Acta. 1996;1302(1):55-60. Lukiw, WJ; Bazan, NG. Neuroinflammatory signaling upregulation in Alzheimer's disease. Neurochem Res. 2000;25(9-10):1173-1184. MacDonell, LE; Skinner, FK; Ward, PE; Glen, AI; Glen, AC; McDonald, DJ; Boyle, RM; Horrobin, DF. Increased levels of cytosolic phospholipase A2 in dyslexics. Prostagland Leukotr Essent Fatty Acids. 2000;63(1-2):37-39. Maire, JC; Wurtman, RJ. Effects of electrical stimulation and choline availability on the release and contents of acetylcholine and choline in superfused slices from rat striatum. J Physiol (Paris). 1985;80(3):189-195. Mancuso, DJ; Jenkins, CM; Gross, RW. The genomic organization, complete mRNA sequence, cloning, and expression of a novel human intracellular membrane-associated calcium-independent phospholipase A(2). J Biol Chem. 2000;275(14):9937-9945. McGahon, BM; Martin, DS; Horrobin, DF; Lynch, MA. Age-related changes in synaptic function: analysis of the effect of dietary supplementation with omega-3 fatty acids. Neuroscience. 1999;94(1):305-314. Mendes, CT; Gattaz, WF; Schaeffer, EL; Forlenza, OV. Modulation of phosopholipase A(2) activity in primary cultures of rat cortical neurons. J Neural Transm. 2005; [Epub ahead of print]. Miller, B; Sarantis, M; Traynelis, SF; Attwell, D. Potentiation of NMDA receptor currents by arachidonic acid. Nature. 1992;355(6362):722-725. Mizuno-Kamiya, M; Inokuchi, H; Kameyama, Y; Yashiro, K; Fujita, A. Ca2+-independent phospholipase A2 activity in apical plasma membranes from the rat parotid gland. Arch Oral Biol. 2001;46(9):789-799. Molloy, GY; Rattray, M; Williams, RJ. Genes encoding multiple forms of phospholipase A2 are expressed in rat brain. Neurosci Lett. 1998;258(3):139-142. Muccioli, G; Raso, GM; Ghe, C; Di Carlo, R. Effect of L-alpha glycerylphosphorylcholine on muscarinic receptors and membrane microviscosity of aged rat brain. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20(2):323-339.
The Role of Phospholipase A2 in Alzheimer's Disease
83
Müller, WE; Koch, S; Scheuer, K; Rostock, A; Bartsch, R. Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain. Biochem Pharmacol. 1997;53(2):135140. Musser, JH; Kreft, AF. 5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors. J Med Chem. 1992;35(14):2501-2524. Nemenoff, RA; Winitz, S; Qian, NX; Van Putten, V; Johnson, GL; Heasley, LE. Phosphorylation and activation of a high molecular weight form of phospholipase A2 by p42 microtubule-associated protein 2 kinase and protein kinase C. J Biol Chem. 1993;268(3):1960-1964. Nishikawa, M; Kimura, S; Akaike, N. Facilitatory effect of docosahexaenoic acid on Nmethyl-D-aspartate response in pyramidal neurones of rat cerebral cortex. J Physiol. 1994;475(1):83-93. Nishizaki, T; Nomura, T; Matsuoka, T; Tsujishita, Y. Arachidonic acid as a messenger for the expression of long-term potentiation. Biochem Biophys Res Commun. 1999;254(2): 446-449. Nitsch, RM; Deng, A; Wurtman, RJ; Growdon, JH. Metabotropic glutamate receptor subtype mGluR1alpha stimulates the secretion of the amyloid beta-protein precursor ectodomain. J Neurochem. 1997;69(2):704-712. Noponen, M; Sanfilipo, M; Samanich, K; Ryer, H; Ko, G; Angrist, B; Wolkin, A; Rotrosen J. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol Psychiatry. 1993;34:641-649. Owada, Y; Tominaga, T; Yoshimoto, T; Kondo, H. Molecular cloning of rat cDNA for cytosolic phospholipase A2 and the increased gene expression in the dentate gyrus following transient forebrain ischemia. Brain Res Mol Brain Res. 1994;25(3-4):364-368. Paxinos, G; Watson, C. The Rat Brain in Stereotaxic Coordinates. San Diego: Academic Press; 1998. Perani, D; Bressi, S; Cappa, SF; Vallar, G; Alberoni, M; Grassi, F; Caltagirone, C; Cipolotti, L; Franceschi, M; Lenzi, GL; et al. Evidence of multiple memory systems in the human brain. A [18F]FDG PET metabolic study. Brain. 1993;116(Pt 4):903-919. Perisic, O; Paterson, HF; Mosedale, G; Lara-Gonzalez, S; Williams, RL. Mapping the phospholipid-binding surface and translocation determinants of the C2 domain from cytosolic phospholipase A2. J Biol Chem. 1999;274(21):14979-14987. Pettegrew, JW; Kanagasabai, P; Moossy, J; Martinez, J; Rao, G; Boller, F. Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer’s disease. Arch Neurol. 1988;45:1093-1096. Pettegrew, JW; Klunk, WE; Kanal, E; Panchalingam, K; McClure, RJ. Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia. Neurobiol Aging. 1995;16(6):973-975. Pickard, RT; Strifler, BA; Kramer, RM; Sharp, JD. Molecular cloning of two new human paralogs of 85-kDa cytosolic phospholipase A2. J Biol Chem. 1999;274(13):8823-8831. Quevedo, J; Vianna, MR; Martins, MR; Barichello, T; Medina, JH; Roesler, R; Izquierdo, I. Protein synthesis, PKA, and MAP kinase are differentially involved in short- and longterm memory in rats. Behav Brain Res. 2004;154(2):339-343.
84
Wagner F. Gattaz, Evelin F. Schaeffer and Orestes V. Forlenza
Rosenberger, TA; Villacreses, NE; Contreras, MA; Bonventre, JV; Rapoport, SI. Brain lipid metabolism in the cPLA2 knockout mouse. J Lipid Res. 2003;44(1):109-117. Ross, BM; Hudson, C; Erlich, J; Warsh, JJ; Kish, SJ. Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2. Arch Gen Psychiatry. 1997;54(5):487-494. Ross, BM; Moszczynska, A; Erlich, J; Kish, SJ. Phospholipid-metabolizing enzymes in Alzheimer's disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity. J Neurochem. 1998;70(2):786-793. Schaeffer, EL; Bassi, F Jr; Gattaz, WF. Inhibition of phospholipase A2 activity reduces membrane fluidity in rat hippocampus. J Neural Transm. 2005;112(5):641-647. Schaeffer, EL; Gattaz, WF. Inhibition of calcium-independent phospholipase A2 activity in rat hippocampus impairs acquisition of short- and long-term memory. Psychopharmacology (Berl). 2005; [Epub ahead of print]. Scheuer, K; Rostock, A; Bartsch, R; Müller, WE. Piracetam improves cognitive performance by restoring neurochemical deficits of the aged rat brain. Pharmacopsychiatry. 1999;32(Suppl 1):10-16. Schievella, AR; Regier, MK; Smith, WL; Lin, LL. Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum. J Biol Chem. 1995;270(51):30749-30754. Sharp, JD; White, DL. Cytosolic PLA2: mRNA levels and potential for transcriptional regulation. J Lipid Mediat. 1993;8(3):183-189. Simonato, M. A pathogenetic hypothesis of temporal lobe epilepsy. Pharmacol Res. 1993;27:217-225. Six, DA; Dennis, EA. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim Biophys Acta. 2000;1488(1-2):1-19. Skinner, ER; Watt, C; Besson, JAO; Best, PV. Lipid composition of different regions of the brain in patients with Alzheimer's disease. Biochem Soc Trans. 1989;17:213-214. Smalheiser, NR; Dissanayake, S; Kapil, A. Rapid regulation of neurite outgrowth and retraction by phospholipase A2-derived arachidonic acid and its metabolites. Brain Res. 1996;721(1-2):39-48. Smith, CD; Gallenstein, LG; Layton, WJ; Kryscio, RJ; Markesbery , WR. 31P magnetic resonance spectroscopy in Alzheimer's and Pick's disease. Neurobiol Aging. 1993;14(1):85-92. Song, C; Chang, XJ; Bean, KM; Proia, MS; Knopf, JL; Kriz, RW. Molecular characterization of cytosolic phospholipase A2-beta. J Biol Chem. 1999;274(24):17063-17067. Stubbs, CD; Smith, AD. The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochim Biophys Acta. 1984;779(1):89-137. Suzuki, N; Ishizaki, J; Yokota, Y; Higashino, K; Ono, T; Ikeda, M; Fujii, N; Kawamoto, K; Hanasaki, K. Structures, enzymatic properties, and expression of novel human and mouse secretory phospholipase A(2)s. J Biol Chem. 2000;275(8):5785-5793. Talbot, K; Young, RA; Jolly-Tornetta, C; Lee, VM; Trojanowski, JQ; Wolf, BA. A frontal variant of Alzheimer's disease exhibits decreased calcium-independent phospholipase A2 activity in the prefrontal cortex. Neurochem Int. 2000;37(1):17-31.
The Role of Phospholipase A2 in Alzheimer's Disease
85
Tanaka, H; Takeya, R; Sumimoto, H. A novel intracellular membrane-bound calciumindependent phospholipase A(2). Biochem Biophys Res Commun. 2000;272(2):320-326. Tomassoni, ML; Amori, D; Magni, MV. Changes of nuclear membrane lipid composition affect RNA nucleocytoplasmic transport. Biochem Biophys Res Commun. 1999;258(2):476-481. Underwood, KW; Song, C; Kriz, RW; Chang, XJ; Knopf, JL; Lin, LL. A novel calciumindependent phospholipase A2, cPLA2-gamma, that is renylated and contains homology to cPLA2. J Biol Chem. 1998;273(34):21926-21932. Visioli, F, Rodriguez-de-Turco, EB, Kreisman, NR, Bazan, NG. Membrane lipid degradation is related to interictal cortical activity in a series of seizures. Metab Brain Dis. 1994;9:161-170. Weichel, O; Hilgert, M; Chatterjee, SS; Lehr, M; Klein, J. Bilobalide, a constituent of Ginkgo biloba, inhibits NMDA-induced phospholipase A2 activation and phospholipid breakdown in rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol. 1999;360(6):609-615. Williams, EJ; Walsh, FS; Doherty, P. The production of arachidonic acid can account for calcium channel activation in the second messenger pathway underlying neurite outgrowth stimulated by NCAM, N-cadherin, and L1. J Neurochem. 1994;62(3):12311234. Winstead, MV; Balsinde, J; Dennis, EA. Calcium-independent phospholipase A(2): structure and function. Biochim Biophys Acta. 2000;1488(1-2):28-39. Woelk, H; Peiler-Ichikawa, K. Zur Aktivität der Phospholipase A2 gegenüber verschiedenen 1-Alk-1'-enyl-2-acyl- und 1-Alkyl-2-acyl-Verbindungen während der multiplen Sklerose. J Neurol. 1974;207:319-326. Wolf, MJ; Izumi, Y; Zorumski, CF; Gross, RW. Long-term potentiation requires activation of calcium-independent phospholipase A2. FEBS Lett. 1995;377(3):358-362. Yang, HC; Mosior, M; Ni, B; Dennis, EA. Regional distribution, ontogeny, purification, and characterization of the Ca2+-independent phospholipase A2 from rat brain. J Neurochem. 1999;73(3):1278-1287. Yoshihara, Y; Yamaji, M; Kawasaki, M; Watanabe, Y. Ontogeny of cytosolic phospholipase A2 activity in rat brain. Biochem Biophys Res Commun. 1992;185(1):350-355. Yoshihara, Y; Watanabe, Y. Translocation of phospholipase A2 from cytosol to membranes in rat brain induced by calcium ions. Biochem Biophys Res Commun. 1990;170(2):484490. Yoshikai, Y. Roles of prostaglandins and leukotrienes in acute inflammation caused by bacterial infection. Curr Opin Infect Dis. 2001;14(3):257-263. Zubenko, GS; Winwood, E; Jacobs, B; Teply, I; Stiffler, JS; Hughes, HB 3rd; Huff, FJ; Sunderland, T; Martinez, AJ. Prospective study of risk factors for Alzheimer's disease: results at 7.5 years. Am J Psychiatry. 1999;156(1):50-57.
In: New Research on Alzheimer’s Disease Editor: Eileen M. Welsh, pp. 87-98
ISBN 1-59454-939-7 © 2006 Nova Science Publishers, Inc.
Chapter III
Low Molecular Weight Glycosaminoglycans and Apoptosis: Potential Treatment of Neurodegenerative Disorders Including Alzheimer’s Disease Bertalan Dudas Neuroendocrine Organization Laboratory (NEO), Lake Erie College of Osteopathic Medicine, Erie, PA 16509, USA.
Abstract Previous studies have shown that apoptosis (programmed cell death) plays a crucial role in the pathomechanism of neurodegenerative disorders. It is a general consensus that apoptosis can be triggered by dysregulation of nerve growth factor physiology and/or oxidative stress processes. Since both of these pathological changes are characteristic to AD, it is conceivable that influencing apoptosis can be a valuable tool in the treatment of neurodegenerative disorders. Glucosaminoglycans (GAGs) exhibit neuroprotective properties in several animal models of AD. Low molecular weight GAG, C3, attenuates Aβ(25-35)-induced tau-2 immunoreactivity, and AF64A-induced cholinergic lesion in rat brain. Recent studies have also revealed that C3 influences p75 nerve growth factor receptor expression. However, the exact mechanism of the neuroprotective attributes of C3 is not elucidated yet. Since apoptosis is believed to play a pivotal role in numerous neurodegenerative disorders, C3 may induce neuroprotection/neurorepair via affecting apoptotic processes. The neuroprotective effect of glucosaminoglycans including C3 thus may involve multiple mechanisms, including an influence on processes that lead to programmed cell death. Since apoptosis is a crucial event not only in neurodegenerative diseases but also
88
Bertalan Dudas in the general process of aging, C3 may be a valuable therapeutic agent in Alzheimer’s disease-related senile dementia and in other age-related malfunctions.
Pathology of Alzheimer’s Disease: Introductory Comments Alzheimer’s disease (AD) is a progressive and irreversible brain disorder that is manifested in dementia, motor lesions and behavioral deficits. Since as many as 10% of the population above 65 years of age is affected by AD in the United States, AD is becoming a growing concern in health care. The unequivocal diagnosis of AD is based on histopathological evidence at brain autopsy or biopsy. The major pathological hallmarks of AD include abnormal biochemical alteration of regular proteins that leads to accumulation of the modified molecules in the brain. Intracellular deposition of hyperphosphorylated, polymerized tau protein, forming flame-like tangles disrupts axonal and dendritic transport by destroying the normal microtubular structure. Pathological cleavage of the amyloid precursor protein (APP) normally present in the brain results in beta amyloid fragments that are aggregated to form extracellular build-up of amyloid plaques. These histological hallmarks are associated with extensive loss of cholinergic neurons, which is believed to be the major cause of symptoms in AD. However, the exact patho-mechanism leading to neuronal death is not yet elucidated.
Apoptosis in Neurodegenerative Disorders Apoptosis (programmed cell death) is a natural process that ensures that damaged cells are packaged and removed by the surrounding cells cleanly, in order to prevent inflammation typical in necrotic processes. Apoptosis (Figure 1) is typically triggered by external stimuli (extrinsic pathway) and internal events (intrinsic pathway). The extrinsic pathway is initiated outside of the cell, when conditions in the extracellular environment determine that a cell must die. Extrinsic pathway is triggered by binding ligands to specific "death receptors" on the surface of the cells, leading to activation of cysteinyl proteases that are called initiator caspases. The intrinsic apoptosis pathway begins when an injury occurs within the cell. Mitochondrial damage, for example, can initiate the intrinsic pathway, when cytochrome-c, released from damaged mitochondria, activates an initiator caspase. The extrinsic and intrinsic pathways merge at caspase-3 that is activated by initiator caspases. Subsequent processes result in multiple events, including degradation of DNA, and packaging of the cell into small units that are easily taken up by neighboring cells. Several studies indicated that apoptosis is one of the crucial factors that may be responsible for neuronal loss, characteristic for neurodegeneratory disorders including AD. Caspases are believed to be involved in generation of toxic fragments of protein substrates, that can trigger the earlier stages of neuronal dysfunction including protein aggregation in Huntington's and Alzheimer's disease [1]. Thus, caspase inhibition may be a valuable adjunct
Low Molecular Weight Glycosaminoglycans and Apoptosis
89
in the treatment of neurodegenerative disorders. Previous findings also demonstrated dysregulation of apoptotic proteins in AD brain, that may play a crucial role in the neuropathology of AD [2,3]. Since the level of cytochrome c has been reported to be unchanged in the frontal cortex of patients suffering from AD [3], apoptosis may occur via the extrinsic death receptor pathway independent of cytochrome c. However, it is generally believed that multiple factors are responsible for the neuronal cell death in AD. For example, neurofibrillary tangles and amyloid plaques are not associated with caspase-3 induction, in contrast to hippocampal neurons, that exhibit vacuolar degeneration and caspase-3 activation [4]. Thus, caspase-3 may not have a significant role in the widespread neuronal apoptosis that occurs in AD, but may contribute to the specific loss of hippocampal neurons involved in learning and memory.
Figure 1. Major processes of the apoptotic pathway. Apoptosis is a natural process that ensures that damaged cells are packaged and removed by the surrounding cells thoroughly, in order to prevent inflammation typical in necrotic processes. Apoptosis is triggered by external stimuli (extrinsic pathway) and internal events (intrinsic pathway). The extrinsic pathway is activated by binding ligands (DL) to specific "death receptors" (DR) on the surface of the cells, leading to activation of initiator caspases of the external pathway (EIC). The intrinsic apoptosis pathway begins with an intracellular lesion that is typically mitochondrial damage, when cytochrome-c (Cc), released from damaged mitochondria, activates initiator caspases of the internal pathway (IIC). The extrinsic and intrinsic pathways merge at caspase-3 (CA3) that is activated by initiator caspases (EIC and IIC). Subsequent processes result in multiple events, including degradation of DNA in the nucleus, and packaging of the cell into small units that are easily taken up by neighboring cells.
It is a common consensus that there are two major pathways playing roles in triggering apoptosis in neurodegenerative disorders: oxidative stress and trophic factor dysregulation.
90
Bertalan Dudas
Oxidative Stress in Alzheimer’s Disease Neuronal cell loss is believed to be responsible for the majority of the clinical symptoms of AD including dementia, motor lesions and behavioral deficits. One of the most important pathways known to trigger apoptosis in the brain is oxidative stress. Oxidative stress refers to the situation of a serious imbalance between production of reactive oxygen species (ROS) and reactive nitrogen species (RNS), and antioxidant defense. ROS/RNS cause cell damage and neuronal death through lipid peroxidation (LPO), oxidation of nucleic acids, and oxidation and nitrosylation of proteins and aminoacids. It is generally thought that the amyloid deposit (i.e. the senile plaque), which accumulates in the brain of Alzheimer’s disease (AD) patients, is the cause of the neurodegenerative changes characteristic of AD, and that oxidative stress induced by amyloid beta peptide (Aβ) is a prominent feature of amyloid-induced neuronal cell death in the AD brain. Indeed, post-mortem studies have shown that 4-hydroxy-nonenal (4-HNE), a lipid peroxidation (LPO) end–product accumulates in the AD brain [5]. Moreover, a recent study has shown that iPF(2α)–IV, another marker of LPO (i.e. oxidative stress) was increased in the urine of patients with mild to moderate dementia and probable AD [6]. Studies have also demonstrated that Aβ can directly cause increases in reactive oxygen species (ROS) and produce 4-HNE [7]. These findings indicate that Aβ-induced oxidative stress is a key feature in AD. The contention that AD pathology is associated with increased levels of oxidative stress has also been confirmed in an animal model of Alzheimer amyloidosis [8]. Levels of urinary and plasma iPF(2α)–IV were higher in APP-transgenic mice than in littermate wild type animals as early as eight months of age, and remained high for the rest of the study. Furthermore, homogenates from the cerebral cortex and the hippocampus of APP-mice had higher levels of iPF(2α)–IV, and this increase in LPO preceded amyloid plaque formation. That increased oxidative damage may, indeed, be the earliest event in AD is suggested by findings showing that increases in 8-hydroxyguanosine, an oxidized nucleoside derived from DNA, and nitrotyrosine, an oxidized amino acid, were quantitatively greatest early in the disease [9]. Data confirming that oxidative stress-induced damage precedes the deposition of amyloid in the brain also come from a study of Down’s syndrome brains [10]. Oxidized nucleic acid, 8-hydroxy guanosine (8-OHG), oxidized protein and nitrotyrosine were found to be increased significantly in the teens and in the twenties, while Aβ deposits only occurred after age 30. These findings suggest that brain oxidative damage must contribute to AD pathogenesis before Aβ (i.e. senile plaques) accumulates in the AD brain. Several risk factors may facilitate oxidative stress in the AD brain. One study has showed reduced antioxidant enzyme activity in AD brain [11], and brains of transgenic mice expressing different Alzheimer-linked presenilin-1 gene (PS1) mutations have been shown to have decreased antioxidant enzyme activity [12]. Another risk factor that may facilitate Aβinduced oxidative brain damage is the epsilon4 allele of apolipoprotein E (APOE), an established risk factor for AD. Levels of LPO were found to be significantly increased in tissues from Alzheimer’s cases which were homozygous for the epsilon4 allele of APOE, compared to AD epsilon3/epsilon3 cases and controls [13], suggesting that oxidative stressinduced injury in the frontal cortex of AD cases is related to the APOE genotype.
Low Molecular Weight Glycosaminoglycans and Apoptosis
91
Activated astrocytes (and microglia) are observed in a wide range of CNS pathologies, including brain inflammation, trauma, ischemia, and stroke; neurodegenerative diseases including AD, and normal aging [14,15]. In AD, activated microglia and astrocytes expressing the inducible form of nitric oxide synthase (iNOS) are found in the amyloid plaques surrounded by dead and dystrophic neurites [16,17], and a growing body of evidence suggests that these activated glia contribute to neurotoxicity through the production of reactive nitrogen species (RNS) derived from increased production of iNOS. Moreover, aggregated Aβ peptide can also stimulate iNOS production in rat glial cell cultures [18]. The concentration of 3-nitrotyrosine, a marker of oxidative damage mediated by peroxynitrite, and the 3-nitrotyrosine/tyrosine ratio was also increased six-fold in AD patients when compared with cerebrospinal fluid samples from age matched controls, and increased significantly with decreasing cognitive function [19]. Strong nitrotyrosine (NT) immunoreactivity was also observed in the absence of tangle formation in most terminal deoxynucleotidyl transferase (TdT)-positive neurones in the visual cortex of AD patients, suggesting that neuronal DNA damage may precede tangle formation and is associated with up-regulation of nitrotyrosine in AD brain [20]. These studies indicate that increased oxidative damage must contribute to the pathogenesis of AD before amyloid deposits occur in the brain. Thus, oxidative stress and increased production of iNOS are early events that appear to be central in determining cell death in AD.
Neurotrophic Factors in Alzheimer’s Disease Since nerve growth factor (NGF) induces neuronal growth and regeneration [21-25], it is generally accepted that NGF may play a pivotal role in the repair processes of neurodegenerative disorders [26] and may be a crucial element of the neuronal loss in AD[27-30]. Several studies revealed that deficiency of NGF may directly trigger apoptosis. Neuronal PC12 cells underwent apoptosis within two days following withdrawal of nerve growth factor (NGF) from the culture medium. [31]. Anti-NGF transgenic mice develop neurodegeneratory lesions characteristic for AD including amyloid plaques and neurofibrillary tangles in cortical and hippocampal neurons associated with extensive neuronal loss [32]. Although NGF is commonly accepted as a major factor promoting neuronal regeneration and survival, recent findings indicated that NGF may also play a role in triggering apoptosis. The ambivalent nature of NGF may be explained by the physiology of the NGF receptors, the tropomyosin receptor kinase A (TrkA) and the 75 kDa NGF receptor (p75NTR). TrkA induces survival and regeneration, whereas p75NTR appears to be a death receptor mediating the apoptotic effect of NGF. Indeed, NGF induced apoptosis in p75NTR-expressing human neuroblastoma SK-N-MC cells, but neurotrophin-3 (NT-3) or brain-derived neurotrophic factor (BDNF) lacked apoptotic effect [33]. Moreover, betaamyloid peptide, commonly present in amyloid plaques in AD, specifically binds the p75NTR in rat cortical neurons, NIH-3T3 cell line and neuronal hybrid cells, and triggers apoptosis [34-36] indicating that neuronal death in Alzheimer's disease may be mediated by the interaction of beta-amyloid with p75NTR. Since p75NTR is up-regulated in
92
Bertalan Dudas
neurodegeneratory disorders, p75NTR might be involved in neuronal cell death related to AD [33].
Alzheimer’s Disease and Glycosaminoglycans There is a growing body of evidence that glycosaminoglycans (GAGs) play a pivotal role in the pathogenesis of Alzheimer’s disease. Glycosaminoglycans are highly sulfated polysaccharides that are common constituents of the extracellular matrix. GAGs bind to Aβ, and attenuate the proteoglycan-mediated protection of Aβ against proteolysis. It has been also shown that GAGs inhibit the aggregation and toxicity of Aβ itself [37]. AteroidR, a mixture of low molecular weight GAGs recently used in Europe to reverse the symptoms of AD, improves age-related behavioral deficits in rats. Moreover, human studies revealed that AteroidR significantly improves dementia [38,39]. C3 is a novel low molecular weight GAG exerting neuroprotective property. C3 is synthesized from unfractionated heparin using a standardized process of γ-irradiation. The chemical and biological properties of C3 have been well characterized including its ability to protect against various lesions in rat animal models. Stereotaxic injection of Aβ fragments (Aβ[25-35]) into the amygdala increases tau-2 immunoreactivity in the rat hippocampus [40]. This phenomenon was blocked by administration of C3 [41]. Moreover, C3 attenuated the cholinergic lesions in the septum and cingulum bundle induced by intraventricular administration of a specific cholinotoxin, ethylcholine aziridinium (AF64A; [42,43]. It has been also shown that C3 increase axonal growth and arborization in the rat hippocampus [44]. Recent studies suggested that GAGs may act via modulating the release of nerve growth factor (NGF) by stimulating the effect of growth factors in cell culture [45,46] and/or reducing the expression of cholinotoxin-stimulated growth factor receptor expression in the rat septum [47]. Glial cell line-derived neurotrophic factor (GDNF), that is vital to the development and maintenance of neural tissues, requires heparan sulphate glycosaminoglycan to promote neuronal survival [48]. However, the exact mechanism of the neuroprotective/neurorepair effect of GAGs is not known. The bioavailability of various GAGs depends on their potential to traverse the blood bran barrier (BBB). Since C3 has been demonstrated to cross the BBB, it may be a valuable adjunct in the treatment of neurodegenerative disorders including AD. Indeed, C3 is in phase I clinical trials at the time of this writing.
Glycosaminoglycans and Apoptosis: Potential Treatment of Alzheimer’s Disease Previous studies revealed that GAGs express neuroprotective properties against various lesions in cell culture [49] and in vivo [41-43,50]. Since neural damage is often associated with apoptotic processes, it is possible that GAGs may protect against neural lesions via
Low Molecular Weight Glycosaminoglycans and Apoptosis
93
influencing stressor-induced apoptosis. Moreover, C3, the low molecular GAG derived from heparin has been shown to penetrate the blood-brain-barrier [51], thus, it is conceivable that C3 and similar molecules can be used as therapeutic agents to protect against neuronal apoptotic processes, that are major hallmarks of neurodegenerative disorders. It is a common premise that GAGs play a pivotal role in the molecular processes of programmed cell death in several cell types. However, the data are ambiguous. Numerous studies indicate that GAGs may participate in the inhibition of apoptotic pathways. Hyaluronan, a major glycosaminoglycan component of the extracellular matrix of the mammalian bone marrow, antagonizes dexamethasone-induced apoptosis of malignant multiplex myeloma (MM) cells [52]. Since GAGs are major constituents of the bone marrow, these findings support the idea that GAGs could play a major role in the survival of MM cells in vivo, and could explain why MM cells accumulate in the bone marrow of patients with MM and escape conventional chemotherapy. Apoptosis in fibroblasts was also attenuated by administration of chondroitin sulfate, and heparan sulfate. Platelet-derived growth factor (PDGF) and beta-D-xyloside treatment protected fetal lung fibroblasts against serum starvation-induced apoptosis probably by stimulating the GAG synthesis/secretion of the cells. Indeed, application of sulfated GAGs, chondroitin sulfate, and heparan sulfate, also resulted in diminished apoptosis in fetal lung fibroblasts, possibly via increasing Bclassociated death promoter phosphorylation and diminished caspase-3 and caspase-7 cleavage [53] Heparin inhibits mesangial cell apoptosis induced by staurosporine, pyrrolidine dithiocarbamate, and ultraviolet light, and also suppresses oxidant-induced apoptosis of NRK49F fibroblasts and Madin-Darby canine kidney epithelial cells. Furthermore, heparin attenuated spontaneous apoptosis of podocytes in explanted glomeruli. These results indicate the novel potential of heparin as an inhibitor of apoptosis in several cell types, including glomerular cells [54]. Moreover, heparin and aspirin has been shown to inhibit trophoblast apoptosis providing an additional mechanism to explain the clinical benefits of heparin and aspirin on recurrent pregnancy loss [55]. In contrast to these findings, induction of apoptosis by GAGs has been reported by several studies, suggesting that GAGs may be used for eliminating tumor cells. Heparin exerts a significant anti-proliferative and an apoptotic effect on human hepatoma cells in vitro [56], and induces apoptosis of human nasopharyngeal carcinoma CNE2 cells [57]. Internalized heparin induces apoptotic cell death probably by interfering with transcription factor function [58]. Derivatives of heparin and chondroitin sulphate substantially reduce cell viability by induction of apoptosis of myeloma and breast cancer cells in vitro [59]. Heparin also induces apoptosis in peripheral blood neutrophils. This phenomenon may help explain the anti-inflammatory effects resulting from the interaction between vessel wall heparan sulphate and chemoattracted peripheral blood neutrophils [60]. Moreover, heparin is not the only GAG exhibiting apoptotic features. A low molecular weight proteoglycan, lumican induced and/or increased the apoptosis of B16F1 cells, probably via the sulphated GAG component of the molecule [61]. Chondroitin sulphate also induces apoptosis of articular chondrocytes [62].
94
Bertalan Dudas
Discussion and Summary Apoptosis is believed to play a pivotal role in the pathogenesis of neurodegenerative disorders including AD. Although the exact function of apoptotic processes in brain pathology is not known, it is a common consensus that two major pathways are responsible in triggering apoptosis in neurodegenerative disorders: (1) oxidative stress and (2) trophic factor dysregulation. Oxidative stress appears to be the major pathological hallmark of AD. Moreover, dysregulation in the release of nerve growth factors, and expression of their receptors are characteristic pathological changes attributed to AD. GAGs are known to exhibit neuroprotective properties in numerous animal models of AD. One possible explanation of the GAG-induced neuroprotection is that GAGs may affect apoptotic processes characteristic in neurodegenerative lesions. The pathomechanism of this phenomenon is not entirely understood; GAGs may affect apoptosis either directly, or via modulating growth factor pathology and/or oxidative stress, that are major hallmarks of AD. Thus, GAGs can be extremely veluable adjunct in the treatment of neurodegenerative disorders. Since a low molecular GAG, C3, is able to cross the blood-brain-barrier, C3 treatment may represent an entirely novel avenue in the therapy of AD. Indeed, C3 has successfully passed the toxicology tests as a low-risk compound, and it is currently in phase I clinical trials.
References [1] [2]
[3]
[4]
[5] [6]
[7]
Rideout HJ, Stefanis L. Caspase Inhibition: A Potential Therapeutic Strategy In Neurological Diseases Histol Histopathol 2001; 16: 895-908. Engidawork E, Gulesserian T, Seidl R, Cairns N, Lubec G. Expression Of Apoptosis Related Proteins In Brains Of Patients With Alzheimer's Disease Neurosci Lett 2001; 303: 79-82. Engidawork E, Gulesserian T, Yoo BC, Cairns N, Lubec G. Alteration Of Caspases And Apoptosis-Related Proteins In Brains Of Patients With Alzheimer's Disease Biochem Biophys Res Commun 2001; 281: 84-93. Selznick LA, Holtzman DM, Han BH, Gokden M, Srinivasan AN, Johnson EM, Roth KA. In Situ Immunodetection Of Neuronal Caspase-3 Activation In Alzheimer Disease J Neuropathol Exp Neurol 1999; 58: 1020-1026. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR. Elevated 4-Hydroxynonenal In Ventricular Fluid In Alzheimer's Disease Neurobiol Aging 1997; 18: 457-461. Tuppo EE, Forman LJ, Spur BW, Chan-Ting RE, Chopra A, Cavalieri TA. Sign Of Lipid Peroxidation As Measured In The Urine Of Patients With Probable Alzheimer's Disease Brain Res Bull 2001; 54: 565-568. Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP. A Role For 4Hydroxynonenal, An Aldehydic Product Of Lipid Peroxidation, In Disruption Of Ion Homeostasis And Neuronal Death Induced By Amyloid Beta-Peptide J Neurochem 1997; 68: 255-264.
Low Molecular Weight Glycosaminoglycans and Apoptosis [8]
[9]
[10]
[11]
[12]
[13]
[14] [15] [16]
[17]
[18]
[19]
[20]
[21]
95
Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM. Increased Lipid Peroxidation Precedes Amyloid Plaque Formation In An Animal Model Of Alzheimer Amyloidosis J Neurosci 2001; 21: 4183-4187. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative Damage Is The Earliest Event In Alzheimer Disease J Neuropathol Exp Neurol 2001; 60: 759-767. Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, Smith MA. Neuronal Oxidative Stress Precedes Amyloid-Beta Deposition In Down Syndrome J Neuropathol Exp Neurol 2000; 59: 1011-1017. Marcus DL, Thomas C, Rodriguez C, Simberkoff K, Tsai JS, Strafaci JA, Freedman ML. Increased Peroxidation And Reduced Antioxidant Enzyme Activity In Alzheimer's Disease Exp Neurol 1998; 150: 40-44. Leutner S, Czech C, Schindowski K, Touchet N, Eckert A, Muller WE. Reduced Antioxidant Enzyme Activity In Brains Of Mice Transgenic For Human Presenilin-1 With Single Or Multiple Mutations Neurosci Lett 2000; 292: 87-90. Ramassamy C, Averill D, Beffert U, Bastianetto S, Theroux L, Lussier-Cacan S, Cohn JS, Christen Y, Davignon J, Quirion R, Poirier J. Oxidative Damage And Protection By Antioxidants In The Frontal Cortex Of Alzheimer's Disease Is Related To The Apolipoprotein E Genotype Free Radic Biol Med 1999; 27: 544-553. Eddleston M, Mucke L. Molecular Profile Of Reactive Astrocytes--Implications For Their Role In Neurologic Disease Neuroscience 1993; 54: 15-36. Kreutzberg GW. Microglia: A Sensor For Pathological Events In The CNS Trends Neurosci 1996; 19: 312-318. Lee SC, Zhao ML, Hirano A, Dickson DW. Inducible Nitric Oxide Synthase Immunoreactivity In The Alzheimer Disease Hippocampus: Association With Hirano Bodies, Neurofibrillary Tangles, And Senile Plaques J Neuropathol Exp Neurol 1999; 58: 1163-1169. Wallace MN, Geddes JG, Farquhar DA, Masson MR. Nitric Oxide Synthase In Reactive Astrocytes Adjacent To Beta-Amyloid Plaques Exp Neurol 1997; 144: 266272. Akama KT, Van Eldik LJ. Beta-Amyloid Stimulation Of Inducible Nitric-Oxide Synthase In Astrocytes Is Interleukin-1beta- And Tumor Necrosis Factor-Alpha (Tnfalpha)-Dependent, And Involves A Tnfalpha Receptor-Associated Factor- And Nfkappab-Inducing Kinase-Dependent Signaling Mechanism J Biol Chem 2000; 275: 7918-7924. Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C. Alterations Of 3Nitrotyrosine Concentration In The Cerebrospinal Fluid During Aging And In Patients With Alzheimer's Disease Neurosci Lett 1999; 269: 52-54. Su JH, Deng G, Cotman CW. Neuronal DNA Damage Precedes Tangle Formation And Is Associated With Up-Regulation Of Nitrotyrosine In Alzheimer's Disease Brain Brain Res 1997; 774: 193-199. Damon DH, D'Amore PA, Wagner JA. Nerve Growth Factor And Fibroblast Growth Factor Regulate Neurite Outgrowth And Gene Expression In PC12 Cells Via Both
96
[22] [23]
[24]
[25]
[26] [27]
[28] [29] [30]
[31]
[32]
[33] [34]
[35]
[36]
Bertalan Dudas Protein Kinase C- And Camp-Independent Mechanisms J Cell Biol 1990; 110: 13331339. Gahwiler BH, Enz A, Hefti F. Nerve Growth Factor Promotes Development Of The Rat Septo-Hippocampal Cholinergic Projection In Vitro Neurosci Lett 1987; 75: 6-10. Hartikka J, Hefti F. Development Of Septal Cholinergic Neurons In Culture: Plating Density And Glial Cells Modulate Effects Of NGF On Survival, Fiber Growth, And Expression Of Transmitter-Specific Enzymes J Neurosci 1988; 8: 2967-2985. Hefti F, Knusel B, Lapchak PA. Protective Effects Of Nerve Growth Factor And BrainDerived Neurotrophic Factor On Basal Forebrain Cholinergic Neurons In Adult Rats With Partial Fimbrial Transections Prog Brain Res 1993; 98: 257-263. Junard EO, Montero CN, Hefti F. Long-Term Administration Of Mouse Nerve Growth Factor To Adult Rats With Partial Lesions Of The Cholinergic Septohippocampal Pathway Exp Neurol 1990; 110: 25-38. Hefti F, Knusel B. Chronic Administration Of Nerve Growth Factor And Other Neurotrophic Factors To The Brain Neurobiol Aging 1988; 9: 689-690. Hefti F, Will B. Nerve Growth Factor Is A Neurotrophic Factor For Forebrain Cholinergic Neurons; Implications For Alzheimer's Disease J Neural Transm Suppl 1987; 24: 309-315. Hefti F, Schneider LS. Nerve Growth Factor And Alzheimer's Disease Clin Neuropharmacol 1991; 14 Suppl 1: S62-S76. Lapchak PA, Hefti F. Emerging Pharmacology Of Nerve Growth Factor Prog Neuropsychopharmacol Biol Psychiatry 1991; 15: 851-860. Phelps CH, Gage FH, Growdon JH, Hefti F, Harbaugh R, Johnston MV, Khachaturian ZS, Mobley WC, Price DL, Raskind M. Potential Use Of Nerve Growth Factor To Treat Alzheimer's Disease Neurobiol Aging 1989; 10: 205-207. Araki W, Wurtman RJ. Increased Expression Of Amyloid Precursor Protein And Amyloid Precursor-Like Protein 2 During Trophic Factor Withdrawal-Induced Death Of Neuronal PC12 Cells Brain Res Mol Brain Resry 1998; 56: 169-177. Capsoni S, Ugolini G, Comparini A, Ruberti F, Berardi N, Cattaneo A. Alzheimer-Like Neurodegeneration In Aged Antinerve Growth Factor Transgenic Mice Proc Natl Acad Sci U S A 2000; 97: 6826-6831. Kuner P, Hertel C. NGF Induces Apoptosis In A Human Neuroblastoma Cell Line Expressing The Neurotrophin Receptor P75ntr J Neurosci Res 1998; 54: 465-474. Yaar M, Zhai S, Pilch PF, Doyle SM, Eisenhauer PB, Fine RE, Gilchrest BA. Binding Of Beta-Amyloid To The P75 Neurotrophin Receptor Induces Apoptosis. A Possible Mechanism For Alzheimer's Disease J Clin Invest 1997; 100: 2333-2340. Tsukamoto E, Hashimoto Y, Kanekura K, Niikura T, Aiso S, Nishimoto I. Characterization Of The Toxic Mechanism Triggered By Alzheimer's Amyloid-Beta Peptides Via P75 Neurotrophin Receptor In Neuronal Hybrid Cells J Neurosci Res 2003; 73: 627-636. Hashimoto Y, Kaneko Y, Tsukamoto E, Frankowski H, Kouyama K, Kita Y, Niikura T, Aiso S, Bredesen DE, Matsuoka M, Nishimoto I. Molecular Characterization Of Neurohybrid Cell Death Induced By Alzheimer's Amyloid-Beta Peptides Via P75ntr/PLAIDD J Neurochem 2004; 90: 549-558.
Low Molecular Weight Glycosaminoglycans and Apoptosis
97
[37] Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA. Arresting Amyloidosis In Vivo Using Small-Molecule Anionic Sulphonates Or Sulphates: Implications For Alzheimer's Disease Nat Med 1995; 1: 143-148. [38] Conti L, Re F, Lazzerini F, Morey LC, Ban TA, Santini V, Modafferi A, Postiglione A. Glycosaminoglycan Polysulfate (Ateroid) In Old-Age Dementias: Effects Upon Depressive Symptomatology In Geriatric Patients Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 977-981. [39] Conti L, Placidi GF, Cassano GB. Ateroid In The Treatment Of Dementia: Results Of A Clinical Trial Mod Probl Pharmacopsychiatry 1989; 23: 76-84. [40] Sigurdsson EM, Lorens SA, Hejna MJ, Dong XW, Lee JM. Local And Distant Histopathological Effects Of Unilateral Amyloid-Beta 25-35 Injections Into The Amygdala Of Young F344 Rats Neurobiol Aging 1996; 17: 893-901. [41] Dudas B, Cornelli U, Lee JM, Hejna MJ, Walzer M, Lorens SA, Mervis RF, Fareed J, Hanin I. Oral And Subcutaneous Administration Of The Glycosaminoglycan C3 Attenuates Abeta(25-35)-Induced Abnormal Tau Protein Immunoreactivity In Rat Brain Neurobiol Aging 2002; 23: 97-104. [42] Rose M, Dudas B, Cornelli U, Hanin I. Protective Effect Of The Heparin-Derived Oligosaccharide C3, On AF64A-Induced Cholinergic Lesion In Rats Neurobiol Aging 2003; 24: 481-490. [43] Rose M, Dudas B, Cornelli U, Hanin I. Glycosaminoglycan C3 Protects Against AF64A-Induced Cholinotoxicity In A Dose-Dependent And Time-Dependent Manner Brain Res 2004; 1015: 96-102. [44] Mervis RF, Mckean J, Zats S, Gum A, Reinhard R, Dudas B, Cornelli U, Lee JM, Lorens SA, Fareed J, Hanin I. Neurotrophic Effects Of The Glycosaminoglycan C3 On Dendritic Arborization And Spines In The Adult Rat Hippocampus: A Quantitative Golgi Study CNS Drug Reviews 2000; 44-46. [45] Damon DH, D'Amore PA, Wagner JA. Sulfated Glycosaminoglycans Modify Growth Factor-Induced Neurite Outgrowth In PC12 Cells J Cell Physiol 1988; 135: 293-300. [46] Lesma E, Di Giulio AM, Ferro L, Prino G, Gorio A. Glycosaminoglycans In Nerve Injury: 1. Low Doses Of Glycosaminoglycans Promote Neurite Formation J Neurosci Res 1996; 46: 565-571. [47] Dudas B, Rose M, Cornelli U, Hanin I. Low Molecular Weight Glycosaminoglycan C3 Attenuates AF64A-Stimulated, Low-Affinity Nerve Growth Factor ReceptorImmunoreactive Axonal Varicosities In The Rat Septum Brain Res 2005; 1033: 34-40. [48] Barnett MW, Fisher CE, Perona-Wright G, Davies JA. Signalling By Glial Cell LineDerived Neurotrophic Factor (GDNF) Requires Heparan Sulphate Glycosaminoglycan J Cell Sci 2002; 115: 4495-4503. [49] Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA. Arresting Amyloidosis In Vivo Using Small-Molecule Anionic Sulphonates Or Sulphates: Implications For Alzheimer's Disease Nat Med 1995; 1: 143-148. [50] Sigurdsson EM, Lorens SA, Hejna MJ, Dong XW, Lee JM. Local And Distant Histopathological Effects Of Unilateral Amyloid-Beta 25-35 Injections Into The Amygdala Of Young F344 Rats Neurobiol Aging 1996; 17: 893-901.
98
Bertalan Dudas
[51] Ma Q, Dudas B, Hejna M, Cornelli U, Lee JM, Lorens S, Mervis R, Hanin I, Fareed J. The Blood-Brain Barrier Accessibility Of A Heparin-Derived Oligosaccharides C3 Thromb Res 2002; 105: 447-453. [52] Vincent T, Molina L, Espert L, Mechti N. Hyaluronan, A Major Non-Protein Glycosaminoglycan Component Of The Extracellular Matrix In Human Bone Marrow, Mediates Dexamethasone Resistance In Multiple Myeloma Br J Haematol 2003; 121: 259-269. [53] Cartel NJ, Post M. Abrogation Of Apoptosis Through PDGF-BB-Induced Sulfated Glycosaminoglycan Synthesis And Secretion Am J Physiol Lung Cell Mol Physiol 2005; 288: L285-L293. [54] Ishikawa Y, Kitamura M. Inhibition Of Glomerular Cell Apoptosis By Heparin Kidney Int 1999; 56: 954-963. [55] Bose P, Black S, Kadyrov M, Weissenborn U, Neulen J, Regan L, Huppertz B. Heparin And Aspirin Attenuate Placental Apoptosis In Vitro: Implications For Early Pregnancy Failure Am J Obstet Gynecol 2005; 192: 23-30. [56] Karti SS, Ovali E, Ozgur O, Yilmaz M, Sonmez M, Ratip S, Ozdemir F. Induction Of Apoptosis And Inhibition Of Growth Of Human Hepatoma Hepg2 Cells By Heparin Hepatogastroenterology 2003; 50: 1864-1866. [57] Li HL, Ye KH, Zhang HW, Luo YR, Ren XD, Xiong AH, Situ R. Effect Of Heparin On Apoptosis In Human Nasopharyngeal Carcinoma CNE2 Cells Cell Res 2001; 11: 311-315. [58] Berry D, Lynn DM, Sasisekharan R, Langer R. Poly(Beta-Amino Ester)S Promote Cellular Uptake Of Heparin And Cancer Cell Death Chem Biol 2004; 11: 487-498. [59] Pumphrey CY, Theus AM, Li S, Parrish RS, Sanderson RD. Neoglycans, Carbodiimide-Modified Glycosaminoglycans: A New Class Of Anticancer Agents That Inhibit Cancer Cell Proliferation And Induce Apoptosis Cancer Res 2002; 62: 37223728. [60] Manaster J, Chezar J, Shurtz-Swirski R, Shapiro G, Tendler Y, Kristal B, Shasha SM, Sela S. Heparin Induces Apoptosis In Human Peripheral Blood Neutrophils Br J Haematol 1996; 94: 48-52. [61] Vuillermoz B, Khoruzhenko A, D'Onofrio MF, Ramont L, Venteo L, Perreau C, Antonicelli F, Maquart FX, Wegrowski Y. The Small Leucine-Rich Proteoglycan Lumican Inhibits Melanoma Progression Exp Cell Res 2004; 296: 294-306. [62] Bali JP, Cousse H, Neuzil E. Biochemical Basis Of The Pharmacologic Action Of Chondroitin Sulfates On The Osteoarticular System Semin Arthritis Rheum 2001; 31: 58-68.
In: New Research on Alzheimer’s Disease Editor: Eileen M. Welsh, pp. 99-123
ISBN 1-59454-939-7 © 2006 Nova Science Publishers, Inc.
Chapter IV
Low Density Lipoprotein ReceptorRelated Protein 1 (LRP1): One of the Hallmarks ofAlzheimer’s Disease and Other Complex Degenerative Processes Christiane Gläser(1,*), Gerd Birkenmeier(2), Susanne Schulz(1,3) and Klaus Huse(4) (1)
Institute of Human Genetics and Medical Biology, University of Halle, Halle, Germany (2) Institute of Biochemistry, University of Leipzig, Leipzig, Germany (3) Department of Medicine III, University of Halle, Halle, Germany (4) Leibniz Institute for Age Research - Fritz Lipmann Institute, Jena, Germany
Abstract Susceptibility to Alzheimer´s disease (AD) is governed by multiple factors. Remarkably, LDL receptor-related proteins (LRPs) and several of their numerous ligands were associated to AD. Alpha2-macroglobulin (A2M), apolipoprotein E (Apo E), but also amyloid precursor protein (APP) belong to the functionally and genetically interesting molecules involved in the complex degenerative processes resulting in AD. LRP1 (CD91) (MIM 107770) is a 4,544-amino acid protein containing a single transmembrane segment and is located on chromosome 12q13.1-12q13.3 within a region shown to be linked to AD. It consists of 84 exons and belongs to the largest human proteins and is highly evolutionary conserved. It could be demonstrated that several genomic variants of LRP1 were associated to AD but also to other degenerative diseases like atherosclerosis and cancer suggesting a complex role in fundamental cellular processes.
*
Correspondence: Dr. Christiane Gläser, Institute of Human Genetics and Medical Biology, Magdeburger Str. 2, D-06097 Halle, Phone +49-345-557 4296, Fax: +49-345-557 4293 e-mail:
[email protected]
100
Christiane Gläser, Gerd Birkenmeier, Susanne Schulz and Klaus Huse LRP1 functions as a clearance receptor for several ligands, including amyloid ß (Aß), and mediates signaling pathways affecting the processes of neurite outgrowth and calcium influx. While clearance of Aß diminishes the extracellular Aß-load the interaction with APP may enhance formation of Aß. LRP1 is expressed in brain, blood vessels as well as in endothelial cells of the brain-blood-barrier mediating the transcytosis of Aß between blood circulation and brain. Internalization via LRP1 concerns also extracellular proteases and protease-inhibitor complexes involved in Aß degradation. In AD as well as in other diseases genetic variations and structure-caused failure of LRP1 leading to dysfunctions as well as alteration in the expression of LRP1 ligands may determine common degenerative processes. Age-related changes in the level of LRP1 and its ligands may increase the risk for degenerative diseases. The modulation of LRP1 and its ligands by cytokines and growth factors was detected in and outside the brain. There are indications that also inflammatory processes play an important role in the development of degenerative diseases.
Abbreviations AD Aß α1-PI BACE1 CAD C. elegans CNS D. melanogaster EGF IDE IL LPS MMP NCBI NEP NPxY PAI-1 PDGF RAP u-PA t-PA TFPI HLA-DR
Alzheimer`s Disease amyloid ß protease inhibitor-1 (PI) ß site amyloid beta A4 precursor protein-cleavage enzyme coronary artery disease Caenorhabditis elegans central nervous system Drosophila melanogaster epidermal growth factor insulin-degrading enzyme interleukin lipopolysaccharide matrix metalloprotease National Center for Biotechnology Information neprilysin, membrane metalloendopeptidase (MME) amino acid motif asparagine-proline-x-tyrosine plasminogen activator-inhibitor-1 (PAI1) platelet-derived growth factor low density lipoprotein receptor-related protein-associated protein 1 (LRPAP1) plasminogen activator urinary (PLAU) plasminogen activator tissue (PLAT) tissue factor pathway inhibitor human leucocyte antigens-DR locus
Low Density Lipoprotein Receptor-Related Protein 1 (LRP1)
101
Common Features of Alzheimer´s Disease To date, the following four main risk markers have been characterized and related to Alzheimer´s disease (AD): amyloid precursor protein (APP, chromosome 21), apolipoprotein E (Apo E, chromosome 19), presenilin-1 (PSEN1, chromosome 14) and presenilin-2 (PSEN2, chromosome 1). It has been suggested that other genetic loci mapped to chromosome 10, 12, and 20, - including the polymorphic genetic variants of alpha-2 macroglobulin (A2M, chromosome 12) and its receptor the low density lipoprotein receptor-related protein (LRP1, chromosome 12), as well as to the mitochondrial genome, contribute to neurodegenerative processes (for review see Tanzi and Bertram, 2005).
Amyloid Precursor Protein The widely expressed cell surface protein, amyloid precursor protein (APP), in particular its proteolytic fragment amyloid ß (Aß) produced by γ-secretase cleavage, has been identified as playing a role in the formation of the plaque core in AD patients and also in older patients with Down syndrome (Masters et al., 1985). Investigations have described that different APP isoforms (Sandbrink et al., 1994) are created by alternative splicing (Yoshikai et al., 1990). Moreover, several mutations within the APP gene were found in familial AD, which denotes APP as being a significant candidate gene. Under physiological conditions clearance and degradation of soluble APP and Aß is mediated by an efficient “cargo” system, including LRP1 and its ligand A2M (Kounnas et al., 1995, Narita et al., 1997). And von Arnim et al. (2005) could demonstrate that LRP1 functions as a novel ß-secretase (BACE1) substrate.
Apolipoprotein E Apo E is an integral part of several lipoproteins involved in the lipid metabolism (Mahley 1988) and it is inherited in three common alleles, ε2, ε3, ε4 (Strittmatter et al., 1993). The Apo E ε4 allele is strongly associated with an increased amyloid burden in AD while Apo E ε2 considerably decreases the risk for AD (Hyman, 1996). The Apo E ε4 isoform was more frequently found in AD patients and was strongly related to a higher risk for late-onset familial AD and sporadic AD (Lendon et al., 1997; Pericak-Vance et al., 1997; Craig et al., 2004).
Presenilin 1 and 2 PSEN1 and PSEN2 are different in gene structure but display similar expression patterns in tissues and intracellular localization (Kovacs et al. 1996). PSEN1 and PSEN2 represent the fundamental features of a γ-secretase (Li et al., 2000) which is responsible for the APP cleavage producing Aß. Mutations found in PSEN1 and PSEN2 that result in functional
102
Christiane Gläser, Gerd Birkenmeier, Susanne Schulz and Klaus Huse
aberration are considered to be the most common cause of familial AD (Berezowska et al., 2005).
Putative Role of LRP1 in Alzheimer´s Disease The Lipoprotein Receptor Family The low-density lipoprotein receptors are comprised of a family of cell-surface receptors which recognize multiple, structurally diverse extracellular ligands and internalize them for degradation by lysosomes (Hussain, 2001; Howell and Herz, 2001, Gliemann, 1998). They are also considered to be recruiting receptors and are able to interact with other proteins for signalling, realized by their cytoplasmic domains. The low-density lipoprotein receptor LDLR is the prototype of this family, whose paralogous members in the human genome are listed in Table 1. Most of these genes also have their orthologs in other vertebrates. Members of the family are even found in D. melanogaster and C. elegans. As the results of several duplications, deletions and subsequent alterations the human proteins are evolutionary distant (Figure 1) and their genes are scattered throughout the human genome. All proteins contain four major structural modules: variable numbers (between two and eleven) of cysteine-rich complement-type repeats, EGF-like repeats, a small cytoplasmic domain, and a membranespanning domain. They serve very different functions in distinct physiological systems among them are lipoprotein metabolism, vitamin transport, virus infection, fibrinolysis, angiogenesis, protease clearance, and intercellular communication. Mutations in these different genes, therefore, cause very different phenotypes. Mutations in the LDLR, for instance, which is mainly responsible for the control of cholesterol metabolism, cause familial hypercholesterolemia and premature coronary artery disease. Several of these types of mutations have been described including missense, some that affect the splice site and expression-relevant ones in the LDLR promoter region. With respect to AD it is noteworthy to mention that alterations in lipoprotein and cholesterol metabolism have been linked to brain Aß levels. Kuo et al. (1998) described that there is a correlation between LDL cholesterol and total serum cholesterol as regards to the amounts of Aß 1-42 in the brains of patients with AD and also reported that receptors involved in cholesterol homeostasis and lipoprotein metabolism are putatively and pathogenetically relevant. LRP2 (megalin) is a major receptor in the proximal tubules absorptive epithelial cells and also functions as an antigenic determinant for Heymann nephritis in rats. It also binds cubilin, which is the receptor for the intrinsic factor complex in vitamin B12, thus providing an uptake mechanism for dietary vitamin B12. Furthermore, homozygous knockout mice manifested abnormalities in epithelial tissues e.g. lung and kidney and died perinatally from respiratory insufficiency (Willnow et al., 1996). This has been suspected to be caused by an insufficient cholesterol supply to the brain; these animals also showed impaired brain development. It has also been suggested that megalin mediates cellular uptake and transport of apolipoprotein J, which is able to bind Aß and mediates transport of this protein across the blood-brain barrier and the blood-cerebrospinal fluid barrier (Zlokovic et al., 1996). The functional importance of
Low Density Lipoprotein Receptor-Related Protein 1 (LRP1)
103
individual receptors may lie in their differential tissue expression. Most of the LRP family members are tissue-specific expressed and some of them are highly expressed in the brain. This is the case concerning LRP8 which is predominantly expressed in brain and is also an apoliprotein E receptor. Although this has not yet been confirmed by independent studies, one synonymous polymorphism in LRP8 has been identified showing a difference in its allele frequencies between AD patients and controls (Ma et al., 2002). The expression regulation of these receptors occurs at the transcriptional level in different ways, for instance, expression of LDLR is regulated by intracellular sterol concentration. However, other members of the family are not regulated by sterols. Equally notable is that all the receptors are regulated by many hormones and growth factors, but the mechanisms of regulation involving hormones are not fully understood. In this context the most frequent studied member of the LRP family is LRP1.
LRP3 LRP12 LRP10 LRP11 LDLR VLDLR LRP8 LRP1 LRP1B LRP2 LRP5 LRP6 SORL1
Figure 1. Evolutionary relationship of the human paralogous members of the LRP protein family. The phylogenetic tree was constructed using ClustalW (Thompson et al., 1994)
LRP1: A Multi-ligand Clearance Receptor The binding of more than 30 different ligands to LRP1 suggests that this receptor affects complex degenerative cellular processes which proceed the onset of AD, Parkinson disease, coronary artery disease or cancer (Hussain 2001; Myllykangas et al., 2000; Boucher at al., 2002; May et al., 2003; Strickland et al., 2003). All these degenerative diseases could be described as cellular dysregulations resulting in the pathogenic accumulation of diverse risk factors.
Table 1: Database summary of the members of the LRP family
Gene symbol
alternative symbols
LDLR
low density lipoprotein receptor precursor
VLDLR LRP1
LRP, A2MR, APR, APOER, CD91
LRP1B
LRP-DIT
LRP2
gp330, megalin
LRP3 LRP5
LR3, LRP7
LRP6 LRP8
APOER2
OMIM
Chromosomal location
mRNA RefSeq
protein RefSeq
606945
19p13.2
NM_000527
NP_000518
very low density lipoprotein receptor
192977
9p24
NM_003383
NP_003374
low density lipoprotein receptor-related protein 1
107770
12q13.1-q13.3
NM_002332
NP_002323
low density lipoprotein receptor-related protein 1B
608766
2q22.1-2q22.2
NM_018557
NP_061027
low density lipoprotein receptor-related protein 2
600073
2q31.1
NM_004525
NP_004516
low density lipoprotein receptor-related protein 3
603159
19q13.11
NM_002333
NP_002324
low density lipoprotein receptor-related protein 5
603506
11q13.2
NM_002335
NP_002326
low density lipoprotein receptor-related protein 6
603507
12p13.2
NM_002336*
NP_002327
low density lipoprotein receptor-related protein 8
602600
1p32.3
NM_004631
NP_004622 NP_054764
LRP10
low density lipoprotein receptor-related protein 10
14q11.2
NM_014045
LRP11
low density lipoprotein receptor-related protein 11
6q25.1
NM_032832
NP_116221
LRP12
low density lipoprotein receptor-related protein 12
8q22.3
NM_013437
NP_038465
11q23.3
NM_003105
NP_003096
SORL1 *
gene product
SORLA1, SORLA, LR11
the major mRNA isoforms only
sortilin-related receptor containing LDLR class
602005
Low Density Lipoprotein Receptor-Related Protein 1 (LRP1)
105
The domain structure of LRP1 has been described in detail (Herz et al., 1988, Brown et al., 1991; Gaeta et al., 1994). Obviously, its huge size (600 kD) enables the binding of diverse ligands such as proteins, peptides and drugs to take place independently and simultaneously. To carry out functional studies the first attempts were made to create LRP1 knock-out mice. (Herz et al., 1992). However, these experiments failed due to impaired embryonic implantations. Now, new approaches involving short interfering RNA (siRNA) techniques were used and hence a selective decline in LRP1 expression was achieved (Laatsch et al., 2004). It has been shown that a decrease in LRP1 levels significantly reduced LRP1-mediated ligand uptake and degradation (Li and Bu, 2003). As a result of the proposed "cargo" function, it is not surprising that LRP1 is expressed in almost all cells with regards to regulating ligand homeostasis and most importantly, on cells of the vasculature, which enables the transcytosis of ligands. LRP1 ligands fall into several functional categories: (i) Pericellular proteolysis (e.g. A2M; α1-PI, MMPs, u-PA, t-PA, PAI-1); (ii) Lipid metabolism (Apo E, Lipoprotein lipase); (iii) Blood coagulation (Factor IXa, Factor VIIIa, TFPI, Antithrombin III; Heparin cofactor); (iv) Inflammation/immune response (complement factors, chaperons, beta2-integrins) (v) Drugs (suramin, saponin) and (vi) Membrane or intracellular scaffold proteins (Fe65, Disabled, PDGF-receptor, G-proteins, APP). It is well known that the deposition of Aß is a critical pathological feature in AD. A recent study has suggested that improper clearance of Aß is as important as Aß production in amyloid deposition (Glabe, 2001). Moreover, there are several interfaces where LRP1 may determine the balance between Aß synthesis and clearance mechanism:
LRP1 and Pericellular Proteolysis Lowering Aß levels may be achieved by inhibiting its generation from APP or by promoting its clearance by transport or degradation and to date three major proteases have been identified in playing a role in degrading Aß. They are as follows: the neutral endopeptidase, neprilysin (NEP), is located on the cell surface which allows hydrolysis of peptides on the extracellular side including Aß 1-40 (Howell et al., 1995) and Aß 1-42 (Iwata et al., 2000). In vivo inhibition of neprilysin by specific inhibitors results in an accumulation of endogenous Aß (Iwata et al., 2000). It has been suggested that age-related decreases of the neprilysin could lead to increased brain concentrations of Aß, plaque formation, and AD (Newell et al., 2003). A second important protease is the insulin-degrading enzyme (IDE); a zinc-containing metalloprotease found in the cytosol, on the cell surface and in the extracellular space (Qiu et al., 1996; Qiu et al., 1998). It cleaves small proteins many of them share the property to form amyloid fibrils, e.g. Aß, insulin, glucagon and amylin (Farris et al., 2003). Both NEP and IDE mediate degradation of soluble Aß but have less ability to degrade Aß once it becomes insoluble or oligomeric (Selkoe, 2001). The only protease that is capable of degrading soluble and fibrilar Aß seems to be plasmin (Tucker et al., 2002). In brain, tPA, uPA and plasminogen are present in low concentrations. Upregulation of plasminogen activators by aggregated Aß indicates that the
106
Christiane Gläser, Gerd Birkenmeier, Susanne Schulz and Klaus Huse
plasmin system is activated in response to Aß deposition. Thus, plasmin confers neuroprotection which may continue until upregulation of the plasmin system is exhausted during the course of the disease (Ledesma et al., 2000). These findings are supported by a recent report showing an association of a single nucleotide polymorphism in the uPA gene with elevated Aß 1-42/40 (Ertekin-Taner at al., 2005). There are indications of a general proteases deficiency in the brain and blood of AD patients (Aoyagi et al., 1992), which has been found to be similar in healthy but elderly patients (Aoyagi et al., 1994). Although, so far a direct link of LRP1 to regulation of NEP and IDE metabolism has not yet been established, it can be anticipated that the activities of both enzymes are regulated by protease inhibitors as it is the case with the pan-protease inhibitor A2M and plasmin (Tucker et al., 2000). The inhibitory action of A2M is mediated by a unique trapping mechanism (SottrupJensen, 1989). Proteases are sterically trapped but retain their activity toward small proteins and peptides. Accompanying conformation changes make A2M ready to accommodate such peptides and to bind to LRP1 for endocytosis (Ashcom et al., 1990). A2M-protease complexes have been shown to degrade bound Aß initiating extracellular amyloid depletion and to continue intracellular lysosomal Aß degradation following receptor-mediated uptake of A2M-protease-Aß complexes (Qiu et al., 1996). This process is very unique and seems to be a common mechanism to down-modulate pathologically elevated levels of bioactive peptides such as Aß or other growth factors (Birkenmeier, 2001). It has recently been shown that the administration of small proteases such as trypsin or chymotrypsin to human blood leads to degradation of radiolabeled Aß mediated by formation of A2M-protease-Aß complexes (Lauer et al., 2001). Up-regulation of Aß catabolism via proteases delivery could probably reduce the risk of developing AD by preventing Aß accumulation in the brain and in the vasculature. Thus, clearance of Aß strongly depends on the presence of extracellular proteases as well as the level of its vehicle, A2M. The plasma concentration of A2M showed significant individual variations ranging from approximately 50mg/100 ml to 500mg/100ml (Birkenmeier et al., 2003). The reason for this diversity is not yet known, but is assumed to be related to different promoter activity. Most interestingly, a steep decline of the A2M level was manifested at an age when late-onset AD starts to develop (Figure 2). Since AD develops slowly over years, a progressive exhaustion of proteases and A2M in combination with an altered modulation of LRP1 would have a tremendous impact on the clearance system of AD-related ligands. Thus, one can speculate that a decreased A2M level in blood is a risk factor for AD. Various attempts to associate the level of A2M to different polymorphisms in the A2M gene have failed and genetic linkage and association studies of polymorphisms with AD have all provided conflicting results (Saunders et al., 2003). However, it cannot be excluded that known variants in A2M might be linked to pathogenic mutations/polymorphism in the A2M gene or in its neighbourhood that have not yet been identified (Saunders and Tanzi, 2003).
Low Density Lipoprotein Receptor-Related Protein 1 (LRP1)
107
Total A2M in plasma (mg/100ml)
600 males females
500
400
300
200
100
0 0
20
40
60
80
100
Age (years)
Figure 2. Distribution of A2M level dependent on age and gender in a population of 400 healthy individuals. The concentration of total A2M was determined by ELISA using the test kits MacroNat (BioMac, Leipzig). Females (open circles), males (black circles) (with permission from Exp Neurol. 2003,184:153-61).
LRP1 and APP LRP1 interacts with APP and its expression facilitates APP processing via the amyloidogenic pathway (Kounnas et al., 1995). This is because receptor-mediated endocytosis brings APP into close proximity to the APP-cleaving enzyme, ß-secretase, which results in elevated generation and secretion of Aß (Ehehalt et al., 2003). Thus, dynamic interactions of APP with its clearance receptors determine the amyloid burden in the extracellular space. This is corroborated by recent results showing that expression of LRP1B, a homologue of LRP1, which also binds APP, produces less Aß probably due to the lower rate of endocytosis when compared to LRP1 (Cam et al., 2004). Similar effects were seen after treating cells with RAP, which blocks the binding of ligands to LRP1 (Ulery et al., 2000). Thus, the contribution of LRP1 to AD is complex because it influences both the production and the clearance of Aß. In addition to recognizing numerous extracellular ligands with the aid of the LRP1 ectodomain, the intracellular domain of LRP1 contains binding sites for many adaptor and scaffold proteins (Gotthardt et al., 2000). Phosphorylated NPxY motifs act as anchors for Fe65, Dab, Jip and Shc and are found in both the cytoplasmic tail of LRP1 as well as in APP. Tyrosine phosphorylation of LRP1 was found to result from interaction with the plateletderived growth factor BB which creates docking sites for Shc. By subsequent phosphorylation, different signalling pathways involving Ras and c-Myc are initiated (Loukinova et al., 2002).
108
Christiane Gläser, Gerd Birkenmeier, Susanne Schulz and Klaus Huse
Similarities between LRP1 and APP also concern the proteolysis of the extra- and intracellular domain. Soluble APP ectodomains are obtained by the action of α- or ßsecretase, whereas the shedding of LRP1 is caused by an unknown metalloprotease (Quinn et al., 1999). Analogously to APP processing, the LRP1 cytoplasmic domain is cleaved by a γsecretase-like activity (May et al., 2002). The released proteolytic products may modulate signalling or may travel to other compartments of the cell.
LRP and ApoE It has been shown that ApoE binds to Aß and the isoform-specific effects of ApoE are related to this action with regards to fibrillogenesis and sequestration (Strittmatter et al., 1993; Sanan et al. 1994; Castano et al., 1995; Carter 2005). Cellular uptake of ApoE is mediated by LRP1, which also mediates the effect of ApoE on neurite outgrowth (Beisiegel et al., 1989; Nathan et al., 2002; Gylys et al. 2003).
LRP1 and Ligand Transcytosis at Blood-Brain-Barrier The expression of LRP1 in brain cells, vessel walls and in brain capillary endothelium has been well documented (Shibata et al., 2000). Late-onset AD patients, who do not have increased Aß production or APP overexpression, are likely to exhibit (i) a failure in Aß clearance from the brain to plasma, (ii) defects in Aß degradation in the CNS or (iii) an increased influx of circulating Aß into the CNS. Although the level of free Aß in extracellular brain fluid is higher than that found in plasma, the absolute amounts of Aß in body fluid exceeds the Aß level in brain fluid by factor 10. Thus, body fluids provide a large reservoir for accommodation and degradation of excessive Aß. Two main receptors are involved in shuttling Aß through the blood-brain barrier between both compartments: (i) AGER (advanced glycosylation end product-specific receptor) mediates influx of Aß into the brain (Mackic et al., 1998) and (ii) LRP1 mediates efflux of Aß into circulation (Shibata et al., 2000). In contrast to the brain, uptake and degradation of Aß in blood seems to be chaperoned by A2M or ApoE, two main ligands of LRP1.
LRP1 and Inflammation In AD and APP transgenic mouse models of AD LRP1 is down-regulated (Shibata et al., 2000). However, little information is available on factors that affect LRP1 expression in the brain. Considerable evidence which has been gained over the past decade has led scientists come to the conclusion that neuroinflammation is associated with AD. The main cellular players in inflammatory processes are microglia and the astrocytes (Akiyama et al., 2000). LRP1 is expressed in both cell types, but expression varies with regards to the state of the cellular activation (Hussaini et al., 1999).
Low Density Lipoprotein Receptor-Related Protein 1 (LRP1)
109
Microglial cells e.g. can be activated by Aß, LPS or other cytokines and they respond to the following: reactive oxidant species, expression of NFkappaB, inflammatory cytokines and HLA-DR (Streit, 2004). Expression of IL-1, α1-antichymotrypsin and complement factors in the AD brain is another indication of ongoing inflammatory processes which take place during the development of AD (Shuguang and Janciauskiene, 2002; Mrak and Griffin, 2001). LPS decreases expression of LRP1 in monocyte lineage cells (LaMarre et al., 1993) and interferon-gamma was found to up-regulate LRP1 and A2M in astrocytoma cell lines (Businaro et al., 1997). Furthermore, LRP1 is a receptor for chaperoned peptides trafficking immunogenic peptides into antigen presenting cells for presentation (Binder et al., 2000). Thus, inflammatory processes will most likely affect the function of LRP1 in the brain and in the blood-brain-barrier, as well. Recent data have suggested that reduced LRP1 expression is a contributing risk factor for AD, possibly because it impedes the clearance of Aß by ApoE and A2M (Kang et al., 2000). Thus, conditions to increase LRP1 expression in the brain could systemically exert beneficial effects on the prevention of AD.
Expression of LRP1 in Alzheimer´s Disease and in Related Degenerative Diseases At present, only limited experimental data have been published describing the in vivo expression of LRP1 with regards to degenerative diseases. Most expression studies have been done on transgenic animals or on post mortem material. Handschug et al. (1998) first described results on in vivo expression of LRP1 in humans by measuring the LRP1 transcripts obtained from patients’ blood monocytes. A mild age-dependent increase in LRP1 expression within a group of healthy controls was recognized. LRP1 transcripts increased from 117.7 ag/cell to 150.2 ag/cell (attogram/cell) in healthy controls ranging in ages from 20-60r, respectively. Surprisingly, Schulz et al. (2003) could show that a high transcription rate was paralleled by a decrease in LRP1 protein concentration and vice versa. Furthermore, LRP1 gene and protein expression were shown to follow a circadian- and gender-specific rhythm, which have to be considered in studies investigating the LRP1 in vivo function. A similar expression profile was also corroborated for disease-related expression studies in patients with degenerative coronary atherosclerosis. A disease-associated significant increase in the LRP1 gene-expression in patients (223 ag/cell) versus controls (122,3 ag/cell) was associated with low LRP1 protein levels in the patient group (1.6 pg/cell) versus controls (6 pg/cell). These data suggest that low LRP1 protein levels are tried to be functionally compensated by a dramatically increased LRP1 transcription rate, acting as an incomplete in vivo feed back mechanism. Motivated by these results, we have done a comparative study of in vivo LRP1 gene expression in patients with degenerative diseases, AD and coronary artery disease (CAD), and compared our results to healthy controls. The impact of age, gender and circadian rhythm on LRP1 expression was taken into account in the statistical analysis (detailed description of materials and methods can be requested from the authors).
110
Christiane Gläser, Gerd Birkenmeier, Susanne Schulz and Klaus Huse
In the whole group of 97 individuals a mean LRP1-mRNA expression of 187.20 ag/cell was detected (Table 2). AD patients showed the highest LRP1 gene expression levels (290.96 ag/cell) followed by patients with coronary degenerative disease (174.49 ag/cell). The healthy controls revealed the lowest levels of LRP1-mRNA expression among all of the three subgroups (158.79 ag/cell). The differences among the three patient groups were statistically significant (Kruskal-Wallis test, p=0.015). A correlation between age and LRP1 gene expression was not detected in any of the three groups (controls: p=0.453, CAD: p=0.650, AD: p=0.871) nor was a correlation found between gender and expression (controls: p=0. 348, CAD: p=0.123, AD: p=0.581); this suggests that the subgroup specific difference in the LRP1-mRNA level is really disease-related. The 83.2 % higher expression of LRP1 found in AD patients indicates that the disordered metabolism of patients suffering from this degenerative disease probably activates mechanisms to help compensate for the loss of function at the protein level. The molecular mechanism causing this inverse relation between the levels of LRP1 transcript and protein is not fully understood. It has been suggested that feed-back control mechanisms do exist (up-regulation of mRNA) but the translation into a protein may be blocked. Unravelling the underlying mechanism will be a challenge concerning therapeutic intervention. It is noteworthy that this is the first report demonstrating a relationship between a cellular blood marker and AD. Further studies are needed to test the feasibility of blood LRP1 as a marker for the onset, the severity or the susceptibility to develop AD. Table 2: Results of a study on in vivo gene expression of LRP1 in AD patients compared with patient suffering from (degenerative) coronary artery disease (CAD) versus healthy controls. There was neither a correlation between LRP1 gene expression and gender nor age.
Number Male Age SD Age min.-max. LRPgene expression (ag/cell) SD Correlation* age/LRP1 expression P Correlation* gender/LRP1 expression P *
All individuals
controls
CAD patients
AD patients
97 71 59.7 7.55 54-86 187.20 80.43
20 18 58.9 3.39 54-65 158.79† 52.12 0.178
68 49 58.4 4.09 54-68 174.49† 66.17 -0.056
9 4 71 8.62 54-86 290.96† 126.83 0.064
0.453 0.222
0.650 0.190
0.871 -0.214
0.348
0.123
0.581
Pearson. † The patient groups differ significantly in their expression levels: p=0.015 (Kruskall-Wallis).
Low Density Lipoprotein Receptor-Related Protein 1 (LRP1)
111
Genetic Predisposition to Alzheimer’s Disease While investigating the possible genetic causes of AD, a variety of different genes was found to be involved in the pathogenesis of this degenerative disease (Bertram and Tanzi, 2004; Williamson and LaRusse, 2004). The autosomal dominant early onset AD was shown to be associated with genes coding for presenilin-1 and -2 as well as amyloid precursor protein. Mutations in these genes lead to the main clinical feature of AD, which is characterized by an increased generation of Aβ and amyloid deposition. However, genomic variations in these genes have been proven to be fully penetrant, but they are very rare events accounting for only 1% to 2% of all AD cases (Gaskell and Vance, 2004). On the other hand, genetic variations of the Apo E lead to an increased risk of late-onset sporadic and familial AD. The ε4 allele of this gene has been established worldwide as a genomic variant predisposing for AD and this allele has been demonstrated to increase for the risk of developing AD in a dose-dependent fashion (Corder et al., 1993). Since the gene encoding ApoE is highly polymorphic the influence of other single nucleotide polymorphisms on the risk of developing AD was studied. However, only a weak effect concerning other SNPs independent of ε4 allele could be demonstrated (Nicodemus et al., 2004). Since Apo E is reported to account for less than 50% of the genetic effects in AD it implies that the onset as well as the progression of the complex disorder AD is triggered by additional genetic and environmental factors which have already been suggested by Sjogren et al. (1952) and St George-Hyslop et al. (1990). A number of genome wide screens have been published investigating the genetic causes of AD. These studies used linkage- or association-based evaluation procedures and reported on genetic locations of interest on different chromosomes (for review see Bertram and Tanzi, 2004). The LRP1 locus on chromosome 12 has also been shown in different studies to be associated with a late-onset form of familial AD (OMIM 602096). Interestingly, a full genome scan for late onset AD which included 292 affected siblings revealed linkage of the locus on chromosome 12 with similar lod scores as for APP (Kehoe et al., 1999). As of June 2005 128 genomic variants of the LRP1 gene have been reported on in dbSNP database of the NCBI Entrez system. Numerous clinical studies were conducted in order to evaluate possible associations of these genomic variants of LRP1 with AD, however, results are conflicting and are controversially discussed (Table 3) (for review see Gläser et al., 2004). Nevertheless, ethnicity and population-specific differences in genotype distributions were shown for a variety of these genomic variants (Gläser et al., 2004) and may account at least in part for the reported conflicting results. To date, only a few studies have been conducted investigating the possible disease related functional consequences of genomic variants of LRP1 (Schulz et al., 2002; Kang et al., 2000). A polymorphism in the promoter region of the gene (c.1-25C>G) has been proven to increase the LRP1 expression on a transcriptional level due to the creation of a CG-box, which is recognized by the SP1 transcription factor (Schulz et al., 2002). For another polymorphism in exon 3 (c.766C>T) a significant increase in LRP1 level could be described for T-allele carriers suffering from AD (Kang et al., 2000).
Table 3: Published important clinical studies evaluating AD related to genomic variants of LRP1. Genomic Variant 5’ Tetranucleotidpolymorphism
Individuals investigated French: 144 sporadic late onset AD patients ↔ 153 controls Caucasians: 182 AD patients ↔ 118 controls French Caucasians: 600 AD patients ↔ 646 controls Americans: 168 AD patients ↔ 157 controls American Caucasians: 62 AD patients ↔ 282 controls American Whites: 216 sporadic late onset AD patients ↔ 106 controls 179 Familial multiplex late onset AD patients, 436 sporadic AD patients ↔ 240 controls Spaniards: 188 sporadic late onset AD patients ↔ 226 controls Japanese: 100 AD patients ↔ 246 controls North Irish: 219 AD patients ↔ 237 controls French Caucasians: 274 AD patients ↔ 290 controls American Whites: 505 late onset AD patients ↔ 522 controls
c.766C>T US Euorpean Whites: 157 late-onset AD patients ↔ 102 polymorphism in exon 3 controls Chinese: 143 AD patients ↔ 129 controls
Whites: 234 AD patients ↔ 103 controls American Whites: 432 AD patients ↔ 106 controls Whites: 558 AD patients ↔ 596 controls
Clinical association to AD Citations Significant decrease of 87bp-allele in AD patients Wavrant –DeVrieze et al., 1997 Significant increase of 87bp-allele in AD patients Lendon et al., 1997 Significant increase of 91bp-allele in AD patients Lambert et al., 1998 None Clathworthy et al., 1997 None Fallin et al., 1997 None Kamboh et al., 1998 None
Scott et al., 1998
None
Bullido et al., 2000
None None None None
Hatanaka et al., 2000 Mc Ilroy et al., 2001 Verpillat et al., 2001 Luedecking-Zimmer et al., 2003 Kang et al., 1997
Significant increase of CC-genotype in AD patients (more pronounced among AD patients with positive familial history of senile dementia Significantly decreased T-allele in AD patients diagnosed pathologically; no association in AD patients diagnosed clinically Significant increase of CC-genotype in AD patients, no correlation to age of onset Significant increase of TT-genotype in controls Increase of CC-genotype and C-allele in AD patients
Baum et al., 1998
Hollenbach et al., 1998 Kamboh et al., 1998 Lambert et al., 1998
Table 3: Published important clinical studies evaluating AD related to genomic variants of LRP1. (Continued) Genomic Variant Individuals investigated Clinical association to AD c.766C>T Caucasians: 225 neuropathologically confirmed AD patients Weak increase of CC-genotype in AD patients polymorphism in exon 3 ↔ 187 controls Japanese : 100 AD patients ↔ 246 controls Association with age of onset Spaniards: 305 sporadic AD patients ↔ 304 controls Weak increase of CC-genotype in AD patients in meta-analysis Caucasians : 212 AD patients ↔ 337 controls Increase of C-allele in controls Higher age of onset in C-allele carriers 133 late-onset AD patients ↔ 70 controls None Spaniards: 199 sporadic late-onset AD patients ↔ 243 None controls Taiwan Chinese: 82 AD patients ↔ 110 controls None North Irish: 219 AD patients ↔ 237 controls None French Caucasians: 274 AD patients ↔ 290 controls None A217V Northern French Caucasians: 648 AD patients ↔ 670 Weak increase of T-allele in controls polymorphism in exon 6 controls US Whites: 536 late-onset AD patients ↔ 511 controls None A775P mutation in exon 14 D2080N polymorphism in exon 39 D2632E mutation in exon 48 G4379S Mutation in exon 85
Citations Beffert et al., 1999 Hatanaka et al., 2000 Sanchez-Guerra et al., 2001 Kölsch et al., 2003 Woodward et al., 1998 Bullido et al., 2000
29 AD patients ↔ 22 controls
No carrier identified
Hu et al., 2000 Mc Ilroy et al., 2001 Verpillat et al., 2001 Wavrant-DeVrieze et al., 1999 Luedecking-Zimmer et al., 2003 Van Leuven et al., 2001
29 AD patients ↔ 22 controls
No carrier identified
Van Leuven et al., 2001
29 AD patients ↔ 22 controls
Only 1 carrier in control group
Van Leuven et al., 2001
29 AD patients ↔ 22 controls
No carrier identified
Van Leuven et al., 2001
Christiane Gläser, Gerd Birkenmeier, Susanne Schulz and Klaus Huse
114
Brain (intracellular)
Brain (interstitial)
Blood
7 Aß
1 6
APP
4 8
10
5
11
A2M
11 LRP1
9
2
3
Figure 3. Schematic diagram of possible interventions by modulation of the LRP1-A2M axis of amyloid ß metabolism. (1)Aß processed via the amyloidogenic pathway (secretases) is released into the interstitial fluid for degradation by IDE, NEP or plasmin. (2) Soluble Aß is bound to proteolytically modified A2M by the action of proteases (e.g. plasmin) that mediates binding to LRP1 for endocytosis and lysosomal degradation (3). Soluble Aß (4) or A2M-Aß complexes (5) are transported via LRP1mediated efflux from the brain into the circulatory system. In blood, soluble Aß is subsequently degraded by proteases (6) or eliminated by LRP1-mediated endocytosis in conjunction with proteaseactivated A2M (9). Possible check points of intervention are the modulation of cytoplasmic binding of scaffold protein to LRP1/APP (10); increasing the expression of LRP1 (11) increasing the expression of A2M in brain and blood (7) and increasing the proteolytic potential in brain (1), and in blood (8) and (9) to support A2M-mediated elimination of Aß.
Clinical and Therapeutic Significance It seems indisputable that LRP1 is one of the most interesting candidate genes, not only for AD and other neurodegenerative diseases such as Parkinson disease but also for other degenerative processes affecting other organs, tissues and vessel-walls causing cellular dysfunctions as in CAD or cell degeneration as in cancer (Gläser et al., 2004). In current consolidated findings significant increased levels of LRP1-mRNA which correspond to a decrease in LRP1-protein expression could be a diagnostic marker in recognizing improper supply and/or disposal processes which are dangerous for cells, tissues and organs. Since an alteration in LRP1 expression is directly transmitted to the level of LRP1-ligands to be cleared in the blood, investigation should be done to determine whether or not a more timesaving analysis of LRP1 plasma ligands is to be preferred. Such a candidate ligand could be
Low Density Lipoprotein Receptor-Related Protein 1 (LRP1)
115
plasma A2M. It exists in two different forms, native A2M and transformed A2M (Birkenmeier, 2001). The latter is the receptor-recognizable species which can easily be determined by immunological assays (Birkenmeier and Stigbrand, 1993; Sinnreich et al., 2004). With respect to LRP1 and its Aß-clearing ligands possible therapeutic interventions should focus on (i) increasing the clearance capacity of LRP1 by elevating its peripheral expression, (ii) increasing the proteolytic activity in the brain and the blood circulation , (iii) increasing the level of A2M in blood and (iv) promoting the LRP1-mediated transfer of Aß from the brain to circulatory system. In addition to current trials and activities to tame AD progression with secretase inhibitors, inhibition of Aß-fibril formation or with vaccinations, the modulation of the LRP1-ligand system seems to be a promising approach (Figure 3).
Data Bases GeneCardsR, Weizman Institute of Science http://bioinfo.weizmann.ac.il/cardsbin/cardsearch.pl OMIMTM - Online Mendelian Inheritance in ManTM: http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?db=OMIM
References Akiyama H, Arai T, Kondo H, Tanno E, Haga C, Ikeda K. Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis Assoc Disord. 2000,14:47-53. Aoyagi T, Wada T, Kojima F, Nagai M, Harada S, Takeuchi T, Isse K, Ogura M, Hamamoto M, Tanaka K, et al. Deficiency of fibrinolytic enzyme activities in the serum of patients with Alzheimer-type dementia. Experientia. 1992,48:656-9. Aoyagi T, Wada T, Kojima F, Nagai M, Harada S, Takeuchi T. Age-dependent decreases in fibrinolytic enzyme activities in serum of healthy subjects. Biol Pharm Bull. 1994,17:348-51. Ashcom JD, Tiller SE, Dickerson K, Cravens JL, Argraves WS, Strickland DK. The human alpha 2-macroglobulin receptor: identification of a 420-kD cell surface glycoprotein specific for the activated conformation of alpha 2-macroglobulin. J Cell Biol. 1990,110:1041-8. Baum L, Dong ZY, Choy KW, Pang CP, Ng HK. Low density lipoprotein receptor related protein gene amplification and 766T polymorphism in astrocytomas. Neuroscience Letters. 1998,256:5-8. Beffert U, Arguin C, Poirier J. The polymorphism in exon 3 of the low density lipoprotein receptor-related protein gene is weakly associated with Alzheimers disease. Neuroscience Letters 1999,259:29-32. Beisiegel U, Weber W, Ihrke G, Herz J, Stanley KK. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature. 1989,341:162-4.
116
Christiane Gläser, Gerd Birkenmeier, Susanne Schulz and Klaus Huse
Berezovska O, Lleo A, Herl LD, Frosch MP, Stern EA, Bacskai BJ, Hyman BT. Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. J Neurosci. 2005,25:3009-17. Bertram L, Tanzi RE. The current status of Alzheimer's disease genetics: what do we tell the patients? Pharmacol Res. 2004,50:385-96. Review. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol. 2000,1:151-5. Birkenmeier G. Targetting the proteinase inhibitor and immune modulatory function of human a2-macroglobulin. Mod Asp Immunbiol. 2001, 2:32-6. Birkenmeier G, Muller R, Huse K, Forberg J, Gläser C, Hedrich H, Nicklisch S,Reichenbach A. Human alpha2-macroglobulin: genotype-phenotype relation. Exp Neurol. 2003,184:153-61. Birkenmeier G, Stigbrand T. Production of conformation-specific monoclonal antibodies against alpha 2-macroglobulin and their use for quantitation of total and transformed alpha 2-macroglobulin in human blood. J Immunol Methods. 1993,162:59-67. Boucher P, Ducluzeau PH, Davelu P, Andreelli F, Vallier P, Riou JP, Laville M, Vidal H. Expression and regulation by insulin of low-density lipoprotein receptor related protein mRNA in human skeletal muscle. Biochim Biophys Acta. 2002,1588:226-31. Brown MS, Herz J, Kowal RC, Goldstein JL. The low density lipoprotein receptor-related protein: couble agent or decoy? Curr Opin Lipidol. 1991,2:65-72. Bullido MJ, Guallar-Castillon P, Artiga MJ, Ramos MC, Sastre I, Aldudo J, Frank A, Coria F, Rodriguez-Artalejo F, Valdivieso F. Alzheimer´s risk associated with human apolipoprotein E, alpha-2 macroglobulin and lipoproteinreceptor related protein polymorphisms: absence of genetic interactions, and modulation by gender. Neurosci Lett. 2000,289(3),213-6. Businaro R, Fabrizi C, Persichini T, Starace G, Ennas MG, Fumagalli L,. Lauro GM. Modulation of the alpha 2 macroglobulin receptor/low density lipoprotein receptor related protein by interferon-gamma in human astroglial cells. J Neuroimmunol. 1997,72:75–81. Cam JA, Zerbinatti CV, Knisely JM, Hecimovic S, Li Y, Bu G. The low density lipoprotein receptor-related protein 1B retains beta-amyloidprecursor protein at the cell surface and reduces amyloid-beta peptide production. J Biol Chem. 2004,279:29639-46. Carter DB.The interaction of amyloid-beta with ApoE. Subcell Biochem. 2005,38:255-72. Castano E.M., Prelli F., Wisniewski T., Golabek A., Kumar R.A., Soto C. and Frangione B. Fibrillogenesis in Alzheimer’s disease of amyloid beta peptides and apolipoprotein E. Biochem J. 1995,306:599–604. Clatworthy AE, Gomez-Isla T, Rebeck GW, Wallace RB, Hyman BT. Lack of association of a polymorphism in the low-density lipoprotein receptor-related protein gene with Alzheimer Disease. Arch Neurol. 1997,54,1289-92. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993,261:921-3.
Low Density Lipoprotein Receptor-Related Protein 1 (LRP1)
117
Craig D, Hart DJ, McCool K, McIlroy SP, Passmore AP. Apolipoprotein E e4 allele influences aggressive behaviour in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004,75:1327-30. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein dependson lipid rafts. J Cell Biol. 2003,160:113-23. Ertekin-Taner N, Ronald J, Feuk L, Prince J, Tucker M, Younkin L, Hella M, JainS, Hackett A, Scanlin L, Kelly J, Kihiko-Ehman M, Neltner M, Hersh L, Kindy M,Markesbery W, Hutton M, de Andrade M, Petersen RC, Graff-Radford N, Estus S,Brookes AJ, Younkin SG. Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease areassociated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. Hum Mol Genet. 2005,1:447-60. Fallin D, Kundtz A, Town T, Gauntlett AC, Duara F, Barker W, Crawford F, Mullan M. No association between the low density lipoprotein receptor-related protein (LRP) gene and late-onset Alzheimer´s disease in a community-based sample. Neuroscience Letters. 1997,233,145-147. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB,Tanzi RE, Selkoe DJ, Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A. 2003,100:4162-7. Gaeta BA, Borthwick I, Stanley KK. The 5'-flanking region of the alpha 2MR/LRP gene contains an enhancer-like cluster of Sp1 binding sites. Biochim Biophys Acta. 1994,1219:307-13. Gaskell PC Jr, Vance JM. Alzheimer's disease genes and genetic testing in clinical practice. JAAPA. 2004,17:25-6. Review. Glabe C. Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. J Mol Neurosci. 2001,17:137-45. Gläser C, Schulz S, Handschug K, Huse K, Birkenmeier G. Genetic and functional characteristics of the human in vivo LRP1/A2MR receptor suggested as a risk marker for Alzheimer's disease and other complex (degenerative) diseases. Neurosci Res. 2004,50:85-101. Gliemann J, Receptors of the low density lipoprotein (LDL) receptor family in man. Multiple functions of the large family members via interaction with complex ligands. Biol Chem. 1998,379:951-64. Review. Gotthardt M, Trommsdorff M, Nevitt MF, Shelton J, Richardson JA, Stockinger W,Nimpf J, Herz J. Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellularcommunication and signal transduction. J Biol Chem. 2000,275:25616-24. Gylys KH, Fein JA, Tan AM, Cole GM. Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-beta protein into synaptic terminals. J Neurochem. 2003,84:1442-51. Handschug K, Schulz S, Schnürer C, Köhler S, Wenzel K, Teichmann W, Gläser C. Lowdensity lipoprotein receptor-related protein in atherosclerosis development: up-regulation of gene expression in patients with coronary obstruction. J Mol Med. 1998,76:596-600.
118
Christiane Gläser, Gerd Birkenmeier, Susanne Schulz and Klaus Huse
Hatanaka Y, Kamino K, Fukuo K, Mitsuda N, Nishiwaki-Ueda Y, Sato N, Satoh T, Yamamoto H, Yoncda H, Imagawa M, Miki T, Ohta S, Ogihara T. Low density lipoprotein receptor-related protein gene polymorphisms and risk for late-onset Alzheimer´s disease in a Japanese population. Clin Genet. 2000, 58:319-23. Herz J, Clouthier DE, Hammer RE. LDL receptor related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell. 1992,71:411-21. Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to LDL receptor suggest a physiological role as a lipoprotein receptor. EMBO J. 1988, 7:4119-27. Hollenbach E, Ackermann S, Hyman BT, Rebeck GW. Confirmation of an association between a polymorphism in exon 3 of the low-density lipoprotein receptor-related protein gene and Alzheimer´s disease. Neurology. 1998,50:1905-7. Howell BW, Herz J. The LDL receptor gene family: signaling functions during development. Curr Opin Neurobiol. 2001,11:74-81. Howell S, Nalbantoglu J, Crine P. Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides. 1995,16:647-52. Hu CJ, Sung SM, Liu HC, Hsu WC, Lee LS, Lee CC, Tsai CH, Chang JG. Genetic risk factors of sporadic Alzheimer´s disease among Chinese. Journal of Neurological Sciences. 2000,181:127-31. Hussain MM. Structural, biochemical and signaling properties of the low-density lipoprotein receptor gene family. Front Biosci. 2001,6:417-28. Review. Hussaini IM, Brown MD, Karns LR, Carpenter J, Redpath GT, Gonias SL, Vandenberg SR. Epidermal growth factor differentially regulates low density lipoprotein receptor-related protein gene expression in neoplastic and fetal human astrocytes. Glia. 1999,25:71–84. Hyman BT. Apolipoprotein E genotype: utility in clinical practice in Alzheimer´s disease. J Am Geriatr Soc. 1996,44:1469-71. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC. Identification of the major Abeta1-42degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 2000,6:143-50. Kamboh MI, Ferrell RE, DeKosky ST. Genetic association studies between Alzheimer´s disease and two polymorphisms in the low density lipoprotein receptor-related protein gene. Neuroscience Letters. 1998,244:65-68. Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, Hansen LA, Thomas RG, Thal LJ, Katzman R. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology. 1997,49:56-61. Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R, Koo EH. Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest. 2000,106:1159-66. Kehoe P, Wavrant-De Vrieze F, Crook R, Wu WS, Holmans P, Fenton I, Spurlock G, Norton N, Williams H, Williams N, Lovestone S, Perez-Tur J, Hutton M, Chartier-Harlin MC,
Low Density Lipoprotein Receptor-Related Protein 1 (LRP1)
119
Shears S, Roehl K, Booth J, Van Voorst W, Ramic D, Williams J, Goate A, Hardy J, Owen MJ. A full genome scan for late onset Alzheimer's disease. Hum Mol Genet. 1999,8:237-45. Kölsch H, Ptok U, Mohamed I, Schmitz S, Rao ML, Maier W, Hein R. Association of the C766T polymorphism of the low-density lipoprotein receptor-related protein gene with Alzheimer´s disease. Am J Med Genet. 2003,121:128-30. Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell. 1995,82:33140. Kovacs DM, Fausett HJ, Page KJ, Kim TW, Moir RD, Merriam DE, Hollister RD, Hallmark OG, Mancini R, Felsenstein KM, Hyman BT, Tanzi RE, Wasco W. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med. 1996,2:224-9. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D, Roher AE. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun. 1998,52:711-5 Laatsch A, Ragozin S, Grewal T, Beisiegel U, Joerg H. Differential RNA interference: replacement of endogenous with recombinant low density lipoprotein receptor-related protein (LRP). Eur J Cell Biol. 2004,83:113-20. LaMarre J, Wolf BB, Kittler EL, Quesenberry PJ, Gonias SL. Regulation of macrophage alpha 2-macroglobulin receptor/low density lipoproteinreceptor-related protein by lipopolysaccharide and interferon-gamma. J Clin Invest. 1993,91 :1219-24. Lambert JC, Wavrant-De Vrièze F, Amouyel P, Chartier-Harlin MC. Association at LRP gene Locus with sporadic late-onset Alzheimer´s disease. The Lancet. 1998,351:1787-88. Lauer D, Reichenbach A, Birkenmeier G. Alpha 2-macroglobulin-mediated degradation of amyloid beta 1-42: a mechanism to enhance amyloid beta catabolism. Exp Neurol. 2001,167:385-92. Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced inAlzheimer's disease brains. EMBO Rep. 2000,1:530-5. Lendon CL, Talbot CJ, Craddock NJ, Han SW, Wragg M, Morris JC, Goate AM. Genetic association studies between dementia of the Alzheimer´s type and three receptors for polipoprotein E in a Caucasian population. Neurosci Lett. 1997,222:187-90. Li Y, Lu W, Bu G. Essential role of the low density lipoprotein receptor-related protein in vascular smooth muscle cell migration. FEBS Lett. 2003,555:346-50. Li YM, Lai MT, Xu M, Huang Q, DiMuzio-Mower J, Sardana MK, Shi XP, Yin KC, Shafer JA, Gardell SJ. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci U S A. 2000, 97:6138-43. Loukinova E, Ranganathan S, Kuznetsov S, Gorlatova N, Migliorini MM, Loukinov D,Ulery PG, Mikhailenko I, Lawrence DA, Strickland DK. Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of thelow density lipoprotein receptor-related protein (LRP). Evidence for integratedco-receptor function betwenn LRP and the PDGF. J Biol Chem. 2002,27715499-506.
120
Christiane Gläser, Gerd Birkenmeier, Susanne Schulz and Klaus Huse
Luedecking-Zimmer E, DeKosky ST, Nebes R, Kamboh MI. Asociation of the 3´UTR transcription factor LBP-1c/CP2/LSF polymorphism with late-onset Alzheimer´s disease. Am J Med Genet. 2003, 117:114-7. Ma SL, Ng HK, Baum L, Pang JC, Chiu HF, Woo J, Tang NL, Lam LC. Low-density lipoprotein receptor-related protein 8 (apolipoprotein E receptor 2) gene polymorphisms in Alzheimer's disease. Neurosci Lett. 2002,332:216-8. Mackic JB, Stins M, McComb JG, Calero M, Ghiso J, Kim KS, Yan SD, Stern D, Schmidt AM, Frangione B, Zlokovic BV. Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40.Asymmetrical binding, endocytosis, and transcytosis at the apical side of brainmicrovascular endothelial cell monolayer. J Clin Invest. 1998,102:734-43. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988,240:622-30. Review. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985,82:4245-9. May P, Herz J. LDL receptor-related proteins in neurodevelopment. Traffic. 2003,4:291-301. May P, Reddy YK, Herz J. Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain. J Biol Chem. 2002,277:18736-43. Marques MA, Crutcher KA. Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer's disease. J Mol Neurosci. 2003,20:327-37. McIlroy SP, Dynan KB, Vahidassr DJ, Lawson JT, Patterson CC, Passmore P. Common polymorphisms in LRP and A2M do not affect genetic risk for Alzheimer disease in Northern Ireland. American Journal of Medical Genetics (Neuropsychiatric Genetics). 2001,105;502-6. Mrak RE, Griffin WS. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging. 2001,22:903-8. Myllykangas L, Polvikoski T, Sulkava R, Verkkoniemi A, Tienari P, Niinistö L, Kontula K, Hardy J, Haltia M, Pérez-Tur J. Cardivascular risk factors and Alzheimer´s disease: a genetic association study in a population aged 85 or over. Neuroscience Letters. 2000, 292:195-8. Narita M, Holtzman DM, Schwartz AL, Bu G. Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem. 1997,69:1904-11. Nathan BP, Jiang Y, Wong GK, Shen F, Brewer GJ, Struble RG. Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-density lipoprotein receptor-related protein. Brain Res. 2002,928:96-105. Newell AJ, Sue LI, Scott S, Rauschkolb PK, Walker DG, Potter PE, Beach TG. Thiorphaninduced neprilysin inhibition raises amyloid beta levels in rabbit cortex and cerebrospinal fluid. Neurosci Lett. 2003,35:178-80. Nicodemus KK, Stenger JE, Schmechel DE, Welsh-Bohmer KA, Saunders AM, Roses AD, Gilbert JR, Vance JM, Haines JL, Pericak-Vance MA, Martin ER. Comprehensive
Low Density Lipoprotein Receptor-Related Protein 1 (LRP1)
121
association analysis of APOE regulatory region polymorphisms in Alzheimer disease. Neurogenetics. 2004,5:201-8. Pericak-Vance MA, Bass MP, Yamaoka LH, Gaskell PC, Scott WK, Terwedow HA, Menold MM, Conneally PM, Small GW, Vance JM, Saunders AM, Roses AD, Haines JL. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA. 1997,278,1237-41. Qiu WQ, Borth W, Ye Z, Haass C, Teplow DB, Selkoe DJ. Degradation of amyloid betaprotein by a serine protease-alpha2-macroglobulin complex. J Biol Chem. 1996,271:8443-51. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A,Hersh LB, Selkoe DJ. Insulin-degrading enzyme regulates extracellular levels of amyloid betaprotein by degradation. J Biol Chem. 1998,273:32730-8. Quinn KA, Pye VJ, Dai YP, Chesterman CN, Owensby DA. Characterization of the soluble form of the low density lipoprotein receptor-related protein (LRP). Exp Cell Res. 1999,251:433-41. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD, et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest. 1994,94,860-9. Sánchez-Guerra M, Combarros O, Infante J, Llorca J, Berciano J, Fontalba A, FernándezLuna JL, Pena N, Fernández-Viadero C. Case-Control study and meta-analysis of low density lipoprotein receptor-related protein gene exon 3 polymorphism in Alzheimer´s disease. Neuroscience Letters. 2001,316:17-20. Sandbrink R, Masters CL, Beyreuther K.. Similar alternative splicing of a non-homologous domain in beta A4-amyloid protein precursor-like proteins. J Biol Chem. 1994,269:14227-34. Saunders AJ, Tanzi RE.Welcome to the complex disease world. Alpha2-macroglobulin and Alzheimer's disease. Exp Neurol. 2003,184:50-3. Saunders AJ, Bertram L, Mullin K, Sampson AJ, Latifzai K, Basu S, Jones J, Kinney D, MacKenzie-Ingano L, Yu S, Albert MS, Moscarillo TJ, Go RC, Bassett SS,Daly MJ, Laird NM, Wang X, Velicelebi G, Wagner SL, Becker DK, Tanzi RE, Blacker D. Genetic association of Alzheimer's disease with multiple polymorphisms in alpha-2macroglobulin. Hum Mol Genet. 2003,12:2765-76. Schulz S, Birkenmeier G, Schagdarsurengin U, Wenzel K, Müller-Werdan U, Rehfeld D, Süß T, Kabisch A, Werdan K, Gläser C. The role of LDL receptor-related protein (LRP) in coronary atherosclerosis. Int J Cardiol. 2003,92:137-44. Schulz S, Schagdarsurengin U, Greiser P, Birkenmeier G, Müller-Werdan U, Hagemann M, Riemann D, Werdan K, Gläser C. The LDL receptor-related protein (LRP1/A2MR) and coronary atherosclerosis--novel genomic variants and functional consequences. Hum Mutat. 2002,20:404. Scott WK, Yamaoka LH, Bass MP, Gaskell PC, Conneally PM, Small GW, Farrer LA, Auerbach SA, Saunders AM, Roses AD, Haines JL, Pericak-Vance MA. No genetic association between the LRP receptor and sporadic or late-onset familial Alzheimer disease. Neurogenetics. 1998,1:179-183.
122
Christiane Gläser, Gerd Birkenmeier, Susanne Schulz and Klaus Huse
Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron. 2001,32:177-80. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM,Miller CA, Strickland DK, Ghiso J, Zlokovic BV. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000,106:1489-99. Shuguang Z and Janciauskiene S. Multi-functional capability of proteins: a1antichymotrypsin and the correlation with Alzheimer´s disease. J Alz Dis. 2002,4:15-122. Sinnreich O, Kratzsch J, Reichenbach A, Gläser C, Huse K, Birkenmeier G.Plasma levels of transforming growth factor-1beta and alpha2-macroglobulin before and after radical prostatectomy: association to clinicopathological parameters. Prostate. 2004,61:201-8. Sjogren, T.; Sjogren, H.; Lindgren, A. G. H.: Morbus Alzheimer and morbus Pick: a genetic, clinical and patho-anatomical study. Acta Psychiat. Neurol. Scand. 1952,82 (suppl.):1152. Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem. 1989,264:11539-42. St George-Hyslop PH, Petit A. Molecular biology and genetics of Alzheimer's disease. C R Biol 2005,328(2):119-30. St. George-Hyslop, P. H.; Haines, J. L.; Farrer, L. A.; Polinsky, R.; Van Broeckhoven, C.; Goate, A.; Crapper McLachlan, D. R.; Orr, H.; Bruni, A. C.; Sorbi, S.; Rainero, I.; Foncin, J.-F.; and 54 others: Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. Nature. 1990,347:194-197. Streit WJ. Microglia and Alzheimer´s Disease. J Neurosci Res. 2004, 77:1-8. Strickland DK, Gonias SL, Argraves WS. Diverse roles for the LDL receptor family. Trends Endocrin Metab 2003,13:66-74. Strickland DK, Ranganathan S. Diverse role of LDL receptor-related protein in the clearance of proteases and in signaling. J Thromb Haemost. 2003,1(7):1663-70. Review. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequencyof type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993,90:1977-81. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 2005,120(4):545-55. Review. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight Matrix choice. Nucleic Acids Res. 1994,22:4673-80. Tucker HM, Kihiko-Ehmann M, Estus S. Urokinase-type plasminogen activator inhibits amyloid-beta neurotoxicity andfibrillogenesis via plasminogen. J Neurosci Res. 2002,70:249-55. Ulery PG, Beers J, Mikhailenko I, Tanzi RE, Rebeck GW, Hyman BT, Strickland DK. Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J Biol Chem. 2000,275:7410-5.
Low Density Lipoprotein Receptor-Related Protein 1 (LRP1)
123
Van Leuven F, Thiry E, Lambrechts M, Stas L, Boon T, Bruynseels K, Muls E Decamps O. Sequencing of the coding exons of the LRP1 and LDLR genes an individual DNA samples reveals novel mutations in both genes. Atherosclerosis. 2001,154:567-77. Verpillat P, Bouley S, Campion D, Hanneqeuin D, Dubois B, Belliard S, Puel M, ThomasAntérion C, Agid Y, Brice A, Clerget-Darpoux F. Use of haplotype information to test involvement of the LRP gene in Alzheimer´s disease in the French population. European Journal of Human Genetics. 2001, 9:464-8. Wavrant-DeVrieze F, Lambert JC, Stas L, Crook R, Cottel D, Pasquier F, Frigard B, Lambrechts M, Thiry E, Amouyel P, Tur JP, Chartier-Harlin MC, Hardy J, Van Leuven F. Association between coding variability in the LRP gene and the risk of late-onset Alzheimer's disease. Hum Genet. 1999,104(5):432-4. Wavrant-De Vrièze F, Pérez-Tur J, Lambert JC, Frigard B, Pasquieir F, Delacourte A, Amouyel P, Hardy J, Chartier-Harlin MC. Association between the low density lipoprotein receptor-related protein (LRP) and Alzheimers´s disease. Neuroscience Letters. 1997,227:68-70. Williamson J, LaRusse S. Genetics and genetic counseling: recommendations for Alzheimer's disease, frontotemporal dementia, and Creutzfeldt-Jakob disease. Curr Neurol Neurosci Rep. 2004,4(5):351-7. Willnow TE, Hilpert J, Armstrong SA, Rohlmann A, Hammer RE, Burns DK, Herz J. Defective forebrain development in mice lacking gp330/megalin. Proc Natl Acad Sci U S A. 1996,93:8460-4 Woodward R, Singleton AB, Gibson AM, Edwardson JA, Morris CM. LRP gene and lateonset Alzheimer´s disease. The Lancet. 1998,352:239-40. Yoshikai S, Sasaki H, Doh-ura K, Furuya H, Sakaki Y. Genomic organization of the human amyloid beta-protein precursor gene. Gene. 1990,87(2):257-63. Erratum in: Gene. 1991, 102(2):291-2. Zlokovic BV, Deane R, Sallstrom J, Chow N, Miano JM. Neurovascular pathways and Alzheimer amyloid beta-peptide. Brain Pathol. 2005,15(1):78-83. Review. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B, Ghiso J. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A. 1996,93(9):4229-34.
In: New Research on Alzheimer’s Disease Editor: Eileen M. Welsh, pp.
ISBN 1-59454-939-7 © 2006 Nova Science Publishers, Inc.
Chapter V
The Role of Peroxisome Proliferator-Activated Receptors in Alzheimer’s Disease Dokmeci Dikmen∗ Department of Pharmacology, Faculty of Medicine, Trakya University, Edirne, Turkey
Abstract Alzheimer’s disease (AD) is characterized by a progressive loss of cognitive function with cerebral deposits of amyloid-β (Aβ) senile plaques and neurofibrillary tangles (NFTs) surrounded by inflammatory cells. Neuroinflammation, oxidative stress and impaired glucose and lipid metabolism are postulated to be the mechanisms playing role in the pathophysiology of AD. Recent evidence suggests that inflammatory events are associated with plaque formation in the brains of patients with AD and non-steroid antiinflammatory drugs (NSAIDs) might influence central nervous system (CNS) inflammation and AD pathology. Reactive oxygen and nitrogen species production may also participate in part to neurodegeneration in AD brains; antioxidant and/or free radical scavengers reduce inflammation in AD via free radical quenching and possess neuroprotective activity. In addition, AD patients show hyperinsulinemia and reduced insulin sensitivity during fasting and glucose tolerance tests; and insulin gene polymorphism might act as a modifier of AD progression. An increased number of insulin receptors are also observed in post-mortem brain tissues of AD patients. Furthermore, augmented plasma insulin levels and reduced cerebrospinal fluid (CSF) levels and CSF/plasma insulin ratio are observed in AD patients. Accordingly, treatment of insulin resistance may reduce the risk or retard the progression of AD.
∗
Correspondence: Assoc. Prof. Dikmen Dokmeci, M.D. Department of Pharmacology, Faculty of Medicine, Trakya University, 22030, Edirne, Turkey. Tel. no.: 90-284-2359742; Fax no.: 90-284-2352476; e-mail:
[email protected],
[email protected]
Dokmeci Dikmen
126
Peroxisome proliferator-activated receptors (PPARs), members of the nuclear receptor family, are ligand-activated transcription factors. To date, three isoforms, encoded by separated genes, have been identified: PPARα [NR1C1], PPARβ (NUC-1 or PPARδ) [NR1C2] and PPARγ [NR1C3]. All PPAR isotypes are detected and found to exhibit specific patterns of localization in the different areas of the brain. PPARs may have specific functions in regulating the expression of genes involved in neurotransmission, and therefore play roles in complex processes, such as neurodegeneration, learning and memory. It is likely that at least some effects of PPAR agonists and NSAIDs on AD pathology are mediated through PPARs, since both PPARs and cyclooxygenase (COX) expression are increased in AD brains. Recently, NSAIDs, activating PPARα and γ, have been identified. In addition, NSAIDs and PPARα and γ agonists have anti-inflammatory, antioxidant and neuroprotective effects. This neuroprotective effect correlates with the modulation of β-catenin levels, inhibition of glycogen synthase kinase-3β (GSK-3β) activity and increased mRNA levels of the Wnt-target genes engrailed-1, cyclin D1 and PPARδ. Thiazolidinediones (TZDs) such as pioglitazone and rosiglitazone are insulin sensitizers, used to control glucose concentrations in patients with type 2 diabetes. These are potent synthetic PPARγ agonists, which exert both anti-inflammatory and antioxidant effects. PPARα and γ ligands, NSAIDs and TZDs inhibit activation of nuclear factor (NF)-κB, signal transducers and activators of transcription-1 (STAT-1), the nuclear factor of activated T-cells (NFAT) and activating protein-1 (AP-1). Moreover, they prevent the expression of COX-2 and inducible nitric oxide synthase (iNOS) and production of inflammatory cytokines such as interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α in human monocytes and arrest the differentiation of monocytes into activated macrophages. In conclusion, the development of new drugs targeting PPARs would be a great interest for future treatments of AD.
Keywords: Alzheimer’s disease, PPARs, neuroprotective effect, neuroinflammation, antioxidant effect, fibrates, thiazolidinediones, NSAIDs, Wnt signaling
Abbreviations AP-1 AGEs AD Aβ APP ApoE JNK CAT CNS CSF CoA COX DAT
activating protein-1 advanced glycation end-products Alzheimer’s disease amyloid-β amyloid precursor protein apolipoprotein E c-jun-NH2-terminal kinase catalase central nervous system cerebrospinal fluid coenzyme A cyclooxygenase dementia of Alzheimer type
The Role of Peroxisome Proliferator-Activated Receptors… DHA FDA GSH-Px GSSGR GSK HDL iNOS IRS IL LPS LDL LMWAs MMP MCI MAPK NFTs NADPH NO NSAIDs (NF)-κB NFAT PPARs PI3K PUFAs PS PG RXR RNS ROS STAT-1 SOD TZDs TNF VLDLs
127
docosahexaenoic acid Food and Drug Administration glutathione peroxidase glutathione reductase glycogen synthase kinase high-density lipoprotein inducible nitric oxide synthase insulin receptor substrate interleukin lipopolysaccaride low-density lipoprotein low-molecular-weight antioxidants matrix metalloproteinase mild cognitive impairment mitogen-activated protein kinase neurofibrillary tangles nicotinamide adenine dinucleotide phosphate nitric oxide non-steroid anti-inflammatory drugs nuclear factor nuclear factor of activated T-cells peroxisome proliferator-activated receptors phosphatidylinositol 3-kinase polyunsaturated fatty acids presenilin prostaglandin retinoid X receptor reactive nitrogen species reactive oxygen species signal transducers and activators of transcription-1 superoxide dismutase thiazolidinediones tumor necrosis factor very-low-density lipoproteins
Introduction Alzheimer’s disease (AD), the most common form of dementia among the elderly population in the world, is a progressive, degenerative disorder of the central nervous system (CNS). Clinically, AD is characterized by impairment in memory, visuospatial skills, complex cognition, language, emotion and personality. Currently, AD affects ~5 million people in the United States and >30 million people worldwide. The prevalence of AD is expected to quadruple by the year 2047. Economically, AD is extremely costly to patients,
128
Dokmeci Dikmen
their families, and society. In fact, the cost of caring for patients with AD was over $110 billion per year in the early 1990s in the United States, and the average annual cost per patient is about $45,000 [1]. There are no definitive diagnostic tests or biological markers of AD. Furthermore, there are no known cures or preventions for AD. Therefore, scientists from different disciplines have been trying to find new drugs for the prevention and treatment of AD for a long time. On the other hand, drug discovery for AD is complicated by the fact that the exact cause(s) of the disease is still unknown and early diagnosis of the disease is not currently available [2]. The early-onset, familial form of AD accounts for nearly 5-10% of all cases of AD and is characterized by early manifestations of dementia, in some cases in patients ~40 years of age. It is caused by multiple mutations in the major genes, such as amyloid precursor protein (APP) on chromosome 21, presenilin (PS)-1 on chromosome 14, and PS-2 on chromosome 1 [2, 3]. In contrast, although the initiating events are still unknown, late onset AD, which is sporadic and accounts for ~90-95% of all patients, results from the combination of genetic risk factors such as aging, apolipoprotein E (ApoE), and α2 macroglobulins, with different epigenetic events [4]. Diabetes, cardiovascular complications, arteriosclerosis, and hypertension are considered to be the risk factors in the development of AD [5, 6]. Neuroinflammation, oxidative stress and impaired glucose and lipid metabolism are also postulated to be the mechanisms playing role in the pathophysiology of AD. Furthermore, peroxisome proliferators-activated receptor (PPAR) expression is increased in AD brains and PPARs seem to play an important role in AD etiopathogenesis [7]. PPARs, a member of the nuclear hormone receptor superfamily, are involved in several physiological processes, such as glucose homeostasis, cellular differentiation, regulation of lipid and lipoprotein metabolism, neurodegeneration, learning and memory, as well as in pathological states including atherosclerosis, inflammation, cancer, diabetes, obesity, infertility, and demyelinization [8, 9]. Hipolipidemic fibrates, antidiabetic thiazolidinediones (TZDs) and non-steroid anti-inflammatory drugs (NSAIDs) are PPAR agonists. In addition, to date, several studies have confirmed the insulin sensitizer, hipolipidemic, antiinflammatory and antioxidant properties of various PPAR agonists in vivo and in vitro. Hence, it is of importance to determine if the efficacy of fibrates, TZDs and NSAIDs in reducing AD risk is a result of the action of these drugs on PPARs.
Neuropathology of AD AD is characterized by a progressive loss of cognitive function with senile plaques, vascular amyloid-β (Aβ) deposits and neurofibrillary tangles (NFTs) as the pathologic hallmarks of the disease. AD brains exhibit a number of other abnormalities: synaptic reduction, neuronal loss, volume loss (atrophy), gliosis, microglial activation, impaired energy metabolism, mitochondrial function, signs of inflammation, and damage secondary to oxygen radicals [10, 11]. NFTs are cytoskeletal lesions largely composed of paired helical and straight filaments, which are intraneuronal aggregates of hyperphosphorylated, microtubule-associated tau protein. After the neurofibrillary tangle-laden neurons die,
The Role of Peroxisome Proliferator-Activated Receptors…
129
extracellular "tombstone" tangles remain visible [12]. Aβ are deposited as extracellular senile plaques composed of the 39-42 amino-acid-long peptide, derived from the β-APP, caused by cleavage with β-secretase and γ-secretase. The α-secretase cleaves the middle of the Aβ region, releasing a secreted ectodomain that contains the first 16 amino acids of the Aβ (sAPPα). In contrast, β-secretase, the novel transmembrane asparatic protease, BACE, cleaves between Met-671 and Asp-672, producing the amino terminal end of the Aβ and ending with Met-671 (sAPPβ). Further processing of the carboxyl-terminal end of sAPPβ, by the activity of γ-secretase, leads to the release of Aβ [12, 13]. Brain levels of both 42-aminoacid form (Aβ42) and 40-amino-acid form (Aβ40) are increased in AD. The Aβ40 is the most abundantly produced Aβ peptide, whereas a slightly longer and less abundant Aβ42 has been implicated as the more pathogenic species. Despite being a minor Aβ species, Aβ42 is deposited earlier and more consistently than Aβ40 in the AD brain. Collectively, these observations provide a strong rationale for selective targeting of Aβ42 and indicate that reducing Aβ42 levels by as little as 20-30% might retard the development of AD [14]. Interestingly, Kitamura and collegues reported that PPARγ expression could be detected by Western analysis in the temporal cortex of the human brain. Significantly, they found approximately a 50% increase in the amount of immunoreactive PPARγ protein in the brains of AD patients [7]. In conclusion, PPARs play an important role in AD etiopathology and may be a promising new therapeutic approach for the treatment of AD.
PPARs PPARs are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors, which includes retinoid, steroid, vitamin D and thyroid hormone receptors that function as heterodimers with the retinoid X receptor (RXR) and contain a highly conserved DNA-binding domain and a carboxy-terminal ligand-binding domain. These receptors regulate the expression of specific target genes by binding as heterodimers with RXR to specific DNA sequences, which are referred to as PPAR response elements [8]. Intensive study of PPARs during recent years has suggested an important role for these nuclear receptors both in normal physiology and the pathology of various tissues [15]. There are three PPAR isotypes, namely PPARα [NR1C1], PPARβ (PPARδ, NUC-1 or FAAR) [NR1C2] and PPARγ [NR1C3], localized on chromosomes 22, 6 and 3, respectively, with distinct tissue distribution and biological activities [8, 9, 15, 16]. As a result of alternative splicing and alternative promoter usage generates three transcripts from the human PPARγ gene; PPARγ1, PPARγ2 and PPARγ3. Both PPARγ1 and PPARγ3 mRNA encode the same protein product expressed in most tissues, whereas the PPARγ2 mRNA encodes the PPARγ2 protein that contains an additional 28 amino acids and is specific to adipocytes [16]. PPARs have been found and identified so far in amphibians, cyclostoma, teleosts, rodents and humans. PPARs are implicated in many cellular processes, from cell cycle to cell proliferation, from inflammation to apoptosis, and crucial for energy homeostasis. In addition, PPARs act as transcription factors, and regulate the expression of numerous genes and affect glycaemic control, lipid metabolism, inflammation and oxidant status [17-19]. Meanwhile, all PPAR isotypes are detected and found to exhibit specific patterns of
130
Dokmeci Dikmen
localization in the different areas of the brain. PPARs have specific functions in regulating the expression of genes involved in neurotransmission, and therefore play roles in complex processes, such as aging, neuroinflammation, neurodegeneration, learning and memory [20]. PPARs may act for a range of compounds including hypolipidemic, antihyperglycaemic drugs, insulin sensitizers, and NSAIDs.
PPARα The first discovered PPAR was PPARα (Issemann and Green, 1990) [21], followed by PPARβ and PPARγ. PPARα is expressed primarily in liver, kidney, heart, adipose tissue, intestine, skeletal muscle and vascular cells [18, 22, 23]. PPARα can be activated by a wide variety of saturated and unsaturated fatty acids including arachidonic acid, oleic acid, linoleic acid, palmitic acid, docosahexaenoic acid (DHA), and eicosapentaenoic acid. Recently, PPARα has also been shown to be activated by very-low-density lipoproteins (VLDLs) in the presence of enzymatically active lipoprotein lipase [24, 25]. PPARα has been shown to regulate lipid metabolism through the control of apolipoprotein expression. Ligand activation of PPARα in vivo lowers triglyceride levels, presumably through its effects on fatty acid and lipoprotein metabolism. PPARα activation is now recognized to be the mechanism of action of the fibrate class of hypolipidemic drugs. The fibrates, amphipathic carboxylic acids that have been proven useful in the treatment of hypertriglyceridemia, are PPARα ligands. Clofibrate is a prototype for this class. Clofibrate and fenofibrate have been shown to activate PPARα with a 10-fold selectivity over PPARγ. Bezafibrate is a pan-agonist that exerts similar potency on all three PPAR isoforms [8]. PPARα transcriptionally regulates fatty acid catabolism and the production of enzymes such as acyl-coenzyme A (CoA) oxidase, the key enzyme in peroxisomal β-oxidation pathway, carnitine palmitoyl transferase I, implicated in the translocation of fatty acids across the inner mitochondrial membrane, as well as CYP4A6, which is an important microsomal ωhydroxylase. Interestingly fatty acids directly affect transcription by activating PPARα [26]. In addition, PPARα is involved in inflammation and in the cell response to reactive oxygen and nitrogen species. PPARα activators also reduce the risk of atherosclerosis, decrease progression of atherosclerotic plaques, and reduce the incidence of mortality from cardiovascular disease [20, 22, 25]. Moreover, PPARα ligands inhibit the inflammatory response in aortic smooth muscle cells, an effect that is lost in the PPARα null mice. This occurs through the inhibition of interleukin (IL)-1-mediated expression of IL-6 and cyclooxygenase (COX)-2. The transcriptional inhibition of this key enzyme of the inflammation process occurs as a result of a PPARα-dependent repression of the nuclear factor (NF)-κB pathway [27].
PPAR β/δ PPARδ is a less well known PPAR isoform, widely distributed in the organism; it is abundant especially in skeletal muscle, skin, placenta and brain. PPARδ interacts with
The Role of Peroxisome Proliferator-Activated Receptors…
131
saturated and unsaturated fatty acids; its ligand selectivity is intermediate between PPARγ and PPARα. Arachidonic acid, palmitic acid, prostaglandin (PG) A1 and PGD2, eicosapentaenoic acid, dihomo-γ-linolenic acid and carbaprostacyclin have been shown to activate PPARδ [8, 25]. Recently, the antiepileptic drug valproic acid has also been shown to activate PPARδ [28-30]. Its physiological role is not well understood, but it has been suggested to play a role in lipid metabolism, myelination and neuronal signaling, particularly in CNS, carcinogenesis, wound repair, epithelial inflammatory response, obesity, reproductive function, fertility, embryo implantation, cell proliferation, apoptosis, keratinocyte, adipocyte, and oligodendrocyte differentiation [8, 20, 22, 25].
PPARγ PPARγ, the best characterized of the PPARs, is expressed in white adipose tissue, pancreas, intestine, spleen, lymphoid tissue, bone marrow, kidney, heart, ovary, testis, liver, bladder, skeletal muscle and vasculature, epithelial keratinocytes and brain [19]. Fatty acids and eicosanoid derivatives bind and activate PPARγ at micromolar concentrations. PPARγ clearly prefers polyunsaturated fatty acids (PUFAs) including the essential fatty acids linoleic acid, linolenic acid, arachidonic acid and eicosapentaenoic acid. LTD4 antagonists, such as pranlukast, are selective agonists for PPARγ [8, 16]. PPARγ is a key regulator of glucose homeostasis and adipogenic differentiation [31]. PPARγ also promotes lipogenesis and exerts anti-inflammatory and antiproliferative actions [20, 25]. PPARγ is also involved in atherosclerosis [9]. It was reported that PPARγ is markedly upregulated in activated macrophages and that natural and synthetic PPARγ ligands inhibit the induction of indicuble nitric oxide syntase (iNOS), matrix metalloproteinase (MMP, called also gelatinase B) and scavenger receptor A gene transcription [32]. Promoter studies have revealed that PPARγ inhibits the transcriptional activity of these genes by interfering with the activating protein-1 (AP-1), NF-κB, the nuclear factor of activated Tcells (NFAT) and signal transducers and activators of transcription-1 (STAT-1) transcription factors. Furthermore, Jiang et al. [33] have shown that incubation of human monocytes with the natural PPAR γ ligand PGJ2 or with synthetic agonists inhibits the production of proinflammatory cytokines, including tumor necrosis factor (TNF)-α, IL-1β, and IL-6. The pharmacological ligands for PPARγ are TZDs and a variety of NSAIDs. TZDs were primarily developed in an effort to improve the antidiabetic actions of the fibrate hypolipidemic agents [8]. These compounds are used as therapeutic agents for treatment of type 2 diabetes. There are currently two members of the TZD class (pioglitazone and rosiglitazone) that have been approved by Food and Drug Administration (FDA) for treatment of Type 2 diabetes [31]. TZDs decrease plasma triglyceride and free fatty acids levels by enhancing their catabolism via the induction of lipoprotein lipase gene expression in adipose tissue. TZDs such as troglitazone, pioglitazone, rosiglitazone, englitazone and ciglitazone also have been postulated to be promising drugs for the treatment of cancer, hypertension, atherosclerosis, multiple sclerosis, psoriasis, ulcerative colitis, asthma, atopic dermatitis, and
132
Dokmeci Dikmen
chronic inflammatory processes. They are also potent neuroprotector compounds, which that inhibit inflammatory activation of cultured brain astrocytes and microglia by diminishing lipopolysaccharide (LPS)-induced IL-6, TNF-α, iNOS, and inducible COX-2 expression. In addition, glycogen synthase kinase (GSK)-3α/β has been recognized as a therapeutic target for the treatment of neuropathological disorders, such as AD. TZDs were first described as GSK-3β inhibitors and were postulated that could be of potential therapeutic use for the treatment of AD [9, 15, 18, 19, 25]. Nitric oxide (NO) is overproduced in adipose tissue and muscle by iNOS in conditions such as chronic inflammation and insulin resistance. Recently, it was shown that PPARγ results in a decrease in iNOS expression in mesangial cells and macrophages via its effects on the NFκB, AP-1 and STAT-1 pathways [31]. NSAIDs are well known COX inhibitors, and some have been indicated recently to activate the PPARs. Hence, NSAIDs were classified into the following theree groups: The first group including aspirin, acetaminophen, tiaramide, and piroxicam shows no agonistic activity for any subtype of PPAR. The second group including indomethacin and diclofenac shows high selectivity for the PPARγ. The last group, e.g. ibuprofen, exerts agonistic activity for all type PPARs [34-36]. NSAIDs exerting PPAR agonistic activity, inhibit activation of NF-κB, STAT-1 and AP-1, and prevent expression of iNOS and production of inflammatory cytokines such as TNF-α and IL-1β. PPAR activators inhibiting COX expression and inflammatory events may have beneficial effects in the treatment of AD patients [7].
The Roles of Glucose Metabolism and PPARs in Alzheimer’s Disease Diabetes mellitus is a metabolic disorder divided into two main types: insulin-dependent and non-insulin–dependent. The various subtypes of diabetes mellitus differ with respect to etiology, pathogenesis, and insulin availability, but share the same consequences of chronic hyperglycemia and impaired insulin actions. Insulin dependent diabetes mellitus (called also Type 1 diabetes) is caused by insulin deficiency as a result of autoimmune destruction of pancreatic islet beta cells. Non-insulin-dependent diabetes mellitus (called also Type 2 diabetes) is the most common form of diabetes that is characterized by hyperinsulinemia and insulin resistance in peripheral tissues. Individuals with Type 2 diabetes have hyperglycemia and hyperinsulinemia. The pathogenesis of insulin resistance in Type 2 diabetes is not completely understood. However, evidence suggests that the insulin resistance is partly mediated by reduced levels of insulin receptor expression (down regulation), insulin receptor tyrosine kinase activity, insulin receptor substrate (IRS)-1 expression, and/or phosphatidylinositol 3-kinase (PI3K) activation in skeletal muscle and adipocytes [37, 38]. Type 2 diabetes is also associated with hippocampal and amygdalar athropy and increasing insulin resistance is associated with more amygdalar atrophy on magnetic resonance imaging [39]. Insulin synthesis and insulin gene expression have been demonstrated in mammalian neuronal cells. Insulin mRNA is distributed in a highly specific pattern with the highest density in pyramidal cells of the hippocampus and a high density in the medial prefrontal
The Role of Peroxisome Proliferator-Activated Receptors…
133
cortex, the enthorinal cortex, perirhinal cortex, thalamus and the granule cell layer of the olfactory bulb. Neither insulin mRNA nor insulin synthesis is observed in glia cells [40]. In 1978, Havrankova et al. [41] localized the insulin receptor in the CNS for the first time, and later insulin receptors are expressed in neurons throughout the CNS, particularly in the cerebral cortex, cerebellar cortex, hippocampus, olfactory bulbs, thalamus, hypothalamus, brainstem nuclei, spinal cord, and retina. In neurons, the binding of insulin to its receptor initiates tyrosine kinase mediated intracellular signaling and this leads to autophosphorylation of the receptor, followed by tyrosine phosphorylation of IRS proteins, which induce the activation of downstream pathways such as the PI3K and the mitogen-activated protein kinase (MAPK) cascades [42-44]. Binding of tyrosine phosphorylated-IRS to p85 stimulates glucose transport and inhibits apoptosis by activating Akt/Protein kinase B and inhibiting GSK-3β. Akt kinase inhibits apoptosis by phosphorylating GSK-3β [45]. Low levels of Akt kinase and high levels of GSK-3β activity are associated with increased neuronal death [46, 47]. Furthermore, insulin inhibits neuronal apoptosis via activation of protein kinase B in vitro, and regulates phosphorylation of tau, metabolism of the APP and clearance of Aβ from the brain in vivo [44]. Glucose, transported from peripheral blood, is the primary nutrient for neurons and the major fuel for oxidative metabolism, and function in the CNS. However, insulin enters the cerebrospinal fluid (CSF) through the blood-brain barrier by insulin receptor-mediated transport process, and exerts neuromodulator, neuroendocrine and neurotropic effects [5, 47]. Margolis et al. [48] showed that peripheral infusion of insulin leads to an increase in insulin levels in CSF. However, the augmentation of the peripheral insulin concentration acutely increases the concentration in the brain and CSF, whereas prolonged peripheral hyperinsulinaemia downregulates blood-brain barrier insulin receptors and reduces insulin transport into the brain [49]. The transport of insulin across the blood-brain barrier shows a saturable character; however, the molecular identity of this transport mechanism remains obscure [50]. Insulin regulates growth, food intake, sympathetic activity, reproductive endocrinology, glucose homeostasis and peripheral insulin action through the inhibition of hepatic gluconeogenesis [44, 51, 52]. In addition, insulin interferes neuronal growth, survival, differentiation and signal transduction; and promotes neurite outgrowth, migration, protein synthesis, neuronal cytoskeletal protein expression, and nascent synapse formation [53]. The brain may utilize insulin from both locally produced and peripheral (pancreatic) sources for different functional requirements including learning and memory. Furthermore, intranasal administration of insulin rapidly augments the insulin concentration in CSF without affecting blood glucose levels [54], and facilitates brain cognitive functions and working memory [55, 56], suggesting that it influences brain function directly and independently of changes in peripheral glucose. Epidemiologic and clinical studies suggest an important interaction between diabetes mellitus, hyperinsulinemia, insulin resistance and the development of AD, and diabetes mellitus significantly increases the risk for the development of AD [5, 57-64]. Furthermore, AD patiens are also more vulnerable to Type 2 diabetes [65]. There is compelling clinical and pre-clinical evidence that abnormalities of glucose metabolism are related to cognitive impairment and specifically to the development of AD. It is likely that insulin and insulin
134
Dokmeci Dikmen
resistance play important roles in this process [5]. Moreover, insulin dysregulation may contribute to AD pathology through several mechanisms including decreased cortical glucose utilization particularly in the hippocampus and entorhinal cortex; increased oxidative stress through the formation of advanced glycation endproducts; increased tau phosphorylation and NFT formation; and increased Aβ aggregation through inhibition of IDE (called also unsulysin) [5]. In addition, pathological filaments with histochemical properties of amyloid are found in human AD pancreas [66], and Aβ-immunoreactive intracellular deposits have been reported in the pancreases of mice overexpressing the 99-amino acid C-terminal fragment of APP [67]. Thus, accumulation of Aβ in islet cells may be an underlying cause of, or at least potentiate the development of, insulin resistance and impaired glucose tolerance in AD [68]. Brain glucose metabolism reduces in AD patients [47]. Individuals suffering from AD have higher plasma insulin and lower CSF insulin concentrations as well as the insulin insensitivity or resistance, indicating impairment in insulin metabolism in the brain [69-71]. Moreover, administration of insulin to Alzheimer’s patients has been demonstrated to result in an improvement on memory and performance [72]. Consistent with the insulin resistant pattern, insulin tyrosine kinase, an insulin transducer, was reduced in the AD brains. Frolich et al. [73] found that brain insulin concentration and insulin receptor densities both decrease with age. Moreover, insulin receptor density is up-regulated in AD disease, and the authors interpreted the increased receptor density as a compensatory upregulation for defective insulin signal transduction [73, 74]. Schubert et al. [75] showed that disruptions of the insulin receptor tyrosine kinase signaling leads to an accumulation of phosphorylated tau in the mice hippocampus. In fact, the reduced CNS expression of genes encoding insulin and its receptor, as well as related signaling molecules, in the AD brain prompted the researchers to consider sporadic AD as a neuroendocrine disease that resembles Type 2 diabetes which was termed ‘’brain diabetes or Type 3 diabetes’’ [47, 63, 76-78]. Aβ40 and Aβ42, the main physiological C-terminal cleavage products of APP, reduce insulin binding and insulin receptor auto-phosphorylation due to reduced affinity of insulin binding to its own receptor, thereby impairing insulin signaling [79]. Aβ accumulations can promote tau hyperphosphorylation and the formation of the AD dementia associated paired helical filament-containing neuronal cytoskeletal lesions (NFTs, neuritic plaques, and neuropil threads) through functional impairment of the insulin signaling cascade, leading to increased levels of GSK-3β activity. It has been shown that Aβ40 and Aβ42 reduce insulin binding to and autophosphorylation of its receptor [80]. Furthermore, insulin protects against Aβ-peptide toxicity in brain mitochondria of diabetic rats [81]. Insulin seems to be involved in clearing Aβ from the brain [82]; on the other hand, inhibits the breakdown of Aβ by competitively blocking IDE. IDE activity is influenced by insulin concentration. IDE is a protease that can cleave a variety of small proteins, such as insulin and glucagons, and regulates the levels of insulin, Aβ -protein, and the Aβ precursor protein [83, 84]. IDE can degrade both intra- and extracellular Aβ as well as APP intracellular domain fragment produced by γ-secretase cleavage of APP [85]. IDE is decreased in Tg2576 mice which will also enhance the accumulation of Aβ [86]. Since both insulin and Aβ are substrates of IDE, insulin may compete with Aβ for IDE and therefore prevent Aβ degradation [61]. IDE deficiency or hypofunction may play a role in the disease
The Role of Peroxisome Proliferator-Activated Receptors…
135
processes of both AD and diabetes mellitus [87], and the use of IDE inhibitors block the degradation of Aβ and may be beneficial in diabetes mellitus and AD therapy. Advanced glycation end-products (AGEs) are sugar-derived protein modifications formed through a series of non-enzymatic glycosylation reactions [5]. Both diabetes mellitus and AD are characterized by accumulation of extra- and intracellular AGEs with the glucose hypometabolism and the metabolic consequences of oxidative stress [88]. There is CNS neuronal insulin resistance in AD brains which is associated with reduced levels of IRS mRNA, IRS-associated PI3K, reduced activation of Akt, and increased activation of GSK-3β activity and APP mRNA expression [89]. Insulin modulates other enzymes involved in tau phosphorylation, such as GSK-3. GSK3 is a serine/threonine kinase originally identified as a protein destined to phosphorylate and inactivate glycogen synthase. There are two GSK-3 isoforms, termed GSK-3α and GSK-3β. The latter is specifically expressed in CNS [90]. Oxidative stress can result in the phosphorylation of GSK-3β and neuronal injury. Hence, Aβ exposure in cultured hippocampal neurons can activate GSK-3β [91]. In addition to the relationship of GSK-3β with Aβ toxicity, GSK-3β can also alter the processing of APP. Involvement of GSK-3β in AD has also been linked to the microtubule-associated protein tau. The hyperphosphorylated tau is the major component of NFT that are composed of paired helical filaments. On the other hand, GSK-3β and PS1 may have an additional relationship through β-catenin. PS-1 can regulate the stability of β-catenin, a substrate of GSK-3β. GSK-3β negatively regulates βcatenin through phosphorylation and degradation. The loss of β-catenin results in an increase in the susceptibility of cells to apoptosis [90]. TZDs were first described as GSK-3β inhibitors and were postulated that could be of potential therapeutic use for the treatment of AD [92]. In conclusion, the precise role of insulin in the pathophysiology of AD is as yet undetermined. Impaired insulin signal transduction pathways, insulin dysregulation and insulin resistance in AD brain play important role in development and progression of AD. Antidiabetic agents including TZDs that reduce hyperinsulinemia might have the effect of diminishing circulating insulin in the CNS and freeing IDE to metabolize Aβ. TZD class of agents is FDA-approved for diabetes mellitus [31]. They bind to the PPARγ, which regulate fat cell differentiation and glucose uptake in adipose tissue. TZDs improve insulin sensitivity, reduce lipid content in skeletal muscle and other non-adipose tissues, and reduce peripheral glucose levels in patients with Type 2 diabetes mellitus. TZDs may also reduce insulin resistance. The use of insulin sensitizers (preferably ones are CNSspecific) would probably provide the best form of therapeutic rescue in the early and intermediate stages of AD [8, 22]. It is possible that the reported salutary effects of PPARγ might arise from improved brain glucose utilization in AD. Interestingly, some studies suggest that treatment for insulin resistance may reduce the risk or retard the progression of AD. Since insulin resistance increases amyloidosis in AD brain, the amyloid-lowering effect of TZDs may also be due to enhanced insulin sensitivity [47, 61]. Activation of this receptor also results in inhibition of a broad range of proinflammatory genes [93]. Treatment of microglial cultures with PPARγ agonists reduces the neurotoxic Aβ-induced inflammatory response [47]. These agents might prove to be disease-modifying treatments in AD [18, 25].
136
Dokmeci Dikmen
Adiponectin is a fat-derived hormone and reduced circulating adiponectin concentrations were found to be strongly associated with the progression or insulin resistance in humans. PPARγ activation enhances adiponectin expression and production in humans and insulin resistant mice, which could contribute to the mechanisms by which PPARγ ligands improve the sensitivity of glucose metabolism to insulin’s action [31]. Uryu et al. [94] suggested that troglitazone, TZD drug and PPARγ agonist, inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons. Gemma et al. [95] demonstrated that administration of a PPARγ agonist, rosiglitazone, reversed an age-related deficit in contextual fear conditioning. Furthermore, PPARγ activation might modulate the beneficial effects of NSAIDs on cognition. The authors attribute the improvement in verbal memory recovery to the insulin-sensitizing effects of rosiglitazone. The Wnt signaling pathway is one of the best-studied signaling cascades implicated in neural development and maintenance of the CNS [96]. Defects of Wnt signaling appears to play role in neurodegenerative disorders, such as AD, and some of these events may be related to the modulation of β-catenin